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Regulatory CD4+
 
 T Cells in the Immune Reconstitution of HIV-Infected Individuals 
Abstract 
Acquired Immunodeficiency Syndrome (AIDS) caused by the human immunodeficiency virus 
(HIV) is characterized by a steady imbalance in the immune system mainly at the level of the cell-
mediated immunity, leading to a final stage of inability to counteract major life threatening 
infections and tumors. With the advent of highly active antiretroviral therapy (HAART), HIV 
infection became manageable as a chronic disease. However, HAART does not fully restore 
health and does not always lead to the recovery of the CD4+
Regulatory T cells (Treg), a specialized subset of T cells, play an essential role in the control of 
immune responses. In the context of HIV infection, Treg may be considered harmful by 
suppressing HIV-specific immune responses or beneficial, by dampening excessive immune 
activation. It has also been hypothesize that their deregulation could hamper immune recovery 
and be involved in the immune reconstitution inflammatory syndrome (IRIS). Despite many 
reports concerning the role of Treg in the immune system recovery of HIV-infected patients under 
HAART, the subject remains controversial. Clarifying Treg function in this process is of paramount 
importance to better understand the immune reconstitution in HIV-infected patients and 
therefore, potentially use this information to improve the disease management.  
 T cell numbers to normal levels.  
Focused on understanding the role of Treg in the immune system reconstitution, we endeavor a 
work involving exclusively HIV-infected patients under HAART. Two studies were performed: a 
cross-sectional study involving HIV-infected patients aviremic under HAART, and a longitudinal 
study involving HIV-infected patients HAART-naïve, who were followed since the initiation of 
therapy, through several time-points and until they have performed two years of HAART (providing 
they were adherent to HAART and the treatment was effective at decreasing the viral load). 
We found that untreated HIV-infected patients in a more advanced stage of the disease (<200 
CD4+ T cells/mm3), tend to show higher Treg percentages among CD4+ T cells (although with 
high inter-individual variability) comparing to healthy controls and that those patients under 
HAART tend to normalize Treg percentage. However, after 2 years (longitudinal study) or even 
more years (cross-sectional study) of HAART, although the median Treg percentage of HIV-
infected patients was not different when compared with that of healthy individuals, the number of 
HIV-infected patients with a Treg percentage ≥10% was significantly superior to the one within the 
healthy group, and patients still demonstrated a more heterogeneous distribution of Treg 
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percentages. We also observed that a Treg subset homeostasis disturbance (lower naïve Treg 
and higher cycling Treg among Treg) was present at baseline and that this disturbance had not 
normalized even after two years under HAART in patients in a more advanced stage of the 
disease (<200 CD4+ T cell/mm3
Concerning immune recovery under HAART, we found, in our cross-sectional study: that amongst 
the patients with nadir values <200 cells/mm
). 
3, the individuals with higher Treg percentages had 
the poorest CD4+ T cell reconstitution; that the well-described direct correlation between the nadir 
value and CD4+ T cell reconstitution was clearly more evident in individuals with high Treg 
proportions; and finally, we also found a strong negative correlation between Treg percentages 
and CD4+ T cell recovery among immunological non-responder HIV-infected individuals. In 
addition, in our longitudinal study, we confirmed a negative correlation between baseline Treg 
proportion and CD4+ T cell counts at 24 months of therapy. However, we found that the 
individuals who presented high Treg percentages at baseline are for the most part the ones with 
lower nadirs and that there was a link between higher Treg percentage and lower CD4+ T cell 
counts at baseline that explained the correlation found (CD4+
One of the patients of the longitudinal cohort has developed a paradoxical toxoplasmosis-IRIS 
therefore allowing us to investigate the Treg and Treg subsets dynamics before, throughout, and 
after the process. We found an accentuated deregulation of Treg percentage and Treg subsets 
which suggests that these cells might have an important role in that condition. 
 T cell counts progression during 
therapy was independent on having high or low Treg percentages at baseline). 
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Células T CD4+
 
 Reguladoras na Reconstituição Imune de Indivíduos Infetados por VIH 
Resumo  
A Síndrome de Imunodeficiência Adquirida (SIDA) causada pelo vírus da imunodeficiência 
humana (VIH) é caracterizada por um desequilíbrio marcado do sistema imunitário, 
principalmente ao nível da imunidade mediada por células, levando a uma fase final de 
incapacidade para contrariar um grande número de infeções e tumores. Com o advento da 
terapêutica antirretrovírica de alta eficácia (HAART), a infeção pelo VIH tornou-se numa doença 
crónica controlável. No entanto, a HAART não restaura completamente a saúde e nem sempre é 
suficiente para que os doentes recuperem totalmente as células T CD4+
As células T reguladoras (Treg), uma subpopulação de células T especializadas em regular a 
resposta imunitária de outras células, desempenham um papel essencial no controlo da resposta 
imunitária. No contexto da infeção pelo VIH, as Treg podem ser consideradas prejudiciais por 
poderem diminuir ou mesmo suprimir as respostas imunitárias específicas anti-VIH ou benéficas, 
ao conseguirem diminuir a ativação imunitária exagerada encontrada no contexto desta doença. 
Tem sido também defendido que a sua desregulação, frequentemente observada em doentes 
com infeção por VIH, poderia dificultar a recuperação imunitária ou ainda estar envolvida na 
patogénese da síndrome inflamatória de reconstituição imunitária (IRIS). Apesar dos muitos 
estudos realizados nesta área, o papel das Treg na infeção pelo VIH ainda é controverso. 
Esclarecer o seu papel nesta doença é de suma importância para se perceber melhor a 
reconstituição imunitária e para, potencialmente, se poder usar essa informação na melhoria do 
manuseamento da doença. 
 para valores que 
possam ser considerados normais.  
Com o objetivo de compreender o papel das Treg na recuperação imunitária em doentes sob 
HAART, realizámos um trabalho que envolveu doentes infetados pelo VIH sob HAART.  
Foi realizado um estudo transversal que envolveu doentes infetados pelo VIH, todos sob HAART, 
e todos com bons resultados em termos de diminuição da carga viral, e um estudo longitudinal 
que envolveu doentes infetados pelo VIH, naïves em terapêutica e que foram seguidos desde o 
início do tratamento, durante vários momentos até atingirem os dois anos de terapêutica (desde 
que aderentes à HAART e sendo esta, eficiente na redução da carga viral). 
Estes estudos mostraram-nos que doentes infetados pelo VIH não tratados e que se encontram 
numa fase mais avançada da doença (<200 células T CD4+/mm3), apresentam percentagens 
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elevadas de Treg (embora com grande variabilidade inter-individual), em comparação com 
controlos saudáveis. Observámos também que a HAART tende a normalizar essas percentagens 
de Treg, ao longo do tempo nesses doentes. No entanto, mesmo após dois (no estudo 
longitudinal) ou mais anos (no estudo transversal) de HAART, apesar da mediana da 
percentagem de Treg dos doentes infetados pelo VIH não ser diferente daquela apresentada 
pelos controlos saudáveis, o número de doentes infetados pelo VIH que apresentavam uma 
percentagem de Treg ≥10% era significativamente maior que no grupo controlo e os doentes 
continuavam a apresentar uma maior variabilidade das percentagens de Treg. Observámos 
também que a desregulação da homeostasia das Treg (uma menor percentagem das Treg 
naïves e uma maior proliferação das Treg dentro das Treg) já presente nos doentes antes de 
iniciarem HAART, não normaliza com a terapêutica, nos doentes em fase mais avançada de 
doença (<200 células T CD4+/mm3
No que diz respeito à recuperação imunitária sob HAART, encontrámos, no nosso estudo 
transversal: que entre os doentes com valores de nadir <200 células/mm
), persistindo alterada mesmo ao fim de dois anos de 
terapêutica antirretrovírica. 
3, os indivíduos com 
percentagens altas de Treg tiveram pior reconstituição de células T CD4+; que a correlação direta 
já bem descrita entre o valor do nadir e o de células T CD4+ era claramente mais evidente em 
indivíduos com percentagens elevadas de Treg; e, finalmente, encontrámos também uma forte 
correlação negativa entre as percentagens de Treg e a recuperação de células T CD4+ entre os 
indivíduos infetados pelo VIH, imunologicamente não respondedores. Além disso, no nosso 
estudo longitudinal, encontrámos uma correlação negativa entre a percentagem de Treg no 
momento do início da terapia e o valor das células T CD4+ aos 24 meses de terapêutica. No 
entanto, verificou-se que os indivíduos que apresentavam percentagens altas de Treg no início do 
estudo eram, na maior parte, aqueles com valores de nadir inferiores e que era o elo entre a alta 
percentagem de Treg e o baixo valor de células T CD4+ no início do estudo, que explicava a 
correlação encontrada (a progressão da contagem de células T CD4+
Um dos doentes da coorte longitudinal desenvolveu uma IRIS paradoxal no contexto de uma 
toxoplasmose, permitindo-nos observar a dinâmica das Treg e das suas subpopulações celulares 
antes, durante e depois dessa intercorrência. Constatámos uma desregulação acentuada da 
percentagem das Treg e das suas subpopulações durante essa intercorrência, o que nos sugere 
que as Treg possam ter um papel importante nesse processo.  
 durante a terapia era 
independente de se ter percentagens de Treg altas ou baixas no início do estudo). 
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General Objectives and Outline of the Thesis 
 
Acquired Immunodeficiency Syndrome (AIDS), a cellular immunodeficiency caused by 
the human immunodeficiency virus (HIV), was first recognized in 1981 and dramatically evolved 
to a global pandemic, with cases reported from virtually every country. Globally, an estimated 
35.3 (32.2–38.8) million people were living with HIV in 2012. There were 2.3 (1.9–2.7) million 
new HIV infections worldwide, and the number of deaths due to AIDS were estimated at 1.6 
(1.4–1.9) million in the same year. 
 Great advances were made until the present in the HIV field. The advances made are a 
result of science, advocacy, political commitment, and effective partnerships with affected 
communities. HIV infection, considered in the beginning a rapidly fatal disease, is now 
considered a chronic disease easy to stabilize, at least, when the patients are early diagnosed, 
where the therapy and laboratory support are available, and when patients adhere to treatment 
and health care. 
Some issues related to this infection remain however a problem, even if patients are 
maintained many years under effective therapy; reservoirs where persistence of virus is the most 
important impediment to achieve a complete eradication of the virus; the persistence of a 
residual immune activation and inflammation accounting for a number of non-AIDS-related co-
morbidities, and also the inability of some patients to completely immune reconstitute being 
more prone to suffer from AIDS-related and non-AIDS-related complications and death. 
In an attempt to better understand the role of various interveners, particularly the human 
regulatory CD4+
The present dissertation is organized in three chapters: Introduction; Results; and Final 
remarks, general discussion and conclusion.  
 T cells (Treg), during the immune reconstitution, we endeavor a work with 
patients selected from Hospital Joaquim Urbano Unity of Centro Hospitalar do Porto, Porto, 
Portugal (HJUU/CHP) where these patients underwent medical care and from whom additional 
blood samples were analyzed at Life and Health Sciences Research Institute, School of Health 
Sciences, University of Minho (ICVS/ECS/UM). Part of the work developed culminated in this 
thesis. 
In Chapter 1, a general introduction is presented describing the state of art concerning 
both infection by HIV, and Treg. In the subchapter concerning infection by HIV, an overview is 
made on several aspects such as: the virus and its replication cycle; the natural history of the 
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infection covering transmission, pathogenesis and clinical spectrum; and the alteration of the 
natural history of the infection by highly active antiretroviral therapy (HAART) administration with 
the consequent immune reconstitution. Some considerations related to incomplete immune-
response that can arise despite efficacious antiretroviral therapy are also made in this 
subchapter. In the subchapter related to Treg, a revision of the theme is made trying to address 
several issues about these cells as where do they come from, how are they characterized and 
how do they work, and what is their role in infections and in particularly, HIV infection. 
In Chapter 2, results are presented in four subchapters: 
In the First subchapter, we explain how we gather a set of clinical, imaging, laboratory, 
and biologic data from HIV-1 infected patients; how patients were selected, what clinical and 
laboratorial data were collected from the hospital, and what supplementary analyses were made 
at ICVS/ECS/UM. Also a characterization of the study populations at baseline is showed in this 
subchapter. In this subchapter, the potentiality of such a set of data is also presented.  
The Second subchapter is composed of a paper, published in Plos One, entitled “Poor 
Immune Reconstitution in HIV-Infected Patients Associates with High Percentage of Regulatory 
CD4+ T Cells”. In a cross-sectional study, high Treg percentages were shown to be associated 
with sub-optimal CD4+ T cell recovery. This was particularly relevant for immunological non-
responders with low nadir values. This work suggested that the Treg proportion may be of clinical 
relevance to somehow predict the immunological reconstitution, at least in patients presenting 
low CD4+
The Third subchapter is presented in the form of article prepared for submission. In a 
longitudinal study performed to better knowledge the temporal order of events taking place in the 
immune reconstitution, we found that individuals, naïve for HAART, with lower CD4
 T cells nadirs at the HAART initiation. 
+ T cell counts, 
not only showed a higher Treg frequency median, but also a higher range of Treg frequencies, 
and both the Treg proportion and the range of those values decrease and tend to adjust to those 
of controls over time under HAART. Moreover, we found that individuals with higher Treg 
percentages at baseline have lower CD4+ T cell counts after 24 months of HAART. But, we also 
found that a higher Treg frequency at baseline was only an indirect predictor of a lower CD4+ T 
cell count at 24th month of antiretroviral therapy as that high Treg percentage was linked to a 
lower CD4+ T cell count at baseline. As the absolute increase in the CD4+ T cell counts and the 
reconstitution CD4+ T cell counts slope are constant and independent of CD4+ T cell counts at 
baseline, those patients with lower CD4+ T cell counts at baseline, show lower CD4+ T cell counts 
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constantly over time under therapy. Thus, the apparently negative impact of regulatory T cells in 
CD4+ T cells recovery (showed in the second subchapter) was not verified in a longitudinal study, 
being that apparent association explained by the existing linkage between low CD4+
In the Fourth subchapter, we present a clinical case report of a patient included in our 
database, which is strongly suggestive of a paradoxical toxoplasmosis-immune reconstitution 
inflammatory syndrome with the involvement of the spinal cord. The rarity, not only of the 
immune reconstitution inflammatory syndrome related with toxoplasmosis, but also the 
localization of the lesions (spinal cord), renders this presentation a case of particular interest.   
We investigated a linkage between this immune reconstitution inflammatory syndrome and the 
CD4
 T cell counts 
and high Treg percentages. Interesting alterations on the sub-populations of the Treg are shown 
and it is highlighted how low nadirs disturb the immune system at distinct levels. 
+ T Treg frequency on CD4+
Finally in the last and Third Chapter, the general discussion of the work developed, as 
well as the final remarks and conclusion are presented. 
 T cells, and Treg subsets dynamics over time before and after 
antiretroviral therapy onset. 
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1.1 Infection by the Human Immunodeficiency Virus (HIV) and the Acquired Immunodeficiency 
Syndrome (AIDS) 
 
1.1.1. Introduction 
 
Acquired Immunodeficiency Syndrome (AIDS) was first recognized in homosexual men in 
the summer of 1981, in the United States [1,2]. Shortly after, the disease was identified in male 
and female injection drug users; in hemophiliacs and blood transfusion recipients; among female 
sexual partners of men with AIDS; and among infants born to mothers with AIDS [3]. By 1983, it 
was demonstrated clearly that a virus, later named – the human immunodeficiency virus (HIV) – 
was the causative agent of this new acquired cellular immunodeficiency [4] that dramatically 
evolved to a global pandemic, with cases reported from virtually every country [5]. More than 
three decades after its recognition, an enormous amount of information in the areas of HIV 
virology, pathogenesis, treatment, and prevention has been flowed and continues expanding. 
 Although two types of HIV are currently recognized, HIV-1 and HIV-2, HIV-1 is responsible 
for the vast majority of cases. HIV-2 maintains a much more restricted geographical distribution, 
predominantly in West Africa nations, namely Republic of Guinea-Bissau, Gambia, Senegal, Cape 
Verde, Ivory Coast, Mali, Sierra Leone, and Nigeria. HIV-2 infection has also been reported in 
European countries, especially the ones with strong historical and socio-economic ties to West 
Africa as France and Portugal [6]. Compared with HIV-1 infection, asymptomatic infection is 
more common in HIV-2-infected individuals, blood virus loads tend to be lower, and transmission 
to partners or neonates is less frequent [7]. 
Globally, an estimated 35.3 (32.2–38.8) million of people were living with HIV in 2012. 
There were 2.3 (1.9–2.7) million new HIV infections globally, and the number of AIDS deaths 
was 1.6 (1.4–1.9) million in the same year. Since its discovery, AIDS has caused an estimated 
36 million deaths worldwide (prevision up to 2012) [5]. 
In Portugal, at the end of 2012, 42580 cases of HIV infection were reported cumulatively 
(1436 - 3,4% - corresponded to HIV-2 infection). In 2012, there were 776 new cases diagnosed 
(32 - 4,1% - of which were caused by HIV-2) and 139 AIDS-related deaths [6]. Porto was the 
second district of Portugal, the first being Lisbon, presented with the largest cumulative number 
of cases - 8637 (20.3%). Hereafter, HIV-1 will be only referred and designated as just HIV. 
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1.1.2. Infection by HIV 
 
1.1.2.1. The Main Characteristics of the HIV 
The HIV belongs to Lentivirus genus, Orthovirinae subfamily and Retroviridae family of 
virus [7,8,9]. The HIV is an enveloped roughly spherical virus that is 80 to 120 nm in diameter 
(Figure 1) and encloses a capsid containing two identical copies of the virus genome composed 
by positive-strand RNA. The virion contains several copies of viral enzymes as the reverse 
transcriptase, protease and integrase [7,8,9]. The genome of this virus consists of three major 
structural genes, and other additional genes (Figure 2). The three major structural genes, namely 
gag, pol and env, encode for structural and enzymatic proteins: gag encodes for the proteins that 
form the core of the virion (capsid – p24, nucleocapside – p7, matrix – p17, and nucleic acid-
binding proteins); pol encodes for the enzymes responsible for protease processing of viral 
proteins, reverse transcription, and integration (protease, reverse transcriptase, and integrase); 
and env encodes for the envelope glycoproteins (three pairs of gp120/gp41 forming a trimeric 
structure). Variations in the gene gag or env originate the different classes, subtypes or 
subsubtypes. The other genes, some of whose proteins are essential to regulate viral replication, 
are: tat, rev, nef, vif, vpr, and vpu. At each end of each of the RNA strands are long terminal 
repeat (LTR) sequences that contain promoters, enhancers, and other genetic sequences used 
for binding different cellular transcription factors [7,8,9]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Organization of the HIV virion (extracted from [10]). 
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Figure 2. Genomic organization of HIV: the typical three structural genes (gag, pol and env), the six accessory genes 
(tat, rev, vif, nef, vpr, and vpu) located mainly between the pol and env genes, and the long terminal repeat (LTR) 
located at each end of the RNA strand (extracted from [11]). 
 
There are four major classes of HIV [12]: M, N, O, and P. Among the virus from the M 
class, which account for more than 90% of HIV infection worldwide, nine subtypes (or clades) 
designated by the letters A-D, F-H, J, and K followed by the number correspondent to the six 
subsubtypes A1-A4 and F1-F2 became recognized. The infection of a cell by two or more viruses 
may generate recombinant forms designated by CRF (circulating recombinant forms – forms that 
give rise to new epidemic outbreaks) or URF (unique recombinant forms), both nominated by a 
number (indicating the discovery order) and letters (indicating the subtypes involved), for example 
CRF01_AE corresponding to the first CRF described that result from a recombination between A 
and E subtypes. When more than two subtypes are involved, the CRFs are designated as 
CRF_cpx (complex) [reviewed in 11]. The clade B, that accounts for only 12% of the infection 
worldwide, is de most common subtype in the Americas and Western Europe. The subtypes non-
B (A, C, D, F-H, J, and K) account for the great majority of the infections in the rest of the world 
being the subtype C the most prevalent (responsible for more than 50% of infections worldwide) 
[11]. As in the American continent, the majority of European isolates of HIV belongs to subtype 
B. However, several countries including Portugal, also reported appreciable numbers of infections 
by non-B subtypes, with particular relevance to the subtype G, C and CRF03-AB [11 and 
references therein]. 
 
1.1.2.2. The Replication Cycle of HIV 
The replication cycle of HIV (Figure 3) [7,8,9,11] begins with the high-affinity binding of 
the gp120 protein (a viral envelope external protein) to its privileged receptor on the host cell 
surface, the CD4 molecule. The CD4 is a protein expressed predominantly by a subset of T 
lymphocytes, the CD4+ T cells or helper T cells, but also expressed on the surface of 
monocytes/macrophages, microglia, follicular dendritic cells of lymphoid tissue, blood dendritic 
cells or their homologues as the Langerhans cells (in skin and mucosa). The binding of the virus 
HIV-1 
10 
 
to the CD4 on the cell surface triggers a conformational change in gp120 allowing the virus to 
bind to a co-receptor (CC chemokine receptor type 5 - CCR5 - or CXC chemokine receptor type 4 
- CXCR4) also expressed on the host cell surface. Following this initial step, the fusion domain of 
HIV gp41 envelope protein is exposed and the fusion of the virus envelope and cellular 
membrane occurs followed by the virus entrance into the target cell. The virus genome, released 
from the capsid, serves as a template to the synthesis of a complementary (the early phase of 
replication begins) negative-strand DNA with the participation of the viral reverse transcriptase 
(RNA-dependent DNA polymerase) and a transfer RNA (tRNA) as a primer. The reverse 
transcriptase is also responsible for the destruction of the template RNA and by the construction 
of the second complementary strand of DNA. A double-stranded DNA is then formed and 
transported into the nucleus (as a complementary DNA - cDNA). The cDNA or “the proviral DNA” 
is integrated into the host chromatin with the aid of the viral integrase enzyme that is also 
transported to the nucleus, thereafter behaving almost like a cellular gene. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Replication cycle of HIV with different sites of action of antiretroviral agents (extracted from [7]). 
 
Cellular activation plays an important role and is required in the efficient integration and 
to the initiation of the late phase of replication. This late phase begins when the proviral DNA is 
transcribed by the host RNA polymerase II, and is regulated by the interaction of host 
transcription factors with promoter and enhancer elements in the LTR portion of the viral 
genome. Both genomic RNA and several mRNA are then produced. The six accessory viral gene 
products, in concert with the cellular machinery, regulate the HIV replication in different stages. 
Newly generated HIV core proteins, enzymes, and genomic RNA assembly inside the cell, and 
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immature viral particles form and bud off from the cell, acquiring their envelope from the cell 
membrane. Yet, the core of the virus is still immature. Final morphogenesis of HIV requires 
protease cleavage of gag and gag-pol polypeptides that continues even after envelopment. 
Infectious viral particles are then ready to infect other cells [7,8,9,11].  
 
1.1.3. Natural History of the HIV Infection 
 
1.1.3.1. HIV Transmission 
The HIV pandemic is still in a dynamic phase in most parts of the world, with continuing 
geographic spread and changing epidemiologic patterns. As already noted, AIDS was initially 
described in young, promiscuous, homosexual men [1,2] and is still prevalent in the gay 
community. However, heterosexual transmission by vaginal intercourse and parenteral 
transmission by intravenous drug abuse (from sharing contaminated syringe needles) have 
become the major routes by which HIV is being spread. Therefore, it can be said that HIV is 
transmitted primarily by sexual contact (both anal and vaginal intercourse); by blood and blood 
products; and by infected mothers to infants intrapartum, perinatally, or via breast milk 
[7,8,9,11]. 
 In Portugal, by December 2012, the transmission category that cumulatively recorded 
the highest number of cases was the "heterosexual category", followed by "intravenous drug user 
category" and “homo/bisexual category” corresponding to, respectively, 44.6%, 38.7% and 
14.1% of total cases notified [6]. Sexual transmission was thus observed in the majority (58.7%) 
of reported cases [6]. The heterosexual transmission has assumed greater importance in recent 
years and in very recent years, an increase in the number of cases referring to homosexuals has 
also been noticed [6]. It is important to take into account that activities undertaken by the 
responsible entities for drug prevention had made impact over time, reducing the number of 
cases associated with intravenous drug use [6]. 
 
1.1.3.2. The Acute Retroviral Syndrome 
Following an exposure of a mucosal surface to HIV, the virus can cross the barrier by 
binding to dendritic or Langerhans cells, or through microscopic rents in the mucosa [8]. Viral 
replication has been shown to occur locally for virus infecting CD4+ T cells that although spatially 
dispersed and partially activated, may be present at lamina propria [8]. Regardless of the route of 
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HIV transmission (whether it occurs through a mucosa barrier, or by direct introduction of the 
virus into the bloodstream), the virus reaches, after about two days of infection, the regional 
lymphoid organs. It appears that dendritic or other cells of the monocyte-macrophage lineage 
play an important role in this process of HIV transportation through the blood [13]. In the 
lymphoid organs, HIV antigens are presented to CD4+
After an active replication in the regional lymph nodes, the spread of the virus throughout 
the body (to other lymph nodes, gastrointestinal tract, brain, liver, spleen) occurs, leading to a 
very high viremia and a significant decrease in the blood CD4
 T cells found in a dense concentration, 
triggering their activation and infection [7,8].  
+ T cell counts [7,8]. An important 
lymphoid organ, the gut-associated lymphoid tissue (GALT), is a major target of HIV infection due 
to its location and the local presence of a large number of CD4+
 
 T cells [8], and may be even the 
first lymphoid tissue to be reached by the virus, and to amplify the virus [13]. The acute retroviral 
syndrome (the early acute phase of the disease), which coincides with this high viremia, occurs 
two to three weeks after infection (in Figure 4 is shown the natural history of HIV infection) [14]. 
At this stage, various unspecific symptoms and signs, acute mononucleosis-like, may occur 
rendering the recognition of the disease possible in its earlier stage, although, most frequently 
not recognized. Common symptoms are fever, prostration, lymphadenopathy, sore throat and 
pharyngitis, erythematous maculopapular rash, arthralgia and myalgia, diarrhea, headache, 
meningeal syndrome and other neurological signs. Patients recover from this phase 
spontaneously and seroconvert (anti-HIV antibodies become detectable in the blood) [11]. 
Antibodies anti-HIV proteins become generally detectable three to six weeks after the 
development of plasma viremia [8]. 
1.1.3.3. The Chronic Asymptomatic or "Latency" Phase 
The development of a humoral and cellular immune response against HIV leads to the 
recovery of the first phase and to the progression to the second phase which is known as the 
chronic asymptomatic or "latency" phase [15,16]. This acquired immune response, although not 
fully effective, appears to have an important impact on the reduction of the plasma viremia to a 
“setpoint” level that is highly predictive of the later course of disease progression [17]. The 
humoral response consists on the production of antibodies against multiple antigens of HIV 
although the precise functional significance of these different antibodies is unclear. The anti-p24 
antibodies appear to contribute to the decline of viremia after acute infection, and the envelope 
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proteins, gp120 and gp41, are the only viral protein to elicit neutralizing antibodies. These 
neutralizing antibodies may be protective, neutralizing HIV directly, preventing the spread of 
infection to additional cells, or participating in antibody-dependent cellular cytotoxicity (ADCC). 
The cellular response is for the most part mediated by cytotoxic CD8+ T lymphocytes (CTLs). 
These CTLs, through their HIV-specific antigen receptors, bind to and cause the lytic destruction 
of HIV-infected cells bearing autologous major histocompatibility complex (MHC) class I 
molecules presenting HIV antigens. Other CD8+ T cells present the ability of inhibiting viral 
replication in a non-cytolytic manner, mediated by soluble factors called CD8 antiviric factors 
[11]. HIV-specific CD4+ T cells are very important in the orchestration of the immune response to 
HIV by providing help to HIV-specific B cells and CD8+
 
 T cells [8,11]. In addition to T-cell 
mediated immunity and ADCC, that involves the killing of HIV-expressing cells by Natural Killer 
cells (NK) armed with specific antibodies directed against HIV antigens, also, NK cells alone have 
been shown to kill HIV-infected target cells in tissue cultures [8,11]. 
 
 
 
 
 
 
 
 
Figure – Natural history of the infection by HIV. 
 
 
 
The immune response is responsible for infection control for several years (on average 7 
to 10 years) [8,11,14]. During this stage, the HIV viral load in the blood remains low, but even 
during this phase, there is a solid and intense virus replication in the lymph nodes [18]. As the 
immune system, at this phase, is able to replenish the number of CD4+ T cells that are being 
destroyed, the number, after the initial recovery, appears to be stable, or slowly decreasing. 
Thus, this phase, although clinically latent, is not virologically latent. The patients may still show 
Figure 4. Natural history of HIV infection (extracted from [14]). 
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nonspecific symptoms such as persistent fever, malaise, weight loss or lymphadenopathy 
[reviewed in 11]. 
HIV, however, is able to elude the immune response through various mechanisms 
[reviewed in 8,11,13], namely: 1) the sustained level of replication leads to viral diversity, via 
mutation or recombination, and consequently, to epitope mutation and evasion of control from 
CTLs and from neutralizing antibodies; 2) apart from epitope mutation, also the glycosylation of 
the envelope or conformational masking of neutralizing epitopes contribute to evasion from 
specific neutralizing antibodies; 3) the production of proteins from tat and nef genes can change 
class I MHC molecules that lose their ability to present HIV epitopes rendering the cytotoxic CD8+ 
T cells less able to recognize HIV-infected cells; 4) the down regulation of MHC-II molecules that 
renders CD4+ T cells less able to effectively participate in the immune response; 5) the 
exhaustion, dysfunction and death of immune cells that render the immune response weaker; 
and finally, 6) the presence of infected cells that are not recognize as infected by the immune 
system, due to their state of latency (not expressing antigens) or to their sequestration in 
immunologically privileged sites such as the central nervous system, contribute to viral 
persistence. All these mechanisms lead to the gradual increase of the HIV viral load and the 
steady reduction in the number of CD4+
 
 T cells with the consequent reduction of cellular 
immunity and the gradual evolution to the next and final stage of the disease. 
1.1.3.4. Mechanisms Responsible for the Reduction of CD4+
There is considerable controversy regarding the relative contribution of the diverse 
mechanisms responsible for the reduction of the CD4
 T Cells Numbers in HIV-
Infected Patients 
+
Reduction of the CD4
 T cells during the course of HIV infection 
that occur through increased destruction, decreased production, and redistribution [reviewed in 
8,13,19,20]. 
+ T cells numbers results in part from the direct effects of infection 
of CD4+ T cells through several mechanisms [reviewed in 19] like: the disruption of the plasma 
membrane owing to the continuous budding of the virions or due to the enhanced permeability 
induced by viral vpu; increased cellular toxicity by the accumulation of nonintegrated viral DNA; 
the alteration by HIV of the normal cellular balance of pro- versus anti-apoptotic proteins resulting 
in the disruption of mitochondrial function and death of the cell; and the short lifespan of giant 
multinucleated cell called syncytium (formed by membrane fusion between infected cells that 
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express gp120 and the CD4 molecule expressed on the surface of all CD4+ T cells). Apart from 
the cytopathic effects of HIV, CD4+ T cells infected by HIV are also directly killed by HIV-specific 
cytotoxic CD8+
The infection of CD4
 T cells, by ADCC, or directly by NK as referred above [8,13,19,20]. 
+ T cells, however, does not appear to be sufficient to explain the 
progressive loss of CD4+ T cells which occurs over the course of HIV disease. In fact, the number 
of apoptotic cells in infected individuals greatly exceeds the number of HIV-infected cells 
indicating that uninfected cells are also killed by bystander indirect detrimental effects of HIV 
infection [8,13,19,20]. Uninfected cells may be eliminated primarily by [reviewed in 8,13,19,20] 
Fas-mediated or TNF-inducing ligand mediated apoptosis; due to the down-regulation of anti-
apoptotic proteins; or as a result of apoptosis stimulated by HIV proteins (such as gp120, tat, nef 
and vpu) released from infected cells [19]. An increased proliferation/turnover as well as death of 
CD4+ T cells is observed [21]. The excessive immune activation consistently observed seems to 
be a major determinant of this scenario [13,19,20,22-25]. Indeed, it is now accepted worldwide 
that the constant stimulation of the immune system plays a pivotal role in the progression from 
HIV infection to AIDS [22]. This activation of the innate and adaptive immune system leads to the 
release of pro-inflammatory mediators (namely TNF, IL-1β, and IL-6) which drives persistent 
inflammation [26]. This induced activation inflammatory condition, in addition of driving CD4+ T 
cell depletion, as already mentioned, may be responsible for the premature age-associated 
changes in the immune system (immunosenescence) demonstrated in HIV-infected patients (as 
many of the abnormalities in T cells observed in older adults are similar to those observed in 
untreated HIV-infected individuals), and for a number of co-morbidities non-AIDS related (to be 
referred later in this chapter) [26,27]. Several mechanisms may drive this immune activation 
such as [reviewed in 26,28]: ongoing HIV replication, microbial bioproducts translocation, mostly 
from the gut, like lipopolysacharide (as a great proportion of the CD4+
In addition to the increased destruction of CD4
 T cells pool in the GALT is 
depleted early in the infection course rendering the immune barrier leaky); increased viral load of 
co-infecting pathogens (CMV, other herpesvirus, and hepatitis virus), disregulation of regulatory T 
cells and other immunoregulatory cells, or lymphopenia per se [28]. 
+ T cells, a decreased production of these 
cells due to the disruption of normal hematopoiesis in the bone marrow and impaired thymus 
function (owing to several mechanisms) seems also to occur in a great proportion of patients 
during HIV infection [8,29]. 
16 
 
The redistribution caused by trafficking of CD4+ T cells from the peripheral blood to 
lymphoid tissue or inflammatory extra-lymphoid tissues could, in addition, account as an 
additional mechanism for CD4+
It is important to refer that the deleterious effects and immune dysfunction due to HIV 
infection are extended to several other cells of the immune system like CD8
 T cell peripheral blood depletion in HIV-infected patients [21]. 
+
 
 T, NK, B, 
nonlymphoid cells like macrophages and dendritic cells [20]. 
1.1.3.5. The Stage of Immunodeficiency or AIDS 
The gradual imbalance that occurs in the immune response, mainly in cell-mediated 
immunity leads early to the occurrence of infections that do not endanger the patient's life [those 
former designed by the Center for Disease Control and Prevention (CDC) as type B clinical 
category] [30], and later, to major life threatening infections/conditions that mark the transition 
of the disease to the final stage - the stage of immunodeficiency or AIDS. This phase results, if 
antiretroviral therapy is not administered, in the death of the individual in about one to three 
years, due to the appearance of several opportunistic infections and tumors. This stage occurs 
essentially when the CD4+ T cell counts in the blood are below 200 cells/mm3 (Table 1 shows the 
correlation of HIV-related complications occurrence with the CD4+
To improve standardization and comparability of surveillance data regarding people at all 
stages of HIV disease, the CDC proposed a classification system for adolescents and adults 
infected by HIV that was updated in 2008 [32]. This ranking is based on the number of CD4
 T cell counts) [31].  
+ T 
cells per mm3
As mentioned before, other clinical conditions (non-AIDS-defining complications), in 
addition to opportunistic infections and tumors (AIDS-defining complications), occur and 
contribute to morbidity and mortality seen in these patients. These non-AIDS co-morbidities, 
many of which are similar to those observed among the elderly, include cancer, heart, liver, 
kidney and bone disease, frailty, and neurocognitive decline, and provide indirect evidence that 
HIV infection might accelerate the aging process [26].  
 of blood (or their percentage in the total blood lymphocytes) and the clinical history 
of the patient as described in Table 2 [32]. 
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CD4+
counts 
 T cell 
(cells/mm3
Infectious 
) 
Complications 
Noninfectious 
Complications 
> 500 
- Acute retroviral syndrome 
- Candidal vaginitis 
- Persistent generalized  
  lymphadenopathy (PGL) 
- Guillain-Barré syndrome 
- Myopathy 
- Aseptic meningitis 
200 – 500 
- Pneumococcal and other bacterial  
   pneumonia 
- Pulmonary tuberculosis  
- Herpes zoster 
- Oropharingeal candidiasis  
- Cryptosporidiosis self-limited 
- Kaposi’s sarcoma  
- Oral hairy leukoplakia  
- Cervical and anal dysplasia  
- Cervical and anal cancer 
- B-cell lymphoma 
- Anemia 
- Mononeuronal multiplex 
- Idiopathic thrombocytopenic purpura   
- Hodgkin lymphoma 
- Lymphocytic interstitial pneumonia 
< 200 
- Pneumocystis pneumonia  
 -Disseminated histoplasmosis and 
  coccidioidomycosis 
- Miliary/extrapulmonary tuberculosis   
- Progressive multifocal   
  Leukoencephalopathy (LMP) 
- Wasting 
- Peripheral neuropathy  
- HIV-associated dementia 
- Cardiomyopathy 
- Vacuolar myelopathy  
- Progressive polyradiculopathy  
- Non-Hodgkin’s  lymphoma  
< 100 
- Disseminated herpes simplex  
- Toxoplasmosis 
- Cryptococcosis 
- Cryptosporidiosis (chronic) 
- Microsporidiosis 
- Candidal esophagitis 
 
< 50 
- Disseminated cytomegalovirus (CMV)  
- Disseminated  Mycobacterium 
  avium complex (MAC)     
- Primary central nervous system  
   lymphoma (PCNSL) 
 
Table 1. Correlation of complications with CD4+
 
 cell counts (adapted from [31]); some conditions listed as 
“noninfectious” are associated with transmissible microbes as lymphoma – Epstein-Barr virus and cervical and anal 
cancers – human papillomavirus). 
Stage 
CD4+
cells/mm
 T cell counts 
(% of total lymphocytes) 
3 Clinical 
1 ≥ 500 (≥ 29%) No AIDS-defining conditions 
2 200-499 (14 - 28%) No AIDS-defining conditions 
3 < 200 (< 14%) 
Or documentation of AIDS-
defining conditions 
Unknown No information No information 
 
Table 2. Surveillance case definition for HIV infection among adults and adolescents (aged ≥ 13 years); 
(adapted from [32]). Individuals classified in the shaded area meet the criteria for AIDS. AIDS-defining conditions: 
Candidiasis of bronchi, trachea, or lungs; Candidiasis of esophagus; Cervical cancer, invasive; Coccidioidomycosis, 
disseminated or extrapulmonary; Cryptococcosis, extrapulmonary; Cryptosporidiosis, chronic intestinal (>1 month's 
duration); Cytomegalovirus disease (other than liver, spleen, or nodes); Cytomegalovirus retinitis (with loss of vision); 
encephalopathy HIV related; Herpes simplex: chronic ulcers (>1 month's duration) or bronchitis, pneumonitis, or 
esophagitis; Histoplasmosis, disseminated or extrapulmonary; Isosporiasis, chronic intestinal (>1 month's duration); 
Kaposi sarcoma; Lymphoma, Burkitt (or equivalent term); Lymphoma, immunoblastic (or equivalent term); 
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Lymphoma primary of brain, Mycobacterium avium complex or Mycobacterium kansasii, disseminated or 
extrapulmonary; Mycobacterium tuberculosis  of any site, pulmonary, disseminated,  or extrapulmonary; 
Mycobacterium, other species or unidentified species, disseminated or extrapulmonary; 
Pneumocystis jirovecii pneumonia; Pneumonia recurrent; Progressive multifocal leukoencephalopathy; 
Salmonella septicemia, recurrent; Toxoplasmosis of brain; Wasting syndrome attributed to HIV. 
 
1.1.4. Alteration of the Natural History of the HIV Infection 
 
1.1.4.1. Highly Active Antiretroviral Therapy (HAART) 
The emergence and administration of drugs with potent antiretroviral activity, and their 
use in combination (highly active antiretroviral therapy or HAART) to treat patients with HIV 
infection started in 1996 and markedly reduced the morbidity and mortality associated with this 
disease.  
An effective HAART (the drugs used in such combinations block several steps of the virus 
replication cycle as shown in Figure 3) is the therapy that conducts to a suppression of the viral 
load (undetectable viral load in the blood considering the detection limit of commercially available 
tests). Sustained viral load suppression leads for most patients to the restoration of CD4+
In the early times of HAART, regardless of all its related advantages, patients faced 
complex drug regimens, involving multiple drugs with a variety of administration schedules, high 
pill burden and troublesome side effects like gastrointestinal symptoms, lipoatrophy, visceral and 
abdominal fat gain, insulin resistance, DNA damage, or mitochondrial dysfunction. It was, in 
those times, difficult to maintain the high levels of adherence to therapy, necessary in order to 
prevent the development of HIV genetic mutations conferring drug-resistant. Since then, huge 
developments occurred: the design of highly potent drugs; new classes of drugs acting in 
different steps of the virus replicating cycle; drugs presenting a better safety profile; drugs with 
longer half-lives allowing once-daily dosing; and the availability of fixed-dose drug combinations 
[33]. It is now simple to define effective and potent, safe, tolerable, and easy-to-take therapeutic 
schemes allowing long-term suppression of HIV replication. 
 T cell 
compartment.  
The development of laboratory techniques that have been useful to: monitor HIV 
replication; detect HIV drug resistance; diagnose early and consequently to prevent and/or to 
treat opportunistic infections more effectively, also contributed to the decline in morbidity and 
mortality of HIV-infected individuals. HIV infection, considered in the beginning a rapidly fatal 
disease, is now considered a chronic disease easy to stabilize, at least, when the patients are 
diagnosed early, where the therapy, laboratory support and health care are available, and most 
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importantly when patients adhere to treatment. However, one must not forget that, even in face 
of sustained undetectable viral loads, there are local "sanctuaries"/reservoirs in the body (central 
nervous system, lymphoid tissue, genital organs) with infected but quiescent non productive of 
new virus CD4+
The ideal moment to start HAART for each patient has long been a subject of intense 
debate. The aim of antiretroviral treatment is not only to prevent CD4
 T cells. These reservoirs, somehow protected from HAART, are places where 
transitory replication and viral persistence are possible, allowing the occurrence of viral 
mutations, contributing to the maintenance of an abnormal level of immune activation, and being 
the most important impediment to achieve complete eradication of the virus in infected patients, 
even if they are maintained many years under HAART.  
+
In the light of the treatment options currently available, the main scientific societies in the 
area of HIV [34-36] (European AIDS Clinical Society - EACS, International AIDS Society - IAS, 
United States Department of Health and Human Services - USDHHS) have their own 
recommendations for the initiation of antiretroviral therapy to naive patients. Portugal, also edited 
its own recommendations [37]. The proposed time to start, and initial regimens recommended 
by each society and by the Portuguese panel are presented in Table 3 [34-37]. 
 T cells depletion and 
preserve its production by suppressing viral replication, but also to reduce the immune activation 
and persistent inflammation counteracting the immunosenescence and multi-co-morbidities non-
AIDS related. Taking this into account, and the existence of safer and comfortable drug schemes, 
it has been proposed that HAART should be initiated earlier and earlier in the course of the 
infection [34-36]. However, therapeutic regimen should only be initiated provided that the patient 
is perfectly elucidated and motivated to adhere to HAART. 
When the therapy is initiated at a late stage of the disease, it should be taken into 
account the possibility that, in the first months and due to immune reconstitution, certain 
infections, which might have remained silently undiagnosed due to the inactivity of the immune 
system, or have already been diagnosed and begun to be treated, became symptomatic, or get 
worse, as the reconstituting immune system might strongly react to these pathogens or antigens 
[38]. Drug interactions between HAART and other treatments/prophylaxis of opportunistic 
infections should also be the subject of our attention. The medication intolerance and toxicity 
seem to occur more often when HAART is initiated in more advanced stages of the disease. Even 
in this situation, when patients are motivated and adherent to the medication, the immune 
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reconstitution has been possible, allowing the subsequently discontinuation of primary or 
secondary opportunistic infections prophylaxis, clear improving their survival and quality of life. 
European AIDS Clinical Society [34] International AIDS Society [35] 
United States Department of Health and Human 
Services [36] 
Ideal time to start 
HAART is always recommended in 
any HIV-positive person with a  
current CD4+
below 350 cells/ mm
 T cell count 
3
For persons with CD4
.  
+
requesting HAART and is ready to 
start, has symptomatic HIV disease 
or various types of (co-morbid) 
conditions. 
 T cell counts 
above this level, the decision to start 
HAART should be individualized and 
considered, especially if a person is  
HAART is recommended 
for all adults with HIV infection, regardless of 
CD4+
The strength of the recommendation* increases 
as CD4
 T cell counts. 
+
CD4
 T cell count decreases and in the 
presence of certain conditions, with the 
following ratings: 
+ T cell count ≤500 cells/mm3
CD4
 (AIa); 
+ T cell count >500 cells/mm3
Pregnancy: AIa 
 (BIII). 
Chronic hepatitis B virus: AIIa 
HIV-associated nephropathy: AIIa 
Acute phase of HIV infection: BIII  
HAART is recommended 
for all HIV-infected individuals 
to reduce the risk of disease progression. 
The strength and evidence for this recommendation* 
vary by pretreatment CD4+
CD4
 T cell count: 
+ T cell count <350 cells/mm3
CD4
 (AI); 
+ T cell count 350–500 cells/mm3
CD4
 (AII); 
+ T cell count >500 cells/mm3
HAART also is recommended for HIV-infected 
individuals for the prevention of transmission of HIV. 
The strength and evidence for this recommendation 
vary by transmission risks: perinatal transmission 
(AI); heterosexual transmission (AI); 
 (BIII). 
other transmission risk groups (AIII). 
Preferential regimens 
Rregimens with optimal and durable efficacy, favorable tolerability and toxicity profile, and ease of use. 
A combination of one NNRTI or a 
ritonavir-boosted PI or an ITI 
and two NRTI 
NRTI: ABC/3TC (use with caution if 
HIV RNA>100000 c/ml ), FTC/TDF 
NNRTI: EFV,  
RPV (if HIV RNA<100000 c/ml) 
Ritonavir-boosted PI: 
ATV/r, DRV/r 
INSTI: RAL, 
EVG + cobi (+ FTC/TDF)  
(co-formulated) 
NNRTI-based regimen:  
EFV/FTC/TDF; EFV + ABC/3TC; 
RPV/FTC/TDF (if HIV RNA<100000 c/ml) 
PI-based regimens: 
ATV/r + FTC/TDF; ATV/r + ABC/3TC; 
DRV/r + FTC/TDF  
INSTI-based regimen: 
DTG + TDF/FTC, DTG + ABC/3TC, 
EVG/cobi/TDF/FTC, RAL + FTC/TDF 
(the combination ABC/3TC was less efficacious 
with HIV RNA>100000 c/ml than TDF/FTC 
when given with EFV or ATZ/r) 
NNRTI-based regimen: EFV/FTC/TDF 
PI-based regimens: 
ATV/r + FTC/TDF 
DRV/r (once daily) + FTC/TDF 
INSTI-based regimen: DTG + ABC/3TC, DTG + 
TDF/FTC, EVG/cobi/TDF/FTC, RAL + FTC/TDF, 
Also recommended if HIV RNA<100000 c/ml: 
EFV + ABC/3TC; RPV/FTC/TDF (if CD4>200/mm3
ATV/r + ABC/3TC 
) 
Preferred regimen for pregnant women: 
ATV/r or LPV/r (twice daily) 
+ ABC/3TC or TDF/FTC or ZDV/3TC  
Alternative regimens 
Regimens that are effective and tolerable but have potential disadvantages compared with preferred regimens. 
An alternative regimen may be the preferred regimen for some patients.  
Alternative regimen components: 
NRTI: TDF + 3TC, ZDV/3TC,  
ddl + 3TC or ddl + FTC 
NNRTI: NVP 
Ritonavir-boosted PI: 
FPV/r, LPV/r, SQV/r  
CCR5 inhibitor: MVC 
NNRTI-based regimen: 
NVP + FTC/TDF; NVP + ABC/3TC 
RPV + ABC/3TC 
PI-based regimens: 
ATZ/cobi + 2 NRTIs, DRV/cobi + 2 NRTIs 
DRV/r + ABC/3TC, LPV + 2 NRTIs 
INSTI-based regimen: 
RAL + ABC/3TC 
NRTIs limiting or sparing:                        
DRV/r + RAL, LPV/r + 3TC, LPV/r + RAL 
PI-based regimens: 
DRV/r + ABC/3TC 
LPV/r + ABC/3TC or FTC/TDF 
(LPV/r once or twice daily) 
INSTI-based regimen: 
RAL+ABC/3TC 
Beware of remarks and precautions to consider of components and combinations 
(pregnancy; cardiovascular risk; allele of major histocompatibility complex, class I,B - HLA B*5701; use of proton pump inhibitors). 
Fixed-dose combinations when possible for patient convenience. 
 
Portuguese recomendations37 
Ideal time to start 
The start of HAART should be individualized and the decision upheld by the following elements: clinical manifestations, number of CD4+ 
The HAART is recommended for all patients with chronic HIV-1 infection with a CD4
T 
lymphocytes, plasma viral load value, presence of co-morbidities (AII) and the patient's level of preparedness. 
+ T lymphocytes <350 cells/mm3
For persons with CD4
 (AI). 
+
(These recommendations are presently under revision – in the next publication HAART will be recommended for CD4
 T cell counts above this level, the decision to start HAART should be individualized and considered, especially if a person 
has symptomatic HIV disease or various types of (co-morbid) conditions, or for the prevention of transmission. 
+ T cells ≤500/ mm3) 
Preferential regimens 
A combination of one NNRTI or a ritonavir-boosted PI or an ITI and two NRTI 
NRTI: ABC/3TC, FTC/TDF; NNRTI: EFV, NVP; Ritonavir-boosted PI: ATV/r, DRV/r; INSTI: RAL 
When NVP or RAL are used, they may be combined with FTC/TDF 
(the next update will recommend also RPV as another NNRTI) 
Alternative regimens 
NRTI: ZDV/3TC; NNRTI: RPV; Ritonavir-boosted PI: FPV/r, LPV/r, SQV/r ; CCR5 inhibitor: MVC 
(the next update will recommend also EVG/cobi as alternative INSTI) 
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Table 3. Ideal time to start, and initial recommended and alternative regimens in antiretroviral-naïve patients, 
according to main AIDS societies and Portuguese panel. Adapted from [34-37]. *Definitions for rating/strength of 
recommendations and the rating/quality evidence: A = Strong; B = Moderate; C = Optional/Limited. Rating of 
Evidence: Ia – Evidence from ≥1 randomized clinical trial (RCT) published in the peer-reviewed literature; Ib - 
Evidence from ≥1 RCTs presented in abstract form at peer -reviewed scientific meetings; IIa – Evidence from non-
RCTs, cohort, or case-control studies published in the peer-reviewed literature; IIb - Evidence from non-RCTs, cohort, 
or case-control studies presented in abstract form at peer-reviewed scientific meetings; III – Recommendation based 
on the panel’s analysis of the accumulated available evidence (IAS panel); and I = Data from randomized controlled 
trials; II = Data from well-designed nonrandomized trials or observational cohort studies with long-term clinical 
outcomes; III = Expert opinion (DHHS panel). NNRTI – non-nucleoside reverse transcriptase inhibitor, NRTI – 
nucleoside (or nucleotide) analogue reverse transcriptase inhibitors, PI – protease inhibitor, INSTI – integrase strand 
transfer inhibitor, CCR5 – CC chemokine receptor 5 inhibitor. ABC – abacavir (only for patients who are HLA-B*5701 
negative), ATV – atazanavir, cobi – cobicistat, ddl –didanosine, DRV – darunavir, DTG – dolutegravir, EFV – 
efavirenz, EVG – elvitegravir, FPV – fosamprenavir, FTC – emtricitabine, LPV – lopinavir, MVC – maraviroc, NVP – 
nevirapine, RAL – raltegravir, RPV – Rilpivirine, SQV – saquinavir, TDF – tenofovir disoproxil fumarate, ZDV – 
zidovudine, 3TC – lamivudine, /r – ritonavir-booster 
 
 
1.1.4.2. Immune Reconstitution 
Under effective HAART, one assists, not only to the redistribution of memory T cells, but 
also to the expansion of naïve T cells. The CD4+ T cells restoration takes place during various 
phases [reviewed in 28,39,40] [Figure 5]. The initial phase of blood CD4+ T cell increment tends 
to be steeper than in other phases, and occurs in the first six months under HAART. This CD4+ T 
cells rise is thought to be mostly due to the liberation of memory CD4+ T cells from lymphoid 
tissues where sequestered (the inhibition of the viral replication leads to a decrease in the 
immune activation which in turn, drives the down-regulation of adhesion molecules and the 
liberation of those cells). Two other phases of CD4+ T cell restoration have been defined; the 
second lasts for most patients up to the end of the second or third year after HAART onset and 
the third phase may last until seven or more years after HAART initiation, when a CD4+ T cells 
plateau is reached. [39] [Figure 5]. Although the mechanisms involved in immune reconstitution 
in the second and third phases are related, the speed of the immune restoration differs between 
them [Figure 5]; it is quicker in the second (although slower than in the first) than in the third 
phase. The mechanisms involved in CD4+ T cell restoration in the second and third phases are: 
increase of thymic output; the decrease of the abnormal rate of cell death allowing the extension 
of CD4+ T cell half life (the reduction in chronic activation leads to a decreased sensitivity to 
apoptosis); and proliferation of the residual CD4+ T cells (by homeostatic peripheral proliferation 
or residual immune activation). Only the first mechanism allows the restitution of the T cell 
repertoire diversity [40]. As less naïve CD4+ T cells are converting to memory cells, a passive 
accumulation of those cells occurs in the periphery after HAART initiation also contributing to the 
immune reconstitution [40].  
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Several studies have analyzed the immune reconstitution in patient groups with 
sustained viral suppression under HAART aiming to discover if this was a limited process in time 
and what are the circumstances that may have hampered T cell reconstitution. The majority of 
studies show a plateau in CD4+ T cell recovery, in most patients, after 3 to 7 years of complete 
virological response under HAART, even if the CD4+ T cell counts are still low [40-45]. Even if 
some patients still have an increase in CD4+ T cells after that period of time, this increase 
appears to be insufficient for patients that initiate HAART at a very low CD4+ T cell counts to 
reach normal (700-1100 cells/mm3) or near normal (>500 cells/mm3) CD4+ T cell values [41-
45]. Others, however, reported continuous reconstitution of these cells after several years of 
HAART (even upon 10 years of HAART [46]) rendering possible that those normal or near normal 
values are reached for most patients despite low CD4+ T cells nadirs [46-49]. Nevertheless, in 
most patients, the CD4+ T cell counts slope as the absolute increase in the CD4+ T cell counts 
seems to be independent of the severity of the immune alterations present before HAART 
introduction. Therefore, the time taken to reach normal CD4+
 
 T cells depends to a great extent on 
the stage of the disease when HAART was initiated [41,47,49,50].  
 
 
 
 
 
 
 
 
 
1.1.4.3. Patients with Incomplete Immune Reconstitution 
A proportion of HIV-infected patients under HAART, and being virological suppressed 
during several years (4 - 7 years), do not reach normal (700-1100 cells/mm3), near normal (> 
500 cells/mm3) or, at least, satisfactory CD4+ T cell counts (higher than 250-350 cells/mm3, a 
level that would enable the patient to be protected from the more severe opportunistic infections), 
and therefore are more prone to suffer from AIDS-related and non-AIDS-related complications and 
death [36,41-45,51-53]. These patients (the proportion ranges between 15-40% depending on 
Figure 5. Kinetics and mechanisms of immune reconstitution of CD4+ T lymphocyte 
compartment after starting HAART (extracted from [40]). 
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the study) are referred to as immunological discordant or incomplete responders, although there 
is no agreement on the definition of immunological response failure and several definitions are 
used in several reports [reviewed in 54]. For example, a reasonable definition taking into account 
a shorter period of time under successfully HAART, could be a rise in CD4+ T cells lower than 
100 cells/mm3 after two years of treatment (i.e. less than half of the expected recovery) [28]. The 
failure in the immune recovery can be explained by insufficient production or by excessive 
destruction of CD4+
1. The irreversible damage (fibrosis) caused by HIV infection of lymphoid organs might lead 
to the failure of the bone marrow to produce hematopoietic stem cell precursors for 
different lineages of blood cells (including the lymphoid progenitor cells), and to an 
impaired thymic function (resulting in a deficient new T cells differentiation and export to 
the periphery). Moreover, local fibrosis in lymph nodes and GALT may alter survival and 
proliferation of CD4
 T cells due to several, multiple, concomitant, and overlapping conditions 
[41,42,47,52,55,56, reviewed in 28,51,54]: 
+
2. An advanced age is linked to a reduced thymus output, to a higher immune activation, 
and to age-associated changes in the immune system (immunosenescence); 
 T cells; 
3. The HIV infection seems to accelerate the aging process causing immunosenescence 
that could be in part irreversible and contribute to immune activation; 
4. Men have been shown to present lower thymus output than female; this has been 
associated to the anti-apoptotic effect of female sex steroids;  
5. Residual viral replication may occur in some cells of some apparently virological 
suppressed patients accounting for ongoing cytopathogenicity of the virus and immune 
activation; 
6. Presence of more cytopathogenic virus as those that use CXCR4 as a co-receptor; 
7. Some antiretroviral agents like zidovudine, that is toxic for haematopoietic progenitor 
cells, have been associated with worse reconstitution; on the contrary, some 
antiretroviral agents like raltegravir and the CCR5 antagonist maraviroc have been linked 
to a favorable recovery (the high accessibility of raltegravir to anatomic compartments 
could efficiently inhibit the residual HIV replication [57] and perhaps maraviroc, due to 
the fact that CCR5 is now recognized as a co-activation molecule, could decrease 
immune activation, though the beneficial role of maraviroc was not verified by all [58]); 
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8. Although T cell activation declines with virologic suppression, it is not abolished and may 
persist elevated in some patients continuing to drive apoptosis; 
9. Enhanced T cell activation and trapping in secondary lymphoid organs (due to high-
expression of adhesion molecules) has been reported; 
10. Some genetic polymorphisms account to an increased susceptibility to activation or 
apoptosis, or to an increased production of pro-inflammatory cytokines; 
11. Relative deficiency in interleukin (IL) -7 (a key cytokine with a positive effect on 
thymopoiesis, a survival factor for CD4+ and CD8+ T cells, and promoting homeostatic 
proliferation of peripheral T cells in lymphopenic conditions) production or function, or 
reduction in IL-7 receptor expression on CD4+ T cells (administration of recombinant 
human (rh) IL-7 to human has been promising in preclinical trials with increases in CD4+
12. Microbial translocation due to a leaker immune barrier may be one of the drivers of 
immune activation; 
 
T cell counts only after a short duration of treatment [59]); 
13. Co-infections by hepatitis C virus (HCV), cytomegalovirus, other herpesvirus, or even by 
Mycobacterium avium complex, could account for an increased immune activation. 
 
A low CD4+
The role of regulatory T cells (Treg) in immune restoration has been debated and while 
some authors refer to them as beneficial, as they diminish immune activation [60], others, 
however, report a harmful role of those cells [53,56,61] perhaps due to the fact that they impair 
specific anti-HIV immune response (via both indirect, by secreting immunosuppressive cytokines, 
and direct, by driving apoptosis of immune cells), they inhibit lymphopenia-induced proliferation 
[61,62], they may drive a more intense microbial translocation (their increase in mucosal barrier 
hampers the Th17 response against several microbes) [63,64] or they may account for 
exacerbated fibrosis of lymphoid tissues prejudicing immune reconstitution (by increasing levels 
of TGF-β1 and hence exacerbating collagen deposition) [65]. 
 T cell count at the therapy onset has consistently been shown to be a good 
predictor for an immunological non-response as in these situations, several of the above 
mentioned conditions are present, among others. An advanced stage of the disease may cause a 
more advanced fibrosis of lymphoid organs, a more intense microbial translocation, the 
development of other co-infections, a more advanced immunosenescence, the emergence of 
more aggressive X4 strains, and therefore, a more intense immune activation. 
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Advances made until present-day in the HIV field are a result of science, advocacy, 
political commitment, and effective partnerships with affected communities. Recently, the report 
of cases of sterilizing cure (elimination of all HIV-infected cells as it occurred in the Berlin patient) 
[66], functional cure (long-term control of HIV replication after HAART suspension as it seemed to 
be achieved in the Mississippi baby [67] or in 14 patients in the VISCONTI cohort [68]), and 
other cases of sustained reduction in HIV-reservoirs [69], had revived the hopefulness in a future 
free of AIDS. Several HIV-cure-related trials are being performed worldwide and although one is in 
the commencement, many now believe there may be a step forward in discovering a cure. The 
optimism persists despite the recently disappointing turn of events for the Mississippi baby (the 
child was found to have detectable HIV levels in the blood during a routine clinical care visit on 
July 2014). 
Until a cure is achieved, clinicians have to diagnose early and establish the most 
appropriate antiretroviral treatment for each patient and observed them clinically and analytically 
for a sustained viral suppression and consequently, a good immune recovery is reached, 
minimizing as much as possible what can hinder this recovery. It is worthwhile to mention that 
effective antiretroviral therapy, although allowing immune recovery, preventing AIDS-related 
complications, and prolonging half-life with better quality of life, it does not fully restore health. As 
mentioned above, immunosenescence, residual persistent immune activation/inflammation, and 
also, some HAART toxicity and prevalence of traditional behavior risk factors (as tobacco or 
intravenous drug use per example), account for a number of non-AIDS-related co-morbidities 
[26].  
Patients should then be encouraged to maintain a proper medication adherence and a 
healthy life in an attempt to prevent the onset of co-morbid conditions which if appear, should be 
promptly diagnosed and treated. Another major challenge is to maintain access to and funding 
for lifelong HAART to the more than 35 million of people with HIV infection worldwide. Efforts 
must be done to reach that aim at manageable costs to health systems.  
Since the incomplete immune recovery under effective long-standing HAART carries long-
term risks of disease progression and death, and there are no efficient therapeutic strategies 
currently in these situations, is of vital importance to find solutions. Scientists, apart from trying 
to discover a sterilizing or at least, a functional cure, have to investigate the immune-virological 
pathways behind insufficient immune recovery providing tools to anticipate it, and/or novel 
therapeutic strategies to treat it. One of the possible pathways involved and still insufficiently 
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explored is one that concerns the Treg. If further research in this field namely functional and 
longitudinal analyses of Treg in HIV infection, will demonstrate a well defined and sustained role 
of this CD4+
 
 T cell subset, immunotherapeutic manipulation or intervention involving Treg-cell 
number and/or function [70] could be attempted in HIV-infected patients already under 
treatment aiming to improve immune restoration. In the next session the role of Treg on HIV-
infection and immune restoration will be detailed.  
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1.2. Human Regulatory CD4+
 
 T Cells (Treg) 
1.2.1. Introduction 
 
One of the supreme tasks of our immune system is immunological tolerance i.e. the 
ability to distinguish self from non-self, offering protection to our own cells while fighting potential 
pathogens through the recognition of strange incoming antigens. Immunological tolerance has 
two components, a central and a peripheral one. Central tolerance comprises the processes of 
positive and negative selection that take place in the thymus where, presumably, only T cells with 
moderate affinity to self-peptides presented by self MHC molecules fully differentiate (positive 
selection) and leave thymus. On the other hand negative selection is responsible to eliminate 
differentiating T cells that show too much affinity/avidity to self-peptides presented by self-MHC 
molecules. However, thymic negative selection is known to be insufficient to avoid the 
differentiation of some T cells that react too strongly towards self-peptides-MHC complexes. In the 
periphery, Treg, a specific subset of T cells, play a very important role in restraining those auto-
reactive T cells [1]. 
The existence of a particular subset of T cells playing a negative immune regulation role 
has been a great controversy among immunologists for many years [2]. In the early seventies, 
Richard Gershon had indorsed the predecessors of these cells, the suppressor cells [3], but that 
field faced a major setback and had been mostly abandoned by the majority of the scientific 
communities after the negative results found using more modern tools for immunological 
investigation [reviewed in 2]. However, in the mid-1990s, immunologists recover their 
enthusiasm about T cells that had as a main function controlling/reducing the activity of other T 
cells - Simon Sakaguchi and his colleagues rediscovered what are now named Treg [4] - the 
discovery that some spontaneous diseases in mice and humans were the consequence of the 
lack of Treg [4-6] has rendered these cells definitely accepted. Changes in their number or 
function were linked to many events, but in particular to autoimmunity [7], cancers [8], allergies 
[9], and the outcome of infectious diseases [10-12] in particularly some chronic infections [11]. 
Treg are essential for the maintenance of the immune system’s equilibrium; playing key 
roles in the maintenance of immunological tolerance, preventing autoimmunity, and limiting 
chronic inflammatory diseases [7]. Moreover, they can be induced to inhibit transplant rejection 
reactions, and can limit immune-mediated tissue damages in infections [8,11,12,13]. However, 
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they also suppress antitumor immunity and may prevent sterilizing immunity against certain 
chronic infections [8,11,12,13]. 
The infection by the HIV leads to a deep imbalance of the immune system and growing 
evidence suggests that Treg may influence the outcome of this infection.  
Human Treg represent a minority of T cells comprising for most individuals less than 10% 
of the blood CD4+
This section will detail information on Treg namely their origin and main characteristics, 
their action mechanisms, and their role in infectious diseases focusing mainly on the 
interrelationship with HIV infection. 
 T cells [13,14], and it seems likely that manipulating the number and function 
of these cells will one day be a useful medical procedure in several diseases [12]. 
 
1.2.2. Where do Treg come from? 
 
Treg can be from thymic origin (named as naturally occurring Treg - nTreg), or be 
induced in the periphery from conventional CD4+ 
 
T cells (designated as induced, adaptive or 
converted Treg - iTreg) [reviewed in 11,12,15-17] (Figure 1 [17]). 
Treg from thymic origin - naturally occurring Treg - nTreg 
The thymus is essential for the differentiation and proliferation of lymphocytes precursors 
into mature T cells, setting up the peripheral T cell pool before birth and early in life. The thymus 
undergoes an age-dependent involution associated with a decline in function and consequently, 
in thymopoiesis. However, it is now generally accepted that thymopoiesis can be maintained even 
up to the eighth decade of life, or reactivated under particular circumstances such as after a 
massive exhaustion of the T cell pool as following haematopoietic stem cell transplantation 
[18,19]. 
In the thymus, T-cell precursors undergo recombination of sequences within its antigen-
binding T-cell receptor (TCR) genes to generate a TCR unique to that cell, expressed on their 
surface. A broad diverse TCR repertoire is thereby generated. As the epithelial cells in the thymus 
have the unique capacity to express most of the human genome, the differentiating T cells can be 
exposed to the normal repertoire of human proteins [20]. T cells expressing nonfunctional TCRs, 
TCRs that cannot interact with self-MHC molecules, or those that react too strongly with MHC 
expressing self-peptides, are eliminated (negative selection) [21,22]. The selection process leads 
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to the generation of MHC class I-restricted cytotoxic CD8+ T cells and MHC class II-restricted 
helper CD4+
Treg whose development program is still unclear, may possibly be an independent 
thymus-derived T cell lineage which commitment may occur earlier than the mature CD4 single 
positive stage [24,25]. How the thymic selection works, deleting self-reactive T cells but also 
giving rise to Treg specific for self-antigens, remains to be elucidated [22]. Avidity of the TCRs to 
these self-antigens-MHC complexes seems to determine the fate of T cell; whereas an 
intermediate affinity TCR to self-antigens would lead to a conventional T cell, a relatively high self-
reactive TCR (but not so much as to be deleted) would originate Treg (a transient expression of a 
functional IL-7 receptor and an increased level of the anti-apoptotic Bcl-2 could protect them from 
negative selection [24]).  
 T cells that are for the great majority self-restricted and self-tolerant. T cells exiting 
the thymus are referred in the periphery as naive recent thymic emigrants (RTE). These cells 
express high levels of CD-31 on their surface [23] together with CD45RA. 
Naturally occurring Treg can be activated and expanded by TCR stimulation and by other 
means [reviewed in 11]. These cells have a diverse TCR repertoire, but they are mainly self-
reactive helping to prevent autoimmunity. However, in an inflammatory response, the released of 
tissue antigens may activate these cells and also maybe due to a possible overlap between the 
TCRs of Treg and non-Treg, they can sometimes react specifically with microbial antigens [11]. 
Alternatives to TCR stimulation, although the exact mechanism is controversial and not fully 
elucidated, may include: 1) stimulation of other receptors either in the nTreg themselves or in 
intermediary cells of the immune system which will then activate Treg: nTreg seem to express 
pathogen recognition receptors (PRRs) like toll-like receptors (TLRs) and others that can be 
triggered by molecules expressed by microbial agents (pathogen-associated molecular patterns - 
PAMPs) [11 and references therein], or by reaction products produced by the host and released 
after infection or inflammation such as galectins (galectin-1 and galectin-9) and cellular 
metabolites (retinoic acid - RA, and others) [26]; or 2) stimulation by cytokines generated in the 
microenvironment of an infection like Interleukin (IL) -2, transforming growth factor-β (TGF-β), or 
tumor necrosis factor-α (TNF-α) [11 and references therein]. 
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Treg induced in the periphery from conventional CD4+ 
The iTreg are derived, in the peripheral lymphoid organs (lymph nodes, spleen, and 
mucosa-associated lymphoid tissue - MALT), from conventional CD4
T cells - induced, adaptive or 
converted Treg - iTreg 
+ T cells [27]. There is an 
induction of the expression of suppressor surface markers after TCR stimulation mainly by non-
self antigens (sub-immunogenic doses of peptides) in an appropriate environment of cytokines 
(TGF-β, IL-10 and IL-2 are of particular interest [28-32], and possibly IL-35 [33]), RA [30,31], and 
co-stimulation. Some dendritic cells (DCs), in some body’s compartments and in certain 
circumstances, are able to produce TGF-β or IL-10, and so, potentially help conventional T cells 
to convert into Treg [31,32]. Also, the anti-inflammatory molecule thrombospondin (TSP-1) 
secreted mainly by platelets and antigen presenting cells (APCs), interacts with CD47 receptor on 
CD4+
 
 T cells promoting their conversion on Treg, as IL-10 and TGF-β seem to do [34]. iTreg 
population seems to be of central importance, for example, to maintain a non-inflammatory 
environment in the gut, suppressing immune responses to commensal microorganism-derived 
antigens, and environment and food allergens [12,17].  
Figure 1. Thymic and peripheral generation of Treg cells. nTreg – naturally occurring Treg, iTreg - induced, adaptive 
or converted Treg, Th1, Th2, Th17, Tfh - CD4+ T cells subsets, FOXP3+ - expression of the master control gene 
forkhead-box nuclear transcription factor P3, TCR - T-cell receptor, Tr1, Th3 – other FOXP3-
 
 iTreg subsets (adapted 
from [17]). 
Bone marrow 
 
T lymphocyte 
precursor 
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IL-2 appears to have an important role in Treg’s (both nTreg and iTreg) initial production, 
and subsequent maintenance in the periphery (due to peripheral expansion and altered death 
rate of existing cells) although its real role in Treg differentiation remains under debate [21,35]. 
Experiences with mouse models demonstrated that this cytokine or its receptor (α chain of IL-2 
receptor or the CD25 molecule highly expressed on Treg’ surface) deficiency resulted in severe 
deficiency of Treg [35]. Additionally, most recently, it has been demonstrated that the large 
proportion of the total CD4+
As well as conventional T cells can be converted into Treg, the opposite seems also to be 
possible as Treg are highly prone to functional plasticity [37-40]. Recent findings suggest that T 
helper cell differentiation is more plastic than previously appreciated and lineage reprogramming 
can occur. Each CD4
 cells expanded due to IL-2 treatment, in patients infected by HIV, 
shared phenotypic, functional and molecular characteristics with Treg [36]. 
+
Under appropriate conditions, the function and phenotype of some subpopulations of 
Treg can change, losing their inhibitory effects and even becoming pro-inflammatory participants. 
The environment that could cause such plasticity, namely one rich in pro-inflammatory cytokines 
and Treg-attracting chemokines, is common in many virus induced inflammatory lesions [11,38 
and references therein]. Thymus-derived nTreg cells and peripherally derived iTreg cells appear 
to differ in their propensity for reprogramming, being the last ones more prone to change their 
function [38]. While TGF-β is required for the differentiation of iTreg and for the maintenance of 
nTreg after their egress from thymus, it is also needed for the development of Th17 (given that 
IL-1β and IL-6 are also present) and may be a relevant link between the two T cells lineages. 
 T cell subset can adopt alternate cytokine profiles in response to cytokine 
environmental changes and to inducible expression of key transcription factors [37-40]. Among 
the T cells subsets, Treg and Th17 cells have been described as displaying the highest 
propensity to switch to other phenotypes [38]. 
 
1.2.3. How are Treg Characterized? 
 
The identification of Treg has been hampered for years due to the lack of specific 
markers. Treg are CD4+ T cells and share many surface marker characteristics with activated 
CD4+ T cells. Treg were first identified on the basis of their high level of CD25 expression [14]. 
Subsequently, they were identified by the expression of the master control gene forkhead-box 
nuclear transcription factor P3 (FOXP3), a key regulatory gene for the development and function 
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of Treg [41]. Further human studies, however, demonstrated that activated CD4+
Even though the utility of other putative Treg markers in mice or in humans (as the 
cytotoxic T-lymphocyte associated antigen 4 - CTLA-4, glucocorticoid-induced TNFR-related 
protein – GITR) [30], is still debated, CD3
 T cells may also 
up-regulate the expression of CD25 and can transiently express FOXP3 [42]. More recently, it 
was shown that Treg express low levels of CD127 (the α chain of IL-7 receptor, negatively 
regulated by FOXP3), and therefore this surface molecule is considered useful as an additional 
marker to identify this population [43,44]. Lately, another surface marker specific for nTreg 
emerged - the orphan receptor glycoprotein A repetitions predominant (GARP or LRRC32) [45,46] 
– a transmembrane protein that seems to be selectively expressed by Treg and mainly by 
activated human Treg, but not by activated effector T cells. Moreover, the GARP seems not only 
to identify activated Treg but also discriminates those with the highest suppressive activity [45-
47]. Thus, GARP could play an important role on the identification of functionally active Treg.   
+ CD4+ CD127low CD25high FOXP3+
Recent studies have also shown that the expression of CD45RA or CD45RO, which are 
mutually exclusive, are particularly useful markers when combined with CD25 and/or FOXP3 
enabling the identification of functionally and phenotypically diverse Treg subsets [30,48-50]. 
Miyara et al [48] have defined, based on the expression of CD45RA/RO, three Treg subsets; 
resting Treg cells (CD45RA
 currently represent the 
most reliable markers set to identify this T cell subset. 
+FOXP3low), activated Treg cells (CD45RA-FOXP3high), both of which are 
suppressive in vitro (although in vivo activated Treg seem to be the main effectors of suppression 
[30]), and cytokine-secreting non-suppressive T cells (CD45RA-FOXP3low
The combination of CD45RA and the homing lymph tissue marker (CCR7) allows the 
classification of T cells in three populations: naïve (CD45RA
). 
+CCR7+), central memory (CD45RA-
CCR7+) and effector memory subsets (CD45RA-CCR7-) [51]. Furthermore, the combination of 
CD45RA and human leukocyte antigen (HLA)-DR may be used to define effector Treg (CD45RA- 
HLA-DR-) and terminal effector Treg (CD45RA-HLA-DR+
Others Treg subsets, like Tr1 and Th3, and the more recently identified - iTreg35 - seem 
to be iTreg converted from non-regulatory T cells under particular conditions, expressing some of 
the Treg surface markers (although, probably do not express FOXP3) and sharing some of the 
suppressive properties of Treg as IL-10, TGF-β or IL-35 secretion [15,33,52,53]. 
) [30]. 
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1.2.4. How do Treg Work? 
 
After activation, Treg are able to modulate the activities of a wide variety of cellular 
components of both innate and adaptative immune responses, reducing the magnitude of the 
protective T cell response and preventing inappropriate or exaggerated immune activation of T 
cells induced by pathogens. Furthermore, these cells down-regulate self-reactive T cells 
promoting tolerance and avoiding autoimmunity. Moreover, during spontaneous lymphopenia-
induced proliferation, Treg faired to be a limitative factor to the disparity of rate proliferation 
between varied T cell clones, and therefore lead to preservation of the TCR repertoire diversity 
and to protection against the development of inflammatory pathology and autoimmunity [54]. 
Suppressive activities of Treg include a reduction in the magnitude of the antigen-specific 
CD4+ and CD8+
The mechanisms used by Treg to exert suppressive function are still unclear. Although, 
studies in vitro and making use of animals models have shown multiple mechanisms that could 
be used by Treg to suppress their counterparts, there is still no absolute certainty if all of them 
are implicated in vivo, and if so in animals models, if they also happen in humans. At least three 
mechanisms of action of these cells [reviewed in 29,30,57,59-61] have been described and one 
of them, the cell-to-cell contact, seems to be the most important (in Figure 2 are shown some 
suppressive mechanisms of Treg [61]):  
 T cell responses by a suppression of activation, proliferation, differentiation and 
function of those cells [55], as well as an inhibitory effect on cell trafficking of activates antigen-
specific T cells to infected sites [56]. Inhibitory effects on APCs, NK, NKT, B and mast cells 
function as well as inhibition of the pro-inflammatory activity of macrophages and neutrophils are 
others mechanisms used by Treg to  control immune response [57,58]. 
1) By cell-to-cell contact, Treg can cause the death or the suppression of responder T 
cells (Figure 2A). The cell death can occur by direct lysis by a perforin/granzyme-dependent 
mechanism, or also by induction of apoptosis through Fas ligand-Fas interactions (human Treg 
have been found to express Fas and FasL). Also, Treg were found to induce death in B cells, 
monocytes and DCs. In addition to causing death of other immune cells, Treg might suppress 
immunological activities through: 1) release of cyclic adenosine monophosphate (cAMP) via gap 
junctions (leads to inhibition of T cell proliferation and IL-2 production); 2) the deliverance of a 
negative signal through surface molecules on Treg (CTLA-4 seems to be the most important); and 
3) generation of pericellular adenosine, catalyzed by CD39 and CD73 in Treg, that via A2A 
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receptor promote the sequential increase in intracellular cAMP. Treg with upregulation of CD39 
or CD73 expression may have a more potent suppressive effect [62,63]. The binding of Treg 
CTLA-4 to CD80/CD86 on the surface of the DCs also indirectly suppress T cell response: via 
modulation of APC function (down-modulating of CD80/CD86 on DCs, outcompeting the 
activating receptor CD28 on T effector cells, and inhibiting DC maturation) and inducing APCs to 
express the enzyme indoleamine 2,3-dioxygenase (IDO). IDO catabolizes conversion of 
tryptophan to kynurenine, a toxic product to the activated T cells (and privating effector T cells of 
tryptophan, an essential amino acid for their survival [12]) (Figure 2B). Apart from CTLA-4, 
several other molecules are reported to contribute to the suppressive function of Treg via direct 
Treg – T effector cells interactions and/or via modulation of APC function like (Figure 2A e 2B): 
lymphocyte activation gene 3 (Lag-3 [64,65]), Ig-like type 1 transmembrane protein (CD83), 
lymphocyte function-associated antigen 1 (LFA-1 or CD11a-CD18), GITR (tumor necrosis factor 
receptor superfamily or TNFRSF18), herpesvirus entry mediator (HVEM or TNFRSF14) [66], or 
programmed death-1 (PD-1 or CD279).  
2) Production of suppressive soluble factors such as the cytokines TGF-β, IL-10 and IL-35 
(Figure 2A). TGF-β may act as a mediator of suppression as a membrane-bound form (although 
this is still controversial), may condition responder T cells to be receptive to suppression, may 
maintain FOXP3 expression and, as mentioned above, may additionally contribute to the 
differentiation of other T cells into Treg-like cells. Suppression via IL-10 production has been 
shown to be a potent immunoregulatory mechanism with anti-inflammatory functions in in vivo 
models of Treg-controlled inflammation and homeostatic expansion [67]. IL-35 not only acts as 
an effector cytokine of Treg, but also appears to regulate Treg homeostasis (it was described to 
expand Treg defined as CD4+CD25+
3) Competition for IL-2, and possibly other growth factors, inducing cytokine deprivation-
mediated apoptosis in responder T effector cells (Figure 2A). In addition, Treg seem to compete 
by biochemical factors, for example, cystine, interfering with its DC secretion to T effector cells, 
indirectly depleting these cells of a factor strongly related with a proliferative and functional 
response [61] (Figure 2B).  
, and to induce a novel T cell population with IL-35-dependent 
regulatory function [33]).  
It is conceivable that the main suppressive pathway involved in Treg action depends on 
the particular disease or compartment involved, or that these multiple suppressive mechanisms 
operate simultaneously and synergistically, not being sufficient the disruption of one of them to 
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impair Treg mediated immune suppression [29]. Nonetheless, CTLA-4-dependent and possibly 
an IL-2-dependent mechanism seem to be the central suppressive mechanisms [29]. 
 
 
Figure 2. Scheme of suppressive mechanisms of naturally occurring Treg. A) Direct suppression and induction of 
apoptosis. B) Modulation of Teffector responses via APCs (extracted from [61]).  
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1.2.5. What is the Role of Treg in Infection? 
 
The study of Treg in human diseases has increased over the past three decades. There 
are countless papers on the possibility of these cells to become a therapeutic option in almost 
any situation where the suppression of an exaggerated/exacerbated immune response may be 
relevant; transplantation, autoimmunity, allergies, cancer, and infectious diseases [59 and 
references therein]. 
Leaning mainly on infectious diseases; for the control of immune responses to infection 
[10-12], several mechanisms are triggered, and accumulating evidence suggests an important 
role of Treg in controlling these responses. The nature of the Treg response in an infection can 
influence the disease’s pathogenesis and outcome [10-12]. There are instances where Treg 
expand in response to an infection by a pathogenic agent leading to an inadequately protective 
immunity, and contributing for the dissemination and/or persistence of the agent. In mice, for 
example, infection by Herpes simplex virus (HSV) has been shown to lead to Treg expansion, 
which delays the recruitment of protective CD8+ T cells to the infected mucosal, facilitating the 
infection of central nervous system [66,68]. Studies also suggest an important role for Treg in 
establishing chronic infection by HCV [69-72], and by multiple other pathogens (virus, bacteria, 
parasite, and fungus) [10,69,72]. Contrariwise, if the pathogen agent inhibits Treg function, that 
could allow a vigorous CD8+ T cell response which contributes for the establishment of an 
effective clearance of the pathogen (perhaps explaining why chronicity is uncommon in hepatitis 
A infection [73]). Sometimes, however, while the presence of Treg facilitates the pathogen 
persistence, that can be useful once the concomitant immunity developed protects the host from 
reinfection [74]. Moreover, the Treg expansion can be beneficial, limiting immune-mediated 
inflammatory conditions, and therefore restraining immune-mediated tissue damages. [75]. 
Indeed, some pathogens lack cytopathogenicity, and tissue damage is mostly due to T-cell-
mediated response to the infection. Controlling the extent of such tissue damage appears to be a 
major function of Treg. In an infection’s environment as pulmonary infection by Respiratory 
Syncytial virus, Treg also showed to influence the timely trafficking of other immune cells to the 
infection site and hence control both the growth and spread of infection and the 
immunopathology during the acute pulmonary virus infection [76]. Moreover, some infectious 
agents modulate Treg trafficking to the infection’s environment through the stimulation of 
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receptors in their surface that are important homing molecules (CD103 expression on Treg and 
skin infection by Leishmania major [77]).  
Concerning chronic and persistent infections, it appears that Treg could play even a more 
consequential role influencing outcome (comparing with acute infections). One human virus, HIV, 
has received the most attention, as it is a major cause of illness and death, and lacks effective 
prophylactic or curative therapy. 
 
1.2.6. What is the Role of Treg in HIV Infection? 
 
Treg, as important immunomodulatory cells, have been investigated as potentially 
relevant in the outcome of HIV infection. Although a great number of papers have been written 
about Treg and HIV infection, results continue to be conflicting. Deciphering the exact role of Treg 
in HIV pathogenesis is of crucial importance to fully understand HIV induced immune 
suppression as well as immune reconstitution. In addition, understanding how Treg influence the 
immune system among HIV-infected patients may contribute to the determination of potential 
new strategies to modulate the disease. 
Concerning HIV infection, different aspects have been investigated, namely: 1) whether 
or not Treg are directly infected and altered by the virus; 2) to what extent they are 
depleted/expanded; 3) if their function is preserved; and 4) what is their role during the HIV 
transmission, the course of disease progression from HIV infection to AIDS, and in the immune 
reconstitution under HAART. 
In relation to the direct infection of Treg by HIV, it has been reported that Treg cells are 
susceptible to HIV infection (these cells express, in addition to CD4, CC chemokine receptor type 
5 - CCR5 and the CXC chemokine receptor type 4 - CXCR4) [78-80]. However, it remains to be 
clarified to what extent Treg are infected, which Treg subsets are preferentially infected and the 
effects of the infection by HIV in Treg [78-83]. Some authors suggest that Treg are highly 
susceptible to HIV infection and are killed by viral replication [78]. Other studies, however, argue 
against the increased cell death of HIV-infected Treg [84,85]. In another study, the transcription 
factor FOXP3, critical for Treg development and function, was shown to modulate the HIV 
promoter’s transcription activity [82]. Thus, permissiveness to HIV replication in Treg may be 
reduced, partly as a result of FOXP3-mediated inhibition of HIV transcription. Others, however, 
suggest that FOXP3 may also facilitate HIV transcription by inhibiting histone deacetylases 
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(HDACs) rendering the proviral form more accessible for efficient transcription [83]. Interestingly, 
although using non-infectious virus with an intact envelope, a study showed that exposure of Treg 
to HIV selectively promotes their survival and expansion via a CD4-gp120–dependent pathway 
(the CD4-gp120 interaction resulted in the inhibition of Treg apoptosis) [81].  
In respect to the level of Treg depletion/expantion in HIV-infected patients, it has been 
reported to vary with several factors namely disease’s phase. Also, some disagreement exists on 
the reported evaluation of Treg role on the evolution from HIV infection to AIDS as well during 
immune reconstitution during HAART. Part of these contradictory data may result from the 
heterogeneity of the cohorts analyzed, from the different gating strategy and/or different set of 
Treg markers used to define Treg, and/or from the use of FOXP3 mRNA measured by reverse 
transcription polymerase chain reaction (RT-PCR) in T cells to define Treg instead of its 
expression by flow cytometry.  
During primary HIV infection, a decrease in Treg percentage was observed in the blood 
[86] reflecting, according to the authors, a susceptibility of these cells to HIV infection [78,79] or 
their recruitment to inflamed sites (lymphoid tissue) [81,84]. Nevertheless, the opposite (an 
increase in Treg frequency during the acute phase of the HIV-infection) was also reported by 
others [87], although in this last study, a lower number of patients were analyzed and a more 
incomplete set of Treg markers was used.   
After the acute phase, during the chronic phase without treatment, although both 
absolute numbers of peripheral Treg and proportions of Treg among total CD3+ T cells are mainly 
found to be decreased in patients comparing to healthy donors, most studies show that the 
proportion of peripheral Treg among CD4+ T cells expand - the numbers of Treg decrease 
progressively over time but at a lower rate than the whole CD4+ T cell population [86-90 reviewed 
in 91,92, and others studies whose references are therein]. Thus, most studies argue for a 
general increase in Treg frequency although this is not reported by all published studies [93,94]. 
The increased Treg representation could be the consequence of reduced HIV-mediated 
destruction comparatively to other CD4+ T cells [81], enhanced generation by thymus [95], 
conversion of uncommitted cells to become Treg (in HIV-infected individuals, DCs seem to be 
more prone to induce Treg [96,97], and some local cells are induced to produce TGF-β 
[81,93,98]), higher survival (relative resistance of Treg to activation-induced cell death), or 
increased proliferation (increased expression of Ki67, a marker of the cell cycle, was found in 
circulating Treg from untreated, chronically infected patients) [89,92,99]. Finally, several studies 
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suggest the presence of Treg responding to HIV proteins, and therefore expanding as a direct 
consequence of HIV infection [81,90,100].  
Successfully HAART treatment seems to result in a decrease of Treg frequencies (even if 
a transient increase in the first months after HAART occurs [89,101]) according to most 
[51,84,88,89,101-106], but not all [87,90,107] studies. Unsuccessfully treated or untreated 
patients, in contrast, often retain high Treg frequencies [106]. 
If the rise in Treg frequency frequently observed in HIV-infected patients represents a 
concomitant increase of a suppressor subset remains to be clarified. Several reports suggest that 
Treg function is preserved in HIV infection and may even, in same stages of the disease, be 
increased [80,81,87,90-92]. It has been reported that Treg with upregulation of CD39+ 
expression (Treg with more potent suppressive effect [62,63]) are expanded in HIV infection 
[88,89,108]. Furthermore, some authors demonstrated an increased sensitivity of effector cells 
to Treg-mediated suppression, in infection by HIV [108,109]. It has also been suggested that HIV 
tat could increase CTLA-4 expression and in addition the suppressive potency of Treg [110]. 
However, recently, the reports by Pion et al. [111] and by Angin et al. [112], have described in 
vitro that HIV-infected Treg show impaired suppressive capacity and a decreased expression of 
genes critical to Treg function. In some instances, the suppressive capacity of Treg may also be 
impaired as it seems to happen in the immune reconstitution inflammatory syndrome (IRIS). IRIS 
is a complication that occurs in a small percentage of patients that initiate antiretroviral therapy 
at a stage of advanced disease. It is characterized by an exaggerated and/or inappropriate 
immune system reaction to a subclinical undiagnosed (unmasking IRIS) or to an already 
diagnosed and under correct treatment (paradoxal IRIS) infection. Although, 
immunopathogenesis of IRIS remains unclear, a dysfunction of Treg (even with a Treg expansion) 
has been proposed by some authors as a potential mechanism responsible for a deregulated 
CD4+
Several roles have been assigned to Treg during HIV infection - a great amount of 
controversy exists and both detrimental and beneficial roles of Treg are suggested.  Detrimental 
 T and/or NK cell response and consequently, on that exacerbated pro-inflammatory 
immune response [102]. Others argue that the Treg dysfunction during IRIS is due to a rapid 
rebound of conventional T cells after HAART initiation, not followed by a comparable rise of Treg, 
leading to a rapid decrease in the frequency of Treg and to an exacerbated immune response to 
pathogens and hence to IRIS [51]. 
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effects of Treg could result from an excessive activity of Treg weakening HIV-specific CD4+ and 
CD8+ T cell responses [86,90,93,113]; a beneficial effect could be associated with the ability of 
Treg to minimize the extension of T cell activation controlling the availability of HIV targets and 
preventing immune-based pathologies [114-116]. It remains to be determined what of these 
contradictory main effects plays a greater role in the disease. Other effects have been suggested; 
a detrimental facet of Treg could be their eventual involvement in the exacerbated collagen 
deposition within T cell zones, shown in simian immunodeficiency virus (SIV) infected simian, 
that could destroy the lymphatic tissue architecture and hamper CD4+ T cells to reach essential 
sites or CD4+
- During the inter-individual transmission of the virus, a high Treg frequency could be 
protective by reducing T cell activation, and consequently decreasing the pool of susceptible CD4
 T cells reconstitution in infected patients (the pathway involved could be the 
increased level of TGF-β produced by Treg) [85]. Also, the ability of Treg to hamper the 
lymphopenia-induced proliferation could be one of the mechanisms involved in the poor immune 
reconstitution reported by some authors [54,117]. It appears that the different roles of Treg 
described above, could be occurring at different times and with different intensity during the 
distinct phases of the disease: 1) transmission of the virus, 2) disease progression, and 3) 
response to HAART: 
+ 
T cells (as have been observed in HIV-exposed seronegative women and in HIV-exposed 
uninfected infants or neonates) [114,118]. Additionally, in untreated acute SIV infection, the use 
of a CTLA-4 blockade procedure (to block Treg function) increased viral replication and CD4+
- During the HIV infection progression without treatment (the chronic infection phase) 
some observations are consistent with Treg playing a detrimental role, or that high levels of Treg 
are, at least, not an advantage for a good evolution of the disease: 1) though not consistently 
found, most studies showed an inverse relationship between Treg frequency and CD4
 T 
cell loss, particularly at mucosal sites (by providing more target cells for the virus by decreasing 
the threshold for T-cell activation) [115]). 
+ T cell 
counts (Treg frequency and plasma viral load were either not or positively correlated) 
[87,89,107,108,117]; 2) long-term non-progressors (HIV-infected individuals who maintain high 
CD4+ T cell counts even in the presence of HIV replication in the absence of therapy) and elite 
controllers (HIV-infected individuals who maintain undetectable viral loads in the absence of 
any treatment) seem to have lower levels of Treg frequency in peripheral blood and/or rectal 
mucosa than other infected individuals (these cell numbers may be similar to [87,88] or even 
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lower than those found in healthy individuals [119,120]), and in addition, these patients seem to 
have a polymorphism which does not allow their Treg to efficiently suppress HIV-specific 
proliferative responses of CD8+
The idea that Treg may play a positive role in the context of HIV infection, by limiting 
exaggerated immune activation, which is a prelude to the onset of AIDS, have also been reported. 
But if that were to be the case, it would be expected that a high Treg frequency would be related 
to a lower immune activation. Several studies investigated the potential ability of Treg to control 
exaggerated immune activation/inflammation in the context of HIV infection without treatment. 
Even though Treg may protect the host against immune-mediated damage (one study showed 
that Treg attenuate HIV-associated neurodegeneration [123]), most studies performed in 
untreated chronically infected patients, or in those interrupting HAART, showed a positive 
relationship between Treg frequencies and T-cell activation regardless of the activation markers 
analyzed (i.e. CD38 and/or HLA-DR or CD69 expressed on CD8 and/or CD4
 T cell [121]; 3) furthermore, some studies showed that extensive 
Treg accumulation within the lymph nodes was associated with a chronic progressive HIV and 
SIV infection [81,93,122]. 
+
- Under an effective HAART, a high percentage of Treg does not seem to be an 
advantage: 1) their percentages decrease with effective HAART; 2) a high percentage of Treg 
seems to limit immune reconstitution in patients under HAART [117,126-128]; 3) and also, in 
chronically SIV-infected HAART-treated macaques, the administration of anti-CTLA-4 blocking 
antibody (to block Treg function) was found to have beneficial virological effects [129]; 4) 
moreover, in two large global randomized controlled clinical trials (ESPRIT and SILCAAT), 
although supplementary IL-2 treatment resulted in a substantial and long-standing increase in 
 T cells) 
[87,88,107,117,124]. Furthermore, rectal Treg frequency was also found to positively correlate 
with rectal T-cell activation in untreated patients (a higher Treg frequency there, could be 
responsible for a lower Th17 response and lower specific response to several microorganisms 
and hence, a higher microbial translocation) [119,125]. Thus, Treg seem to be inefficient to 
control high immune activation in viremic patients. However, it could be that, for example 
concerning the beneficial effect of Treg decreasing immune activation, the most important would 
be absolute numbers (found to be decreased in these patients) instead of Treg percentages and 
some studies point into that direction as exploring the relation between Treg measured by 
absolute numbers and immune activation and found a negative relation between Treg absolute 
numbers and immune activation [88,106,116]. 
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CD4+ T cell counts compared to antiretroviral therapy alone [130], it has been demonstrated that 
a substantial proportion of the CD4+
While it is well known that HAART leads to CD4
 T cells expanded shared phenotypic, functional and 
molecular characteristics with Treg. Apparently, this seems to be the cause of the unexpected 
clinical outcome observed in those patients - they presented more potentially life-threatening 
events [36].  
+ T cell counts recovery preventing AIDS 
related complications, it does not prevent several complications typically associated with aging 
which tend to prematurely commit long-term treated patients [131,132]. These conditions seem 
to be related in part to immune activation [131,132]. Under successfully treatment, CD4+ and 
CD8+ T-cell activation dramatically decrease with viral suppression, but remains higher compared 
to healthy controls [131]. Treg frequency seems not to be crucial in reducing immune activation, 
as in most studies a successful treatment results in decrease of both immune activation and Treg 
frequency [88,89,101,102,131]. However, in the viral control situation under HAART, Treg 
frequency was found to negatively correlate with residual immune activation [133,134]. 
Interestingly, this negative relationship between Treg frequency and CD8+ T-cell activation was 
lost after treatment interruption (that resulted in viral rebound) [124]. Also, in HIV elite 
controllers, peripheral T-cell activation is lower than in patients with progressive disease, but 
higher than in HAART-treated aviremic patients, an observation that could be related to lower 
Treg frequency in HIV controllers than in successfully HAART-treated patients [103]. We can then 
conclude that in most HIV controllers, low levels of Treg could contribute to the high specific anti-
HIV CD8+
Hence, it appears that Treg may be able to control low levels of T-cell activation, but the 
effect may not be adequate to control high levels of immune activation as is often present, 
especially when levels of viral replication are high [91]. This could happen due to a decrease in 
the absolute number of Treg or because Treg, due to their plasticity in some environments rich in 
pro-inflammatory cytokines and Treg-attracting chemokines, can enter inflammatory locations, 
but after an initial anti-inflammatory effort could change function, be induced to secrete the pro-
inflammatory cytokine IL-17 and contribute to tissue damage and immune activation 
[39,48,91,135]. 
 T-cell responses described, but also for the relatively higher immune activation levels 
compared to HAART-treated patients [91].  
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 To conclude peripheral and mucosal Treg seem to trigger several effects that could be 
either beneficial or detrimental during the HIV infection, each of them playing different roles 
depending on the phase of the disease and possible other characteristics of individuals patients..  
Treg may have an overall beneficial effect during early acute HIV infection; before HIV-
specific immune responses are fully activated, by controlling T cell activation and decreasing the 
availability of target cells for HIV replication and transmission [114,115,118]. In contrast, during 
the late acute and chronic phases, increased Treg frequency may have an overall-negative role, 
as the Treg suppressive effect on HIV antiviral immune responses predominates and those cells 
seem be unable to counter immune activation [87,88,90,113,117,124]. In addition, a hampered 
CD4+
The influence of Treg in HIV infection/AIDS outcome seems to depend on the equilibrium 
between the negative effect of suppressing desired effector T cell responses and the positive 
effect of decreasing unwanted/exacerbated immune activation. If we could identify a particular 
subset of Treg able to suppress immune activation without suppress pathogen-specific immune 
response and unable to reprogrammed themselves, it would be of great interest for immune-
based therapy in chronic infectious diseases namely the HIV infection. The boundary between the 
beneficial effect and adverse effect of Treg seems to be very weak, and any impetuous action 
may cause the disruption of this equilibrium and have disastrous consequences. 
 T cell reconstitution likely due to exacerbated fibrosis of lymphoid tissues could contribute 
to this overall negative role [85]. The inhibition of the lymphopenia-induced proliferation, by these 
cells, could also explain the poor immune reconstitution sometimes observed [54,117,127]. 
However in virological suppressed patients under HAART, a higher Treg frequency could account 
for a reduced immune activation [124]. 
Several strategies have been developed aiming towards the abrogation of Treg that could 
be helpful in some diseases. The use of those strategies could be useful in HIV infection if the 
real role of Treg in the different phases of disease and/or the patient variables that influence this 
outcome would clearly known. To achieve this goal, much research has to be performed.  
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2.1. Construction of a Clinical and Biologic Database 
 
2.1.1. Introduction 
 
The emergence of HAART to treat  HIV-infected patients markedly reduced the morbidity 
and mortality associated with this infection. This is mainly achieved due to immune system 
recovery. However, some of the patients, although being under effective HAART, do not reach a 
normal (700-1100 cells/mm3), a near normal (>500 cells/mm3) or, at least, a satisfactory CD4+ 
T cell counts (a number higher than a threshold of 250-350 cells/mm3
 Trying to better understand the role of various interveners during the immune 
reconstitution, we gathered a set of clinical, imagiological, laboratorial, and biological data from 
HIV-infected patients undergoing HAART. 
, a level that would enable 
patients to be protected from more severe opportunistic infections). For this reason, these 
individuals are more prone to suffer from AIDS-related and AIDS non-related complications and 
death. There is considerable controversy regarding the relative contribution of various 
mechanisms of sub-optimal T cell recovery. 
The patients were selected from the hospital where these patients undergo medical care 
(HJUU/CHP). Blood samples of these patients were collected at HJUU/CHP and processed at 
the ICVS/ECS/UM. At the ICVS, the blood samples were analyzed, plasma was isolated and 
frozen and surplus blood cells were frozen for future analysis. Computer databases for all the 
data (clinical, imagiological and laboratorial data) were generated. 
 
2.1.2. Construction of a Cross-Sectional and a Longitudinal Cohort to Study Immune 
Reconstitution among HIV-Infected Patients under HAART 
  
Patients were enrolled for two independent type of studies: cross-sectional and 
longitudinal studies: 
 
2.1.2.1. The Cross-Sectional Study 
The cross-sectional study allowed to promptly examine a segment of patients infected by 
HIV and on HAART, and evaluated several parameters of their immune reconstitution in a single 
time-point taking into account information on their clinical history.  
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The number of patients included in this cohort was not pre-defined, and until now, 123 
adult patients were included, with the following criteria: 1) infection by HIV-1; 2) receiving or not 
HAART (regardless of the scheme used); 3) when on HAART, presumably being regular in 
therapy compliance. All participants have signed an informed consent (Annex 1) on a volunteer 
basis after explanation and prior to their enrollment in the study. This study was approved by the 
institutional review board of the HJUU/CHP under the protocol number 168/CES [addenda 
number 127/12 (NA-DEFI/089-CES)] (Annex 2 and 3). 
Participants in this study were randomly chosen among patients that were attending the 
hospital for routine analysis, on a day also randomly chosen, and subjected in that day to the 
only visit of the study. The patients’ physician informed and explained to patients about the study 
and if patients agreed in participating, a written informed consent was sign. Apart from the blood 
collected for the pre-programmed follow-up evaluation of these patients (performed at the 
hospital’s reference laboratory), additional blood samples were collected into heparinized tubes 
and transported to the ICVS to be processed on the same day as described in section 2.1.3.  
Clinical and demographic data was collected by patients’ physician from the clinical file 
(using a specific form – Annex 4) such as: patient’s epidemiological characteristics (gender and 
age); transmission mode of HIV; probable date of infection; date of HIV infection diagnosis; 
clinical history including infections/tumors HIV/AIDS-related and other relevant clinical 
conditions; hepatitis C virus (HCV) or B virus (HBV) co-infections. For patients under HAART: 
HAART onset date, nadir and/or baseline value of CD4+ T cell counts, clinical and laboratorial 
progression since HAART was initiated, and HAART schemes history and respective compliance. 
Viral load and CD4+
A computer database was constructed and data analysis performed. 
 T cell counts were determined by referenced laboratory of the hospital on the 
same day of the visit. 
This database 
allowed the study described in Subchapter 2.2 and other studies that resulted in Master's thesis 
and 
Epidemiological, virological and immunological characteristics of the cohort (n=123) are 
described in Table 1. 
which are currently supporting other studies. 
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Paramater Results 
Age, in years 
Mean ± SD (range) 
Median, (IQR) 
N=123 
45,19 ± 9,10 (24-76) 
44,00 (51–38) 
Sex – male, female n (%) 103 (83,7), 20 (16,3) 
Patients under HAART 
Yes (%)/No (%) 
N=123 
104 (84,55)/19 (15,45) 
Time between HAART onset and 
study visit, in years 
Mean ± SD (range) 
Median, (IQR) 
N=102 
6,38 ± 4,57 (0–17) 
5,50 (11–2) 
CDC CD4 cell category [2] 
n (%) 
N=119 
(1) ≥500/mm3 
(2) 200-499/mm
– 56 (47,06) 
3
(3) <200/mm
 – 54 (45,38) 
3 – 9 (7,56) 
CD4+ T cell count (cell/mm3
Mean ± SD (range) 
) 
Median, (IQR) 
N=119 
537,70 ± 282,24 (41–1372) 
486,00 (747-345) 
CD4+ T cell count (cell/mm3
(CD4
) increase 
+
Study visit - HAART onset) 
 T cell count: 
Mean ± SD (range) 
Median, (IQR) 
N=101 
309,88 ± 224,28 (-161 - +909) 
283,00 (432,00-132,50) 
Viral load (VL) copies/ml 
On treatment  
Mean ± SD (range) 
Median, (IQR) 
N=99/104 
<50 (virological supressed): 81 (81,82%) 
≥50: 18 (18,18%): 
33510,28 ± 101351,98 (51-413000) 
296,50 (2057,50–93,50)  
Viral load (VL) copies/ml 
Without treatment 
Mean ± SD (range) 
Median, (IQR) 
N=17/19 
96335,29 ± 178610,44 (1670-639000) 
25800,00 (100400,00–4785,00) 
 
Tabela 1. Epidemiological, clinical, virological and immunological characteristics of the cohort. 
 
2.1.2.2. The Longitudinal Study 
The longitudinal study aims to better understand the temporal order of events to 
determine the direction and the magnitude of potential cause-and-effect relationships between 
factors/interveners and outcomes (several grades of immune reconstitution process after HAART 
onset). Patients were enrolled according to pre-defined parameters and followed-up in defined 
time-points according to a protocol described below. In each time-point, coincident with routine 
appointments, patients were questioned about symptoms, underwent a medical examination and 
blood was collected and analyzed at the hospital (routine analysis) and at the ICVS. The data was 
collected and organized in the database. The first study (described in subchapter 2.3) describes 
70 
 
the evolution of Treg along therapy, an obvious follow up of our first report using the cross-
sectional study. This longitudinal cohort is presently being used for other studies. 
In the longitudinal study, a number of 100 patients were pre-defined to be included (a 
number of patients that it will be feasible to clinical care and whose blood will be economically 
feasible to be analyzed), and so, 100 adult patients were enrolled with the following criteria: 1) 
infected by HIV-1; 2) naïve on HAART; 3) having criteria to initiate HAART. All participants have 
signed an informed consent (Annex 5) on a volunteer basis after explanation of the entire 
protocol. A local Ethical Committee approval was received for the study (reference 168/CES on 
2th October 2009) (Annex 6).  
The patients were included between 29-04-2010 and 11-10-2012 (35 in 2010, 50 in 
2011 and 15 patients in 2012) when our aimed number of patients - 100 - was achieved. The 
start of HAART defined the study visit “0” or baseline visit. The decision to initiate HAART was 
individualized and upheld by the existence of at least one of the following elements: symptomatic 
clinical manifestations (presence of previously designed as category B and of any of the AIDS-
defining conditions by the Centers for Disease Control and Prevention – CDC [2,3]); number of 
CD4+ T lymphocytes or CD4+ T lymphocytes percentage of total of lymphocytes, <350 cells/mm3 
 
or <14%, respectively; plasma viral load value >100000 copies/ml in at least two determinations; 
presence of co-morbidities (cardiovascular disease or high risk for cardiovascular disease, HIV 
associated nephropathy – HIVAN, chronic hepatitis B virus or hepatitis C virus infection) or age 
>60 years. The patient's level of willingness and readiness was assessed, indorsed, and 
confirmed before HAART initiation [4-7]. 
Antiretroviral Therapy 
The HAART scheme chosen for each patient took into consideration scientific policy and 
National and International Guidelines and the price [4-7]. The first option was a combination of 
two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) and one Non-Nucleoside Reverse 
Transcriptase Inhibitor (NNRTI), of which efavirenz (EFV) was the first option. The choice of NRTIs 
depended on the viral load; if the viral load value was below 100000 copies/ml, with no 
cardiovascular risk, and the allele of major histocompatibility complex was not HLA-B*5701, the 
option was abacavir (ABC) and lamivudine (3TC) coformulation (Kivexa®), if the viral load was 
above 100000 copies/ml, the option was then tenofovir (TDF) and emtricitabine (FTC) 
coformulation (Truvada®). When NNRTIs - EFV - could not be used (existence of hipersensibility, 
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mutations for resistance, or co-morbidities like psychiatric diseases that preclude his use), a 
Protease Inhibitor (IP) boosted with ritonavir was chosen being darunavir once daily, the first 
option. One patient, a woman, initiated zidovudine (AZT) + 3TC + nevirapine (NVP); she was 
suffering from cryptococcal meningitis and CMV encephalitis so the avoidance of EFV was due to 
its potential neuropsychiatric effects that could worsen the patient’s clinical state and, also, the 
use of potentially better central nervous system (CNS)-penetrating drugs like AZT or NVP (her viral 
load in cerebrospinal fluid - CSF - was about 157000 copies/ml) was tried. Two other patients 
initiated, as the third drug, lopinavir boosted with ritonavir (LPV/r); they were the first two 
patients using IPs in this cohort, they had CNS infections (tuberculosis meningitis and CMV 
encephalitis) and a high CSF HIV viral load, and LPV/r at the time was thought to be one of the 
more CNS-penetrating drugs. 
 
Protocol of study visits 
The patients were evaluated prior to initiation of HAART, the day they started HAART 
(baseline visit) and regularly thereafter following a protocol (Annex 7). The duration of this study 
was initially planned to be of three years. However, to have more time of follow-up would be 
suitable to the purposes of our aim; to better characterize the direction and the magnitude of 
cause-and-effect relationships between variables, it was decided to keep the patients in 
semiannual study visits after completion of three years until, at least, five years. At present, the 
study is yet ongoing. 
Prior to enrolment, the study and the entire protocol were explained to patients that 
signed the informed consent. In some cases, this visit was the first at the hospital and the first 
medical visit after the patient was informed that he/she was infected with HIV. Therefore, before 
the study explanation, a long conversation was taken, explaining to the patient the natural course 
of the infection, what are the medical tools to counteract the disease’s evolution, all the scientific 
advances made since the beginning of the epidemic, the therapy schemes and their potential 
adverse effects, and the need to be adherent to the therapies due to the ability of HIV to acquire 
mutations conferring resistance to HAART. Additionally, recommendations as how to lead a 
healthy life and about precautions to take to avoid the infection of others were provided. Also in 
this visit, a complete and exhaustive clinical assessment (questions about medical history, history 
of present illness if it was the case, and physical examination) was performed. 
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During the baseline visit, HAART was given according to a resistance test and to other 
conditions already described. Again an explanation regarding the medication was also given. In 
this visit, the first blood collection to be analyzed at ICVS was performed.  
In the follow-up visits, an evaluation consisting of clinical, analytical and imaging studies 
was performed. The analytical study included study routine, assessment of CD4+
The study visits were always made by the physician responsible for the patient/study – 
Ana Horta. Additional visits, blood collects, or hospitalizations were performed when the clinical 
condition of the patient demanded it. These decisions were made also by Ana Horta and when 
she was not available, made by the emergency physician. When hospitalized, patients were 
assigned to a physician in the rotation scheme instituted by the Infectious Diseases Department. 
 T lymphocytes 
and viral load and other analyses to evaluate potential infections (latent or active). All blood 
collections were performed at the hospital laboratory on the same day of the medical visits. On 
each visit, additional blood was also collected and transported to the ICVS, where it was 
processed the same day. 
Epidemiological, clinical, virological and immunological characteristics of this cohort at 
baseline are described in Table 2. Primary resistance to HAART (to NRTIs, to NNRTIs, and/or 
IPs) was present in 25 patients (some of them revealing mutations conferring resistance to more 
than one class of antiretroviral drugs) and the resistance mutations involved are reported in Table 
3. In Table 4, indicator conditions defining AIDS [3]) present at baseline are shown (in six cases, 
more than one condition were simultaneously present). 
When an AIDS-indicator condition was diagnosed previous to HAART initiation, the 
median period of time between the diagnosis/treatment onset for that condition, and the 
beginning of HAART (baseline) was 69,35 ± 75,19 day, 12 – 360 (Mean ± SD, range) or 44,50, 
90,00 - 19,50 (Median, IQR).  
Symptomatic conditions that are not included in AIDS-indicator condition definition, but 
are attributed to a cell-mediated immunity defect or for which the clinical course or management 
is complicated by HIV infection (prior classified in the classification from 1993 by CDC, as 
category B symptomatic-indicator conditions) [2] presented at baseline or referred as recently 
presented by patients are shown in Table 5. In sixteen patients, more than one condition was 
present. Others medical conditions present at baseline and not directly related to HIV infection 
are reported in Table 6. Data related to infection by hepatitis virus, at baseline, are shown in 
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Table 7. Baseline HAART combinations prescribed for the 100 patients at baseline are shown in 
Table 8.  
Paramater Results 
Age, in years, N=100 
Mean, SD, (range) 
Median (IQR) 
40,44 ± 10,42 (22–67) 
41,00 (46,75-32,00) 
Sex - male, female - n (%), N=100 79 (79), 21 (21) 
Transmission mode of HIV 
n=% 
N=100 
IVDUs – 20 
Heterosexuals – 43 
IVDUs and Heterosexuals – 5 
MSM – 29 
Unknown – 3 
HIV subtype and 
circulating recombinant forms (CRFs) 
n=% 
N=100 
B – 47, G – 25, C – 10 
Others – 9 
(A-3, A/D-2, CRF02_AG-1, 
CRF14_BG-1, F-2) 
Unknown – 9 
Time between diagnosis of HIV infection and 
baseline, in months, N=100 
Mean, SD, (range) 
Median (IQR) 
25,64 ± 34,97 (0-178) 
8,00 (37,75-2,25) 
Time between primo infection by HIV (known or 
likely) and baseline in months, N=17 
Mean, SD, (range) 
Median (IQR)  
28,59 ± 24,93 (3-76) 
26,00 (50,00-5,00) 
CDC clinical category [2] 
n=%, N=100  
A – 30, B – 44, C – 26 
CDC CD4 cell category [2] 
n=% 
N=100 
(1) ≥500/mm3 
(2) 200-499/mm
– 7 
3
(3) <200/mm
 – 49 
3 – 44 
CDC stage C or (3) (AIDS) [2,3] 
n=%, N=100 
48 
CD4+ T cell count (cell/mm3
Mean, SD, (range) 
), N=100 
Median (IQR)  
244,57 ± 192,37 (4-1033) 
247,50 (320,50-92,00) 
CD8+ T cell count (cell/mm3
Mean, SD, (range) 
), N=99 
Median (IQR)  
1025,19 ±  570,48 (150-2776) 
897,00 (1353,00-605,00) 
Viral load - copies/ml, log 10 copies/ml 
Mean, SD (range) 
Median (IQR)  
N=100 
859025,90 ± 1844752,70 (6790-10M), 
5,42 ±  0,64 (3,83–7,00) 
228500,00 (89400-583000), 
5,36 (4,95–5,77)  
Presence of mutations associated with resistance 
to drugs, by genotypic assays, N=96 
Yes - 25 (26,0%) 
No – 71 (74,0%) 
HAART resistance mutations detected 
by genotypic assays 
(detected in 25 patients) 
NRTI – 3 (12,0%) 
NNRTI – 10 (40,0%) 
IP – 15 (60,0%) 
[NNRTI + IP – 3 (12,0%)] 
HLA-B*5701 
N = 76 
Positive - 3 (4%) 
Negative – 73 (96%) 
 
Table 2. Epidemiological, clinical, virological and immunological characteristics of the cohort at baseline. 
SD – standard deviation, IQR – interquartile range, IVDUs – intravenous drug users, MSM – men having sex with 
others men, CDC – Centers for Disease Control and Prevention, HAART – antiretroviral therapy, NRTIs - Nucleoside 
Reverse Transcriptase Inhibitors, NNRTIs - Non-Nucleoside Reverse Transcriptase Inhibitors, IPs - Protease Inhibitors, 
HLA-B*5701 – allele of major histocompatibility complex, class I, B. 
74 
 
NRTIs resistance mutations 
(3 patients) 
T69N 2 
T215S 1 
Total 3 
NNRTIs resistance mutations 
(10 patients) 
K101E 1 
K103N 2 
E138A 1 
V179D 3 
Y188L 1 
G190A 1 
G190E 1 
Total 10 
IPs resistance 
mutations 
(15 patients) 
L10I 2 
K20I 7 
M46L 1 
T74S 4 
L90M 6 
Total 20 
Table 3. Resistance mutations to HAART presented at baseline (in 25 patients of 96 tested). 
NRTIs - Nucleoside Reverse Transcriptase Inhibitors, NNRTIs - Non-Nucleoside Reverse Transcriptase Inhibitors, IPs - 
Protease Inhibitors. 
 
AIDS-indicator conditions N (26 patients) 
Mycobacterium 
tuberculosis disease 
Pulmonary 
11 
7 
Extrapulmonary 4 
Pneumocystis jiroveci pneumonia 10 
Candidiasis esophageal 4 
Kaposi’s sarcoma 4 
Cytomegalovirus (CMV) encephalitis, 
esophagitis and/or colitis 
3 
Mycobacterium avium complex 
disease 
1 
Cryptococcal meningitis 1 
Cerebral Toxoplasmosis  1 
Table 4. Indicator conditions in case definition of AIDS at baseline (in 26 of 100 patients) 
(in six cases, more than one condition were simultaneously present). 
 
ategory B symptomatic conditions N (44 patients) 
Oropharyngeal candidiasis (thrush) 38 
Herpes zoster (shingles), involving two or more episodes or 
at least one dermatome 
9 
Diarrhea lasting >1 month 4 
Cervical dysplasia (moderate or severe)/cervical carcinoma in situ 1 
Vulvovaginal candidiasis, 
persistent or resistant 
1 
Angular cheilitis 1 
Table 5. Category B symptomatic conditions (by CDC) [2] present or referred as recently presented by 44 of 100 
patients at baseline (sixteen patients presented more than one condition). 
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Medical conditions 
not related to HIV infection 
N 
(53 patients) 
Syphilis 
VDRL 
positive – 17 
FTA-ABS positive - 28 
(Latent – 15, 
Secondary – 2, 
Early disease - 2 
Cured - 9) 
Genital Herpes 6 
Condyloma acuminata 5 
Molluscum contagiosum 2 
Neisseria gonorrhoeae urethritis 1 
Community-acquired Pneumonia 6 
DPOC 3 
Urinary tract infection 3 
Psoriasis 3 
Neoplasms 3 
Diabetes Mellitus 3 
Gallstones 2 
Nephrolithiasis 1 
Porphyria Cutanea Tarda 1 
Acute myocardial infarction 1 
Situs inversus 1 
Influenza A/H1N1 1 
Gastroenteritis 1 
 
Table 6. Others medical conditions present at baseline and 
not directly related to HIV infection (in 53 of 100 patients). 
VDRL – Venereal Disease Research Laboratory test, 
FTA-ABS – Fluorescent Treponemal Antibody Absorption 
 
  
 
Paramater Results 
Anti-HCV positive 
N = 100 
30 
(24 – HCV  RNA +; 
6 patients – spontaneous clearance) 
HCV genotypes 
(performed in the 24 patients 
with HCV RNA+) 
G1 – 15 (68,2%): 1a - 12, 1b – 2, 1 - 1  
G3 – 5 (22,7%) 
G4 – 2 (9,1%) 
G? - 2 
HCV RNA (IU/ml) 
Median, SD, (range) 
(performed in the 24 patients 
with HCV RNA+) 
5170180,83 ± 4861594,17 
(609 - 15400000) 
HBsAg positive (N = 100) 
HBV DNA (IU/ml) 
1 
 (Baseline HBV DNA = 171000000) 
 
Table 7. Data related to infection by hepatitis virus, at baseline. 
Anti-HCV – Hepatitis C virus antibody, HBsAg – Hepatitis B surface antigen. 
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NRTIs pairs N (100 patients) Total 
FTC + TDF 78 
100 3TC + ABC 21 
AZT + 3TC 1 
3th N (100 patients)  Drug Total 
NNRTI 
EFV 85 
86 
100 
NVP 1 
IP 
DRV/r 12 
14 
LPV/r 2 
Table 8. Initial regimen of HAART prescribed to the 100 patients, at baseline. 
NRTIs - Nucleoside Reverse Transcriptase Inhibitors, NNRTIs - Non-Nucleoside Reverse Transcriptase Inhibitors, IPs - 
Protease Inhibitors, FTC – Emtricitabine, TDF – Tenofovir, 3TC – Lamivudine, ABC – Abacavir, EFV – Efavirenz, NVP 
– Nevirapine, DRV – Darunavir, r – Ritonavir as boosted, LPV/r – Lopinavir boosted with ritonavir 
 
 To evaluate potential latent or active tuberculosis, a tuberculin skin test (TST or Mantoux) 
and interferon-gamma release assays (IGRAs) - Quantiferon® were performed in the vast majority 
of the patients. The Mantoux test was performed using the intradermal injection of five tuberculin 
units (5TU) of purified protein derivative (PPD). The results obtained are shown in Table 9. 
 
Diagnostic test Results 
Tuberculin skin test (TST) 
N=97 
Negative – 86 
Positive (> 5mm) – 11 
(Tuberculosis disease - 2 
Latent Tuberculosis assumed - 9) 
IFN-Gamma release assay (IGRA) 
Quantiferon® 
N = 98 
Negative – 84 
Positive – 8 
(Tuberculosis disease – 1 
Latent Tuberculosis assumed - 7) 
Table 9. Tuberculin skin test and Interferon-gamma release assay results at baseline. 
 
Thymus computed tomography 
Since the thymus has been shown to play an important role on the immune 
reconstitution of HIV-infected patients, a mediastinic non-contrast computed tomography (CT) 
was performed to evaluate thymic structure and dimension in 46 patients on the baseline visit (or 
just before) and upon 1 year on HAART, at Computerized Medical Service Image, SA (SMIC), 
Porto. The determination of the thymic volume and index were performed independently, and in a 
blinded manner by two appraisers. The results at baseline and at 1 year of follow-up were 
thereafter compared, between each other and to flow cytometry results. Those results were 
presented in an integrated Master thesis in Medicine (unpublished data) and are presently been 
processed for a future publication. 
 
77 
 
A database of healthy controls (age and gender matched) was constructed from 
individuals recruited from both institutions. The establishment of this database will not be 
described in the context of this work. The data base of controls included 252 adults without HIV 
infection. 
 
2.1.3. Samples Processing and Data Analysis – Work Performed at Laboratory 
 
The processing of samples from patients and healthy controls, regardless the type of 
study or the time-point of the longitudinal study was essentially the same. Whenever there was a 
difference, this was highlighted. Importantly, all the blood was sent to the ICVS and processed on 
the same day it was collected. 
The blood samples were processed as depicted in Figure 1. A blood sample collection 
into a tube without anticoagulant (performed only for longitudinal study) was centrifuged (2500 
rpm, 10 min), the serum was collected and stored in aliquots at -80ºC for subsequent analysis of 
different molecules such as cytokines and/or chemoquines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Several tasks performed at ICVS with blood transported from UHU/CHP. Boxes in yellow: blood processed 
for multiparametric flow cytometry analysis after staining with a combination of monoclonal antigens – analysed 
presently. Boxes in blue: to be processed and analyzed in the future FACS – Fluorescence-activated cell sorting, 
PBMCs - Peripheral Blood Mononuclear Cells 
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A proportion of blood was processed for multiparametric flow cytometry analysis to allow 
the phenotypic characterization of distinct cell populations. Four different sets of monoclonal 
antibodies combinations were used (Table 10); three of them performed on total blood and 
uniquely for the identification of surface markers (M1, M2, and M3) and the fourth performed on 
peripheral blood mononuclear cells (PBMCs) to evaluate surface and intracellular markers (M4). 
A brief description of the protocol performed is described afterwards. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 10. Combination of monoclonal antibodies performed. Each antibody was titrated using serial dilutions until 
optimal concentrations was determined. All antibodies were from Biolegend except for the anti-FOXP3 
(eBiosciences), anti-CD3 V500 (BS Horizon) and anti-Ki67 (BD Biosciences). 
 
Staining Antibody Clone Flurofore Aim 
M1 
CD3 OKT3 PE 
Granulocytes 
B and T cells 
CD15 W6D3 PerCP 
CD19 HIB19 FITC 
TCRαβ IP26 Alexa Fluor 647 
M2 
CD3 OKT3 Pacific Blue 
CD4+ and CD8+
activation 
 T 
cells 
CD4 RPA-T4 APC-Cy7 
CD8 RPA-T8 APC 
CD45RA HI100 FITC 
CD45RO UCHL1 PerCP-Cy5,5 
CD69 FN50 PE 
HLA-DR L243 PE-Cy7 
M3 
CD3 OKT3 PE  
CD4+ and CD8+
T cells subsets: 
       
Recent thymus emigrant 
(RTE) 
Naive 
Memory 
Central memory 
Effector memory 
 
CD4 RPA-T4 APC-Cy7 
CD8 RPA-T8 BV 
CD31 WM59 PE-Cy7 
CD45RA HI100 FITC 
CD45RO UCHL1 PerCP-Cy5,5 
CCR7 TG8/CCR7 Alexa Fluor 647 
 
 
 
M4 
CD3 UCHT1 V500 
 
 
Treg and its 
subsets: 
Naives 
Memory 
RTE 
Proliferation 
CD4 RPA-T4 APC-Cy7 
CD25 BC96 APC 
CD31 WM59 PE-Cy7 
CD45RA HI100 Pacific Blue 
CD127 AO19D5 PerCP-Cy5,5 
 
FOXP3 PCH101 PE 
 
 
Ki67 MOPC-21 FITC 
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Isolation of PBMCs 
PBMCs were isolated using gradient centrifugation with Histopaque 1077 (Sigma-Aldrich) 
(Figure 1). After centrifugation (1500 rpm, 30 min), at room temperature, the plasma (upper 
phase) was collected to cryovials (stored at -80°C) and the interface between the plasma and the 
Histopaque 1077, containing PBMCs, was collected to a new tube with apyrogenic phosphate 
buffered saline (aPBS) (GIBCO/Life Technologies). After washing twice with the aPBS, the cell 
pellet was re-suspended in 500 μL of RPMI supplemented with 10% fetal bovine serum (FBS) 
(both from GIBCO/Life Technologies) and cells were counted using trypan blue to exclude dead 
cells. After taking cells to perform fluorescence-activated cell sorting (FACS) staining (M4), the 
remaining cells were frozen in aliquots of 5x106
 
 PBMCs each, in a media containing 80% RPMI, 
10% FBS and 10% DMSO. 
Staining for surface markers for flow cytometry 
For the surface marking, 100 (M1 and M2) or 200 μl (M3) of whole blood were 
incubated for 15 min, at room temperature, with a defined set of monoclonal antibodies (Table 
10). Afterwards, erythrocytes were lysed by incubation with FACS Lysis Buffer (BD Biosciences, 
San Jose, CA, USA) for 15 min at room temperature. Cells were washed with FACS buffer. 
 
 Staining for intracellular markers for flow cytometry 
 By the time these studies were initiated, no reliable methods were available for the 
staining of FOXP3 on total blood cells. For that reason, this staining had to be performed in 
isolated PBMCs. 
From the PBMCs suspension previously prepared, two million of fresh PBMCs were 
stained for M4 (Table 10). Cells were first incubated with the antibodies for the surface markers 
for 15 min at room temperature. After the excess antibody was washed out, cells were fixed and 
permeabilized using the FOXP3 Staining Buffer Set (eBioscience, San Diego, CA, USA). Cells 
were incubated with a mix of anti-Ki67 and anti-FOXP3 (intracellular markers) and after being 
washed with permeabilization buffer and FACS buffer. 
 
Sample acquisition on the flow cytometer 
All samples were acquired the same day they were processed on a BD LSR II flow 
cytometer (equipped with 3 lasers and 8 fluorescence detectors) using FACS DIVA software 
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(Becton and Dickinson, NJ, USA). Data was analysed using FlowJo Software (Tree Star, OR, 
USA). 
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Abstract
CD4+ regulatory T cells (Tregs) are essential for the maintenance of the immune system’s equilibrium, by dampening the
activation of potential auto-reactive T cells and avoiding excessive immune activation. To correctly perform their function,
Tregs must be maintained at the right proportion with respect to effector T cells. Since this equilibrium is frequently
disrupted in individuals infected with the human immunodeficiency virus (HIV), we hypothesize that its deregulation could
hamper immune reconstitution in patients with poor CD4+ T cell recovery under highly active antiretroviral therapy
(HAART). We analysed Tregs percentages amongst CD4+ T cells in 53 HIV-infected patients under HAART, with suppression
of viral replication and distinct levels of immune reconstitution. As controls, 51 healthy individuals were also analysed. We
observed that amongst the patients with Nadir values (the lowest CD4+ T cell counts achieved) ,200 cells/mL, the
individuals with high Tregs percentages ($10% of total CD4+ T cells) had the worse CD4+ T cell reconstitution. In
accordance, the well-described direct correlation between the Nadir value and CD4+ T cell reconstitution is clearly more
evident in individuals with high Tregs proportions. Furthermore, we observed a strong negative correlation between Tregs
percentages and CD4+ T cell recovery among immunological non-responder HIV+ individuals. All together, this work shows
that high Tregs frequency is an important factor associated with sub-optimal CD4+ T cell recovery. This is particularly
relevant for immunological non-responders with low Nadir values. Our results suggest that the Tregs proportion might be
of clinical relevance to define cut-offs for HAART initiation.
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Introduction
Infection with HIV initiates a series of events that ultimately
lead to profound immunosuppression, caused by functional
abnormalities in the immune system, mainly due to severe
depletion of CD4+ T cells [1].
The introduction of HAART has led to very important declines
in both mortality and morbidity due to HIV infection [2];
however, even though many patients steadily recover their CD4+
T cell compartment over several years post-HAART initiation, the
degree of immune recovery achieved is highly variable. On this,
studies indicate that even after several years of treatment, a
proportion of patients (from 15% to 40%) feature abnormally low
CD4+ T cell counts despite suppression of HIV replication
[3,4,5,6]. This group of individuals is referred to as immunological
discordants or non-responders and, unlike full responders, they are
at increased risk of clinical progression to acquired immunodefi-
ciency syndrome (AIDS)-related and non-related illnesses and
death [2].
Sub-optimal CD4+ T cell recovery may result from excessive/
premature cell death, decreased peripheral proliferation and/or
reduced production of these cells by the thymus. Several factors
have been suggested to contribute to this limited ability of the
CD4+ T cell compartment to normalise (reviewed in [7]) such as
advanced age [8], low baseline CD4+ T cell counts [6,8,9],
residual HIV replication [10], chronic immune activation [11],
abrogated thymic function [12,13], gender [14,15] and genetic
polymorphisms associated with increased programmed cell death
[16,17]. While all these factors are definitely relevant in
establishing different immune reconstitution profiles, there may
be other factors also contributing to this process [7].
Tregs are essential for the maintenance of self-tolerance and
immune homeostasis [18] and have been widely studied in the
context of HIV infection. Most studies have focused on whether or
not these cells are directly infected by HIV, to what extent are they
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depleted/expanded, and their role during the course of disease
progression from HIV infection to AIDS. The ability of HIV to
directly infect Tregs is still a subject of debate. Whilst it has been
reported that they are susceptible to HIV infection in vitro [19,20],
other studies showed that exposure of Tregs to HIV selectively
promotes their survival via a CD4-gp120–dependent pathway
[21]. Moreover, the accumulation of Tregs in the gut or in the
tonsils of HAART-naı¨ve HIV+ patients also argues against
increased killing of these cells in compartments where viral
replication is occurring [22,23].
During the course of disease progression in HAART-naı¨ve
patients, Tregs seems to act as a double-edged sword. On one
hand frequencies of these cells have been shown to negatively
correlate with the levels of immune activation [24,25,26,27,28],
which is one of the key contributors to HIV disease progression
[29,30,31]; on the other hand, high levels of Tregs have also been
linked with suppression of HIV-specific CD4+ and CD8+ T cell
activity and, thus, in this way Tregs could be linked to a worse
disease prognosis [32,33,34]. Tregs have also been investigated in
the context of HAART-associated immune reconstitution, al-
though to a much lesser extent. Results so far also lack a
consensus. Some authors found elevated levels of Tregs in
aviremic HIV+ patients in comparison to healthy controls
[35,36,37,38], whilst others described Tregs frequencies as
following a ‘‘biphasic curve’’ during the first year of HAART
[39], with an initial increase and a subsequent return to levels
comparable to controls [22,23,39]. The observation that the
proportion of Tregs in HAART-treated aviremic HIV+ individuals
is quite diverse prompted us to explore whether distinct values
were associated with differences in CD4+ T cell recovery. Thus,
we investigated how the percentage of Tregs within CD4+ T cells
correlated with CD4+ T cell count recovery and other parameters
of immune reconstitution in HAART-treated HIV+ individuals.
Understanding the mechanisms that limit T cell recovery during
HAART is essential to help adjust guidelines for HAART
initiation, and to prompt investigation of complementary immune
therapies that could enhance immune reconstitution.
Materials and Methods
Ethics Statement
This study was approved by the institutional review board of the
Hospital Joaquim Urbano under the protocol number 168/CES
[addenda number 127/12 (NA-DEFI/089-CES)]. Study subjects
gave written, informed consent prior to their participation.
Study population
A cross-sectional study was performed with 53 HIV+ individuals
recruited from Hospital Joaquim Urbano, Porto, Portugal (4368
years old, range 31 to 58 years old; 79% were males) and 51
healthy individuals recruited from the same hospital and from the
Life and Health Sciences Research Institute, Braga, Portugal
(3969 years old, range 27 to 56 years old; 49% were males).
Inclusion criteria for HIV+ individuals were: infection with HIV-1;
receiving HAART for at least 1 year; being regular on HAART
compliance (with no history of irregular compliance in the past);
plasma viral loads #50 copies HIV RNA/mL; and baseline CD4+
T cell counts #500 cells/mL. Information regarding patient’s
gender, hepatitis C virus (HCV) co-infection, HAART compli-
ance, baseline CD4+ T cell counts, Nadir value and actual CD4+
T cell counts was collected by patients’ physician. CD4+ T cell
counts were obtained by a reference laboratory. CD4+ T cell count
progression for each individual were calculated by subtracting the
baseline CD4+ T cell counts (immediately before HAART
initiation) from the actual CD4+ T cell counts. The CD4+ T cell
slopes (b1) for each individual during the first 12 months of
HAART were calculated by the least square estimation method
using MO Excel (CD4+ T cell count = b0+b16time; b0 being the
CD4+ T cell counts at 0 months of HAART); analysis was
restricted to those subjects who had at least three CD4+ T cell
measurements during the first year after HAART initiation.
Flow cytometry
All samples were processed for flow cytometric analysis on the
day the blood was collected. To stain for cell surface molecules
100 mL of whole blood were incubated with a defined set of
antibodies for 15 min at room temperature, followed by 15 min
with FACS Lysis Buffer (BD Biosciences), washed and acquired.
To determine the expression of the intracellular marker FOXP3, 2
million peripheral blood mononuclear cells (PBMCs), obtained
from heparinized blood by Histopaque 1077 (Sigma-Aldrich)
gradient centrifugation, were stained for cell surface markers for
20 min, washed, fixed, permeabilized and stained using the
FOXP3 Staining Buffer Set (eBiosciences). Antibodies used were
anti-CD4 (clone RPA-T4; BD Biosciences), anti-CD3 (clone
OKT3 or UCHT1), anti-CD45RO (clone UCHL1), anti-HLA-
DR (clone L243), anti-CD127 (clone PHCD127), anti-CD25
(clone BC96, all from Biolegend) and anti-FOXP3 (clone
PCH101, eBiosciences). Optimal concentration was determined
for each antibody by testing serial dilutions. All samples were
acquired on a BD LSR II flow cytometer using FACS DIVA
software (Becton and Dickinson, NJ, USA) and data were analysed
using FlowJo Software (Tree Star, OR, USA).
Statistical analysis
The normality assumption for parametric tests was tested using
the Kolmogorov-Smirnov test (with Dallal-Wilkinson-Lilliefor
Significance Correction); since the Tregs percentages from HIV+
individuals did not follow a normal distribution all tests applied
were non-parametric. Groups’ medians, variances and proportions
were compared using the Mann-Whitney, Levene’s and Chi-
square tests, respectively. Spearman’s rank correlation coefficient
was performed to assess the correlation between two variables. P-
values less than 0.05 were considered statistically significant.
Results and Discussion
Heterogeneous distribution of Tregs percentages among
HIV+ individuals under HAART
Human Tregs were first identified on the basis of their high-
level expression of CD25 (the IL-2Ra chain) [40,41,42] and
subsequently by the expression of the Forkhead-box transcription
factor FOXP3 [43,44]. However, further human studies have
shown that activated CD4+ T cells also up-regulate the expression
of CD25 and can transiently express FOXP3 [45,46]. More
recently, it was shown that Tregs express low levels of CD127 (the
IL-7Ra chain), and therefore this molecule is considered useful as
an additional marker to identify this population [47,48,49,50].
Even though the utility of these, and other putative Tregs markers,
is still debated, they currently represent the best available markers
to identify this cell subset. With this in mind, we chose to identify
Tregs within CD4+ T cells (CD3+CD4+) as the CD127lowCD25-
highFOXP3+ population (Figure 1A).
Using this gating strategy to define Tregs the vast majority of
our control individuals (75%) featured Tregs percentages between
5% and 10% (Figure 1B), frequencies similar to those reported by
other groups using the same markers and gating strategy [51]. By
comparing the median Tregs percentages no differences were
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observed between the HIV+ and control individuals (p = 0.8250,
Mann-Whitney test; Figure 1B). However, the range of Tregs
percentages observed was higher amongst HIV+ individuals
(p = 0.0020, Levene’s test; Figure 1B). It was interesting also to
note that the number of individuals with Tregs percentages $10%
was significantly higher in the HIV cohort as compared to control
(p = 0.0313, Chi-Square test; Figure 1C).
As studies of HAART-treated HIV+ individuals have yielded
conflicting data regarding Tregs percentages
[22,23,35,36,37,38,39], we sought to understand if other variables
could be influencing this parameter. We found that neither
individual’s age, number of years in therapy, overall immune
activation or infection by the hepatitis C virus (HCV) impacted
upon Tregs percentage in our HIV population (Figure S1).
Overall, whilst there were no differences in the median
percentage of Tregs in HIV+ and control individuals, there was
a wider distribution of Tregs percentages among HIV+ individuals,
ranging from 3% to 19%. Furthermore, Tregs frequencies were
not related to age, number of years of treatment, overall immune
activation or infection by HCV (Figure S1).
The majority of HIV+ individuals with high Tregs
percentages featured low Nadir value and incomplete
CD4+ T cell recovery
To evaluate whether distinct Tregs percentages were related to
different degrees of CD4+ T cell recovery amongst HAART-
treated HIV+ individuals, we assessed potential correlations
between distinct parameters to evaluate CD4+ T cell reconstitution
and Tregs percentages. As shown in Figure 2A, we found no
correlation between Tregs percentages and CD4+ T cell counts,
CD4+ T cell progression or CD4+ T cell slope (R =20.2130 and
p = 0.1270; R =20.2409 and p = 0.0823; R =20.1836 and
p = 0.2633, respectively, Spearman’s correlation). While there is
no clear correlation between the CD4+ T cell reconstitution and
Tregs percentage, as previously reported by others [37,39], it is
interesting to note that amongst HIV+ individuals with high Tregs
proportions ($10%) the majority featured low CD4+ T cell
numbers (,500 cells/mL), low CD4+ T cell recovery and low
CD4+ T cell slope (Figure 2A).
To further dissect the link between low CD4+ T cell counts and
high Tregs percentages in HIV+ individuals we re-assessed the
relationship between these two variables taking into account the
gender, number of years on treatment and the Nadir value, all of
which are factors known to influence immune reconstitution
[3,4,5,15,52,53]. No clear correlations were observed between the
Tregs percentages and CD4+ T cell counts when patient’s gender
(R =20.2480 and p = 0.1090 for males; R =20.2480 and
p = 0.4920 for females, Spearman’s correlation), years of therapy
(R =20.0772 and p = 0.7534 for ,5 y HAART; R =20.2598
and p = 0.1379 for $5 y HAART, Spearman’s correlation) and
the Nadir value (R =20.07719 and p = 0.0648 for ,200 cells/mL,
R = 0.0,0963 and p = 0.6893 for $200 cells/mL, Spearman’s
correlation) were taken in consideration (Figure 2B).
Of notice, we observed that almost all individuals with Tregs
percentage $10% and CD4+ T cell counts #500 cells/mL had
Nadir values ,200 cells/mL (Figure 2B). Since the Nadir value has
been considered one of the key factors influencing immune
reconstitution [3,4,5], we considered relevant to further explore
this association. To do so we analysed CD4+ T cell counts in HIV+
individuals divided on the basis of their Nadir values (,200 and
$200 cells/mL) and subdivided according to their Tregs frequency
(,10%, Figure 3A). As previously reported [3,4,5], we observed
that individuals with low Nadir values (,200 cells/mL) had lower
CD4+ T cell counts upon treatment (p = 0.0234, Mann-Whitney
test, Figure 3A). Interestingly, this difference lost statistical
significance when only those individuals with Tregs percentages
,10% were analysed (p = 0.1934 by Mann-Whitney test,
Figure 3A).To address the influence of Tregs percentages on the
well-established correlation between CD4+ T cell recovery and
Nadir value [3,4,5], a correlation between these two variables
separating the individuals according to the Tregs percentages was
performed. As shown previously by others we observed that CD4+
T cell counts positively correlate with the Nadir value when all
HIV+ individuals are considered (R = 0.4481 and p = 0.0008,
Spearman’s correlation; Figure 3B). Of interest this correlation
Figure 1. High variability of Tregs percentages in HIV+ individuals. A. Representative dot plots from an HIV+ individual illustrating the gating
strategy for Tregs analysis. Lymphocytes (selected according to FSC and SSC) were gated on CD3+CD4+ cells, on low or no expression of CD127 and
on the expression of FOXP3 and high levels of CD25. B. Tregs percentages amongst CD4+ T cells in control and HIV+ individuals. Each dot represents a
single individual and the lines the median Tregs percentages within CD4+ T cells. Dashed lines represent the range of Tregs percentages among total
CD4+ T cells described for healthy individuals (between 5% and 10%) [51]. C. Percentage of individuals with Tregs #5% and $10% in controls and
HIV+ individuals. P-value for the comparison of these proportions (Chi-square test) and the 95% confidence interval are depicted.
doi:10.1371/journal.pone.0057336.g001
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was much stronger when only those individuals with $10% Tregs
were taken into account (R = 0.8392 and p = 0.0006 by Spear-
man’s correlation; Figure 3B) indicating that CD4+ T cell recovery
of individuals with low Nadir is hampered by high proportions of
Tregs.
Results reported by Gaardbo et al. [36], who analysed a
correlation between CD4+ T cell counts and Tregs percentages in
patients sub-divided according to baseline CD4+ T cell counts (,
and .200 cells/mL), did not find any differences. Their analysis
focused on HIV+ patients with over 2 years of treatment. Since we
have observed that time in treatment seems to have no impact on
the CD4+ T cell counts vs. Tregs proportion relation, the
discrepancy is most likely due to the use of different markers to
define Tregs or to the fact that they used baseline CD4+ counts
instead of Nadir values.
Strong correlation between Tregs percentages and CD4+
T cell counts progression in immunologically non-
responders HIV+ individuals
While the observation that some individuals are unable to
reconstitute the CD4+ T cell numbers to normal values, even after
several years of therapy and suppression of viral replication, there
is still a lack of consensus on the definition of immunological non-
responder individuals [7]. The most well accepted definition for
immunological non-responders patients are the ones whose CD4+
T cell counts remained below a threshold (from 350 to 500 cells/
mL) after a variable period of time of treatment (from 4 to 7 years)
[3,4,5]. Considering as immunological non-responders the indi-
viduals under regular HAART for at least 5 years and whose
CD4+ T cell counts were ,500 cells/mL (14 out of 53 individuals
in our population), we observed a strong correlation between
Tregs percentages and CD4+ T cell progression (R =20.7765 and
p = 0.0004, Spearman’s correlation, Figure 4), which strengthens
the observed association between high Tregs percentage and poor
CD4+ T cell reconstitution.
The biological processes that could lead to different Tregs
percentages in HIV+ individuals remain unclear. Whilst some
studies have shown that Tregs are permissive to HIV infection in
vitro [19,20], which could lead to the depletion of this subset in
HIV+ individuals, others have shown that HIV selectively
promotes Tregs survival by reducing apoptosis levels in this
subset, and thereby increasing their proportion within the CD4+ T
Figure 2. HIV+ individuals with high Tregs percentages feature low CD4+ T cell counts and Nadir values. A. Percentages of Tregs
amongst HIV+ individuals were plotted against CD4+ T cell counts, CD4+ T cell progression and CD4+ T cell slope (for the first year of HAART). Each dot
represents a single individual. B. Tregs percentages were plotted against CD4+ T cell counts in HIV+ individuals grouped by gender) number of years
under HAART and the Nadir value.
doi:10.1371/journal.pone.0057336.g002
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cell pool as a whole [21]. Several hypotheses have been put
forward in order to explain the observed differences in Tregs
percentages, such as increased Tregs thymopoiesis [37] or even
conversion of conventional CD4+ T cells to Tregs [54,55]. Further
studies are still needed in order to fully understand Tregs kinetics
during immune reconstitution in HAART-treated HIV+ individ-
uals.
Altogether, our data show that high proportions of Tregs during
treatment in individuals who reached low Nadir values (,200
CD4+ T cells/mL) have a synergistic/cumulative negative associ-
ation with incomplete CD4+ T cell recovery. While the clear
association of high percentage of Tregs with low Nadir and
incomplete reconstitution would suggest a potential negative
impact of Tregs on CD4+ T cell recovery, it cannot be excluded
the possibility that Tregs, in individuals with incomplete immune
reconstitution, play an important role preventing excessive
expansions of oligoclonal populations. This could be of importance
to better decide when to start treatment. If during the course of
HIV infection an individual already has a high Tregs percentage,
our results would support the need for HAART initiation even if
CD4+ T cells counts remain relatively high. Further studies
involving longitudinal follow up are needed in order to fully
understand how the high percentage of Tregs abrogates the CD4+
T cells recovery. Moreover, these studies could also help defining
the parameters that synergise with high Tregs frequencies and low
Nadir for sub-optimal T cell recovery.
Supporting Information
Figure S1 Tregs percentages are not affected by HCV
infection, age, time in treatment or immune activation.
A. Tregs percentages were compared in HIV+ individuals when
divided according to co-infection with HCV (p = 0.1250, Mann-
Whitney test). B. Relationship between the Tregs percentages and
age (left panel; R =20.1520, p = 0.2773; Spearman’s correlation),
years in therapy (middle panel; R =20.0682, p = 0.6277; Spear-
man’s correlation) and overall immune activation (right panel;
R = 0.1400, p = 0.3660; Spearman’s correlation). Each dot
represents a single individual.
(TIF)
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Figure 3. Individuals with high Tregs percentages feature the strongest correlation between CD4+ counts and Nadir values. A. HIV+
individuals were subdivided according to their Nadir counts (,200 and $200 cells/mL) and grouped according to Tregs percentages (all individuals
and individuals with ,10% Tregs) and the CD4+ T cell counts are shown for each group. Each dot represents a single individual and the line the
median value for each group. P-value for the comparison of the CD4+ T cell counts is indicated (Mann-Whitney test). B. Scatter plots illustrating the
correlation between Nadir value and CD4+ T cell counts during HAART. Each dot represents a single individual. P-value for the correlation between
CD4+ T cell counts and the Nadir value is shown (Spearman’s correlation).
doi:10.1371/journal.pone.0057336.g003
Figure 4. Immunological non-responders present a strong
correlation between Tregs percentages and CD4+ T cell
progression. Scatter plot illustrating the correlation between Tregs
percentages and CD4+ T cell progression. Patients were selected on the
basis of being under HAART for at least 5 years and whose actual CD4+
T cell counts are ,500 cells/mL or .500 cells/mL. Each dot represents a
single individual.
doi:10.1371/journal.pone.0057336.g004
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Figure_S1: Treg percentages are not affected by HCV infection, age, time in treatment or 
immune activation. A. Treg percentages were compared in HIV+ individuals when divided 
according to co-infection with HCV (p = 0.1250, Mann -Whitney test). B. 
 
Relationship between 
the Treg percentages and age (left panel; R = −0.1520, p = 0.2773; Spearman's correlation), 
years in therapy (middle panel; R = −0.0682, p = 0.6277; Spearman's correlation) and  overall 
immune activation (right panel; R = 0.1400, p = 0.3660; Spearman's correlation). Each dot 
represents a single individual. 
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2.3. The Dynamics of Regulatory T Cells on the Immune Recovery of Individuals Infected by the 
Human Immunodeficiency Virus on Antiretroviral Therapy 
 
2.3.1. Abstract 
 
Background: The introduction of highly active antiretroviral therapy (HAART) to treat individuals 
infected by the human immunodeficiency virus (HIV) resulted in a tremendous decrease in 
morbidity and mortality. Nevertheless, a sizeable percentage of HIV-infected individuals on 
HAART fail to increase their CD4+
Methods: A longitudinal study on 81 HIV-infected patients was performed. All individuals had 
criteria to initiate HAART, and were followed from the moment they initiated HAART (baseline) 
and during the following 24 months. CD4
 T cell counts, despite showing viral load suppression. Several 
factors have been put forward to explain this immune reconstitution impairment. Among them, 
the effect of regulatory T cells (Treg) has been widely discussed, although the dynamics and the 
role of Treg remain controversial. 
+
Results: Treg percentages from baseline and up to 6 months of HAART are higher in comparison 
to healthy controls, mainly for the individuals with <200 CD4
 T cell counts, Treg percentages and specific Treg 
subpopulations (naïve and cycling cells) were evaluated. 
+ T cells/μL at baseline. Of notice 
there is great diversity on the values, particularly for this last group of individuals. Despite the 
evolution of Treg percentages to levels similar to healthy controls, the percentage of CD45RA+ 
(naïve) and of Ki67+
Conclusions: The fact that some patients reach very low CD4
 (cycling) cells among Treg remained altered throughout the 24 months of 
follow-up.  
+ T cell counts before HAART 
initiation leads to a deregulation of the Treg subpopulations that are not fully recovered, even 
after 24 month of efficient HAART. These patients are not just unable to recover the CD4+
Running title (26/40 characteres): Treg dynamics during HAART. 
 T cells 
to numbers considered normal but in addition the quality of the reconstitution is also jeopardize. 
Keywords: Human Immunodeficiency Virus; Antiretroviral therapy; Immune reconstitution; 
Regulatory T cells. 
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2.3.2. Introduction 
 
During the course of the infection by the human immunodeficiency virus (HIV) various 
mechanisms contribute to the gradual depletion of CD4+
The emergence of drugs with potent antiretroviral activity, and their use in combination 
for the treatment of HIV infection markedly reduced the negative effects of HIV infection. The 
highly active antiretroviral therapy (HAART) dampens viral replication for the vast majority of the 
patients with a consequent increase of the CD4
 T cells. The deleterious effects and 
immune dysfunction are extended to other cells of the immune system. As a result, a steady 
imbalance occurs mainly at the level of the cell-mediated immunity termed as acquired 
immunodeficiency syndrome (AIDS). If left untreated, AIDS will lead to a final stage of inability to 
counteract major life threatening infections and some tumors, resulting in high morbidity and 
mortality rates [1]. 
+ T cell counts, culminating to what is called 
immune reconstitution [2]. However, among the HIV-infected individuals that initiate HAART and 
become virologically suppressed during several years (4 to 7 years), 15 to 40% of them (number 
that varies depending on the study) fail to reconstitute the CD4+
The failure of the immune system to recover might result from insufficient production 
and/or excessive destruction of CD4
 T cell counts. These individuals 
are referred to as immunological non-responders [3]. 
+ T cells. Several conditions may contribute, individually or in 
combination, to this defect such as [3-5]: failure of the bone marrow to produce hematopoietic 
stem cells; impaired thymic function; advanced age; immunosenescence; residual viral 
replication; infection by more cytopathogenic virus as those that use CXCR4 as a co-receptor; 
enhanced T cell activation and apoptosis; gut microbial translocation that could lead to increased 
T cell activation and destruction; or co-infections by hepatitis C virus, cytomegalovirus, or other 
herpes virus. It is worth noticing that some of these conditions can be associated to each other, 
being one the cause or effect of the others. Low CD4+ T cell counts at the therapy onset has 
consistently been shown as a strong predictor for worse CD4+
The role of regulatory T cells (Treg) in HIV infection pathogenesis has been extensively 
debated [9]. These cells may play a beneficial role by dampening the immune activation [10-12] 
and suppressing HIV-replication within conventional CD4
 T cell counts recovery even for 
virologically suppressed patients undergoing HAART [6-8].  
+ T cells [13]. On the other hand, Treg 
may have a harmful role by impairing specific anti-HIV immune response [14-17], inhibiting 
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lymphopenia-induced proliferation [18, 19], contributing for gut microbial translocation [20, 21] 
and for an exacerbated fibrosis of lymphoid tissues [22].  
Most of the studies describe that Treg percentage among CD4+
The effect of Treg percentages on the immune recovery of patients on effective HAART 
has also been explored. Despite high Treg percentages have been related to an impaired immune 
reconstitution [18, 31-34], none of these studies have correlated the Treg percentage at HAART 
onset with immune recovery. To better understand the temporal evolution of the Treg 
(percentages and subpopulations) during HAART and the potential effect of Treg percentages, at 
baseline and during therapy, on the immune reconstitution, we evaluated longitudinally 81 HIV-
infected individuals since the moment they initiated HAART and for the following 24 months. 
 T cells in chronic HIV-
infected patients naïve for HAART is higher in comparison to healthy controls [23-28], though 
some studies observe no differences [10, 14]. The evolution of Treg percentage upon HAART 
initiation is even more controversial; despite that most studies describe a decrease in the Treg 
percentage among individuals receiving HAART [24-26, 28-30], many claim that these values are 
maintained above the ones considered normal from healthy controls [24, 26, 27, 29]. The lack of 
consensus in this aspect might be related to different factors, namely differences on the study 
groups characteristics (cross-sectional over longitudinal studies; patients heterogeneity over 
homogeneity at HAART onset; differences on the size of the cohorts analyzed, being most of 
them relatively small) and/or from different strategies used to identify Treg.   
 
2.3.3. Materials and Methods 
 
Ethics Statement 
Individuals undergoing medical care at the Hospital Joaquim Urbano Unity of Centro 
Hospitalar do Porto, Porto, Portugal (HJUU/CHP) were selected for this study. After explanation 
of the entire study protocol, all the patients signed an informed consent prior to their enrollment 
in the study. A local Ethical Committee approval was received for this study (reference 168/CES 
on 2nd
 
 October 2009). It should be noted that HJUU/CHP is the one that follows a great 
proportion of the HIV infected individuals from the city of Porto and surrounding as its main focus 
is on infectious diseases.  
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Study Population 
Individuals were enrolled in this study with the following criteria: age over 18 years; 
chronically infected by HIV-1 (from now on referred simply as HIV); naïve for HAART but with 
criteria to initiate HAART. The moment of HAART initiation is referred in the study as 0 months or 
as baseline. The individuals were followed thereafter at 2, 6, 9, 12, 16, 20 and 24 months. 
HAART schemes chosen (Table 1) for each individual took into consideration the scientific policy, 
national and international guidelines [35], particular characteristics of each individual and drug 
cost, as it is usual for all individuals being followed at our care unit. 
At the end of the 24 months follow-up, only those patients that had been regular on 
therapy compliance and had plasma viral loads bellow 50 copies/mL, were included in this study 
in a total of 81 (demographic features depicted in Table 1). From these, two individuals had a 
virological blip at 24 months despite being regular on HAART; these individuals were maintained 
in the study after confirming virological suppression at 28 months (all virological blips were under 
200 copies/mL; Figure S1). In two patients, the data relative to 28 months of follow-up were 
used instead of 24 months (one has missed the 24 months visit and the other patient had 
pneumonia at 24 months, AH031 and AH030, respectively, in Supplementary Table 1). In 
parallel, we enrolled a group of age- and gender-matched HIV-uninfected subjects (Table 1). 
 
Sample processing and flow cytometry 
In each study visit blood was collected and sent both for routine analysis by a reference 
laboratory (CD4+
For the multiparametric flow cytometry surface staining, 100μL of whole blood was 
incubated for 15 min, at room temperature, with a defined set of monoclonal antibodies directed 
to human molecules (all from Biolegend): Pacific anti-CD3 (clone OKT3), anti-CD4 (clone RPA-
T4), anti-CD8 (clone RPA-T8), anti-CD45RA (clone HI100), anti-CD45RO (clone UCHL1) and anti-
HLA-DR (clone L243). Afterwards, erythrocytes were lysed upon incubation for 15 min in FACS 
Lysis Buffer (BD Biosciences, San Jose, CA, USA), at room temperature. Cells were washed with 
FACS buffer, and acquired on a flow cytometer. 
 T cell counts and HIV viral load) and for complementary multiparametric flow 
cytometry analysis. These procedures were performed on the same day the blood was collected. 
The analysis of Treg was performed in peripheral blood mononuclear cells (PBMCs) 
isolated upon gradient centrifugation with Histopaque 1077 (Sigma-Aldrich). Two million PBMCs 
were first labeled with the surface markers for 15 min at room temperature: anti-CD4, anti-CD25 
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(clone BC96), anti-CD45RA, anti-CD127 (clone AO19D5, all from Biolegend) and anti-CD3 (clone 
UCHT1, BD Horizon). After the excess antibody was washed out, cells were fixed and 
permeabilized using the FOXP3 Staining Buffer Set (eBioscience, San Diego, CA, USA), 
accordingly to the manufacturer’s instructions. Cells were afterwards incubated for 30min with 
anti-FOXP3 (clone PCH101, eBiosciences) and anti-Ki67 (clone MOPC-21, BD Pharmigen). Cells 
were washed and acquired on the flow cytometer. 
 
Variable HIV-infected 
(n=81) 
Control 
(n=44) 
Age, years (mean, range) 1 41 (22-67) 2 39.5 (22-56) 
Male gender (%, n)  77.8% (63) 68.0% (30)  3 
HIV transmission mode (n) 
Intravenous drug users 
Men who have sex with men 
4 
Heterosexuals 
Unknown 
 
19 
23 
37 
2 
NA 
CD4+ T cell counts, cells/μL (mean, range) 274 (8-1033) 1 NA 
log10 viral load, copies/mL(mean, range) 1 5.33 (3.8-7.0) NA 
With criteria for AIDS (%, n) 44.4% (36)  5 NA 
Hepatitis C virus-positive (%, n) 6 22.2% (18) NA 
Hepatitis B virus-positive (%, n) 1.2% (1) NA 
With viral mutations of resistance (%, n) 18.5% (15) NA 
HAART regimen components (n) 
2 NRTIs 
  TDF+FTC 
  ABC+3TC 
  ZDV+3TC 
3rd Drug (NNRTI or PI/r) 
EFV/NVP 
DRVr/LPVr 
 
 
61 
19 
1 
 
68/1 
10/2 
NA 
 
Table 1. Demographic information of the study individuals. 
1At baseline; 2No significant difference between the mean age of the two groups (unpaired T-test; p=0.533); 3No 
significant difference between the percentage of males on the two groups (Fisher exact probability test; p=0,285); 
4Five of these patients presented also heterosexual risk for HIV transmission; 5Accordingly to the guidelines of Centers 
for Disease Control and Prevention [36]; 6 
Abbreviations: ABC, abacavir; DRVr, ritonavir boosted darunavir; EFV, efavirenz; FTC, emtricitabine; LPVr, ritonavir 
boosted lopinavir; NA, not applicable; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside (or 
nucleotide) analogue reverse transcriptase inhibitors; NVP, nevirapine; PI/r, ritonavir boosted protease inhibitor; TDF, 
tenofovir disoproxil fumarate; ZDF, zidovudine; 3TC, lamivudine. 
Positive for hepatitis C virus antibodies and RNA. 
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Each of the antibodies used were titrated using serial dilutions until the optimal 
concentrations were determined. All samples were acquired on a BD LSRII flow cytometer using 
FACS DIVA software (Becton and Dickinson, NJ, USA) and data were analyzed using FlowJo 
Software (Tree Star, OR, USA). 
 
Statistical analysis 
To evaluate normal distribution of the variables, skewness and kurtosis values were 
calculated and approximate normal distribution was defined for variables with absolute values of 
skewness below 3 and kurtosis below 8 [37]. 
As all variables followed a normal distribution, parametric tests were performed: Pearson’s 
correlation coefficient test to relate two distinct variables; unpaired T-test to compare two group’s 
means; one-way ANOVA followed by Bonferroni’s multiple comparison tests to compare more 
than two independent groups’ means; ANOVA repeated measurements (using the Geisser-
Greenhouse correction for sphericity) followed by Bonferroni’s multiple comparison tests to 
evaluate progression; and two-way ANOVA repeated measurements followed by Sidak’s multiple 
comparison test to compare and evaluate progression of more than two independent groups of 
individuals. To evaluate the predictors of a specific event, hierarchical linear regression models 
were used. Overall, significance was assumed when p<0.05 and represented in the graphs as *. 
To perform repeated measurements analysis, missing values are not allowed; to overcome 
this limitation (and only to perform these statistical analysis in Figures 1C, 1D and 5), these 
values were estimated by calculating the mean of the neighbor values (estimated values 
represented 1.25% and 2.89% of all the CD4+
Statistical analyses were performed using the IBM SPSS v.22 or the GraphPad Prism v.6. 
 T cell counts and Treg proportions measurements, 
respectively). It should be noted that the analysis was also performed excluding subjects who had 
at least one estimated value and the results were similar to those obtained using estimated 
values. Supplementary Table 1 depicts the raw data and highlights the values that were 
estimated.  
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Patient 
ID 
%Treg among CD4+ T cells   CD4+ T cell counts 
over time on HAART   over time on HAART 
0 2 6 9 12 16 20 24   0 2 6 12 16 20 24 
AH001 31,5 6,9 12,0 6,6 8,8 7,7 7,9 6,4 
 
11 59 116 180 301 373 382 
AH003 19,5 6,0 12,0 7,5 7,5 7,6 7,0 6,0  22 135 128 186 159 182 191 
AH004 11,5 9,3 8,2 10,2 11,9 12,9 8,5 6,5 
 
292 571 460 519 451 467 435 
AH005 12,9 5,3 7,3 7,5 7,0 9,3 5,8 6,6  257 413 370 549 604 585 344 
AH006 
 
14,0 13,4 15,7 10,2 13,4 11,7 14,8 
 
43 177 274 252 304 367 363 
AH007 12,5 9,9 10,8 5,1 11,0 11,8 8,1 11,3  147 414 425 534 819 629 679 
AH009 10,9 5,7 8,3 8,7 12,4 1,2 7,4 13,6 
 
310 544 427 555 451 625 600 
AH010 9,0 7,4 7,4 6,6 6,8 7,0 7,8 9,6  316 285 325 365 379 675 473 
AH011 12,6 13,9 20,3 4,9 16,4 15,3 19,9 11,5 
 
182 176 208 198 220 301 304 
AH012 12,2 10,7 13,3 10,4 9,8 10,0 6,5 9,8  230 347 508 472 532 646 641 
AH013 2,6 21,7 23,3 15,2 19,3 11,4 10,2 7,8 
 
30 60 190 204 329 273 303 
AH014 4,6 4,1 4,7 9,1 5,6 4,4 10,8    334 948 635 639 612 624 751 
AH015 6,7 8,7 7,7 6,5 6,3 6,8 4,2 7,3 
 
291 120 111 141 102 134 138 
AH016 7,9 9,1 7,9 9,4 9,9 10,6 11,1 9,7  974 1078 1284 1257 1035 1449 1380 
AH017 15,4 17,8 14,6 14,5 11,4 12,2 10,8 11,7 
 
408 448 524 486 468 443 374 
AH018 12,5 10,3 11,2 10,8 8,7 10,1 9,4 10,5  338 456 576 1042 850 818 747 
AH021 12,6 7,9 5,0 7,0 8,9 7,7 4,0 6,4 
 
239 529 746 649 693 665 644 
AH022 13,4 11,4 10,7 12,1 12,3 9,8 13,9 11,6  268 321 435 395 344 538 506 
AH023 18,0 12,0 10,4 11,5 10,9 8,1 12,0 10,8 
 
314 459 530 626 691 641 658 
AH025 12,7 6,5 10,0 8,9 3,2 7,2 6,4 3,0  278 287 201 245 243 288 378 
AH026 6,4 6,6 6,6 7,7 3,7 5,0 1,1 3,1 
 
665 1030 655 996 1180 799 1242 
AH027 7,5 6,1 5,5 8,0 1,7 4,6 5,5 2,2  415 441 393 658 840 667 972 
AH030 5,0 4,2 7,0 4,5 5,1 5,2 5,0 2,3 
 
330 390 419 449 567 519 477 
AH031 6,5 8,5 8,9 10,5 8,1 3,9 6,0 7,4  228 323 339 300 345 318 458 
AH032 12,1 14,7 12,4 13,7 12,2 13,0 10,8 11,5 
 
303 333 464 400 504 480 452 
AH033 7,3 11,6 14,5 17,4 8,7 11,0 6,2 6,7  68 270 282 428 512 515 454 
AH034 3,2 3,6 3,8 3,6 2,8 4,6 4,0 3,7 
 
306 400 475 507 392 612 588 
AH035 11,1 13,1 10,2 11,5 10,9 11,6 11,4 10,9  25 229 178 285 250 360 299 
AH036 7,8 8,7 9,2 8,4 8,2 1,1 8,4 7,8 
 
263 327 330 392 439 494 411 
AH037 2,6 12,5 21,6 17,4 12,2 3,6 8,8 6,6  92 163 169 133 322 368 322 
AH039 17,3 42,9 42,2 20,9 19,1 22,3 16,6 16,1 
 
9 77 72 100 155 121 152 
AH040 10,2 10,4 9,0 12,5 8,0 9,8 11,9 10,4  422 475 329 402 563 398 452 
AH041 8,1 11,5 13,6 9,7 7,3 4,8 6,7 8,3 
 
397 674 535 692 692 622 659 
AH042 9,6 15,8 13,5 14,4 11,3 12,6 17,1 10,3  262 366 386 426 425 397 538 
AH044 0,4 8,5 12,9 14,7 13,7 9,3 9,5 8,6 
 
56 489 463 537 505 434 439 
AH045 8,1 7,5 7,0 8,1 5,9 6,5 2,1 6,5  481 771 880 809 817 830 811 
AH046 9,9 9,2 9,5 8,5 6,4 5,0 7,3 3,0 
 
388 598 1002 725 890 972 724 
AH047 9,4 9,6 9,8 7,5 7,2 6,1 8,6 7,0  321 428 308 363 399 524 486 
AH048 22,1 24,9 24,3 20,0 12,1 29,7 17,0 12,4 
 
63 205 126 221 207 236 202 
AH049 6,8 8,9 9,6 9,2 11,9 11,6 11,0 8,4  415 420 424 488 599 533 503 
AH050 12,9 17,2 16,7 11,9 12,2 10,2 16,3 6,8 
 
303 514 435 389 452 481 581 
AH051 7,1 9,3 8,5 7,6 7,0 7,1 8,1 6,3  784 649 852 757 1039 761 998 
AH052 8,0 8,4 9,3 5,7 6,5 7,7 7,4 2,2 
 
107 165 213 300 290 360 348 
AH053 15,3 20,1 21,1 20,0 9,1 10,4 10,0 10,7  32 244 256 518 475 526 337 
AH054 7,6 9,3 8,5 6,5 8,2 7,2 6,3 6,7 
 
286 505 579 747 652 477 581 
AH058 10,1 12,8 12,6 13,7 10,2 7,5 13,3 8,0  326 272 295 414 385 406 373 
AH059 5,3 5,6 6,8 6,4 2,6 7,4 0,7 7,4 
 
1033 872 960 847 895 888 933 
AH060 5,1 15,8 10,8 11,0 11,7 9,3 0,7 6,3  341 516 524 872 614 864 629 
AH061 16,9 5,5 5,8 6,3 4,2 5,6 3,8 5,7 
 
339 410 398 398 537 546 642 
AH062 15,5 10,0 10,4 10,8 10,0 9,3 2,5 8,3  205 391 361 444 473 565 512 
AH063 13,4 8,7 7,9 6,8 8,3 7,6 4,9 7,6 
 
146 262 293 248 335 358 300 
AH064 11,8 13,2 10,7 10,7 10,0 10,2 1,4 8,9  603 580 724 772 865 713 694 
AH065 12,1 8,7 6,4 8,7 6,9 7,2 5,7 7,0 
 
319 433 673 593 654 708 716 
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AH066 29,4 48,6 14,9 9,9 14,7 14,1 10,1 9,6   12 112 155 209 274 475 375 
AH067 10,4 8,8 5,2 7,6 5,5 6,1 5,1 5,6 
 
504 631 744 791 857 968 950 
AH068 9,6 6,9 5,1 5,2 6,7 7,5 6,5 7,4  540 680 887 1093 866 911 1097 
AH069 11,3 9,9 21,5 8,4 5,8 6,6 6,7 4,6 
 
334 350 397 546 595 521 624 
AH070 8,4 7,4 6,1 4,8 6,1 7,3 3,9 4,3  269 521 574 575 660 659 630 
AH073 35,4 23,9 5,9 9,2 9,8 7,7 11,3 11,9 
 
37 85 118 104 106 140 222 
AH074 18,1 20,0 21,8 17,9 13,9 9,3 14,1 13,6  61 201 341 354 331 337 380 
AH075 7,1 5,3 5,8 4,7 7,2 6,2 5,0 2,1 
 
319 412 608 350 462 468 468 
AH076 7,8 8,9 8,6 6,1 8,9 8,3 5,9 11,0  296 352 407 550 604 623 544 
AH077 8,9 11,5 13,4 3,6 8,5 7,3 5,3 6,9 
 
471 748 1227 1145 930 1355 1213 
AH078 6,6 5,3 5,7 4,4 2,6 5,8 2,3 7,6  208 426 297 422 518 447 412 
AH079 15,4 14,3 5,0 8,6 7,9 5,9 8,4 5,7 
 
47 142 166 253 176 226 307 
AH080 7,5 11,4 6,3 12,3 10,9 8,3 9,2 9,1  14 167 197 197 263 327 302 
AH081 11,2 9,4 1,6 7,2 7,8 1,8 7,7 7,6 
 
181 262 324 320 327 463 467 
AH082 14,6 11,0 2,0 6,4 6,8 5,6 6,6 6,1  176 218 272 370 363 347 409 
AH083 27,3 16,1 4,0 14,2 12,1 0,8 8,7 13,0 
 
181 325 353 508 467 768 589 
AH084 8,0 6,1 10,1 5,3 3,5 2,1 9,2 13,4  243 273 336 332 379 448 387 
AH085 17,6 15,1 16,5 12,7 12,1 14,7 11,9 
  
8 43 47 65 119 174 186 
AH086 8,6 10,0 10,7 16,4 11,6 10,0 5,1 8,8  92 202 159 159 191 165 214 
AH087 1,5 11,6 20,5 10,8 7,0 6,9 8,0 7,7 
 
42 142 188 335 347 414 511 
AH088 5,6 13,6 10,1 10,5 9,1 8,1 10,0 9,7  174 227 238 180 241 277 274 
AH089 5,1 13,4 3,3 8,3 10,7 8,3 9,6 8,9 
 
143 396 254 328 240 304 263 
AH090 16,2 12,2 13,4 7,6 9,3 6,0 6,0 4,9  20 143 165 249 320 404 380 
AH091 
 
8,5 9,7 5,4 2,7 7,2 6,7 6,3 
 
97 157 167 192 213 247 218 
AH092  11,6 14,3 8,7 3,2 12,0 9,7 10,2  164 461 310 628 401 514 428 
AH093 
 
6,7 10,5 0,8 2,4 7,8 3,9 2,0 
 
193 404 602 774 707 766 726 
AH095 5,8 7,3 8,2 4,8 9,2 8,5 5,3 5,3  94 308 222 253 266 319 341 
AH096 10,1 11,6 18,8 7,1 16,4 26,4 16,9 17,4   216 424 375 550 590 745 692 
 
Supplementary Table 1. Treg percentage among CD4+ T cells and CD4+
 
 T cell counts for each HIV-infected individual 
enrolled in the study. Estimated missing values are underlined.  
 
2.3.4. Results 
 
Evolution of Treg percentages during HAART varies accordingly to the CD4+
In our cohort of HIV-infected patients, HAART resulted in a rapid and strong decline of the 
plasma viral load for all patients (Figure S1) and in an overall increment of the CD4
 T cell counts 
at baseline 
+
The selection of markers to define Treg is a controversial issue. We chose to identify Treg 
within CD4
 T cell counts 
over time of therapy (Figure S2) in accordance with what has been described for other cohorts 
following similar HAART regimens [35]. 
+ T cells (CD3+CD4+) as the CD127lowCD25highFOXP3+ cells accordingly to Sakaguchi et 
al. [38] using the gating strategy described before [33]. As previously shown by most of the 
studies [23-28], Treg percentages are significantly higher in HIV-infected individuals naïve for 
HAART in comparison to healthy controls. During therapy, Treg percentages tend to normalize for 
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the majority of the individuals reaching values that are not statistically significant different from 
healthy controls at about 9 months of HAART (Figure 1A). 
 
 
Figure S1. HAART leads to a decrease in the plasma viral load of all treated HIV-infected individuals. Each dot 
represents a single individual, the horizontal black lines the mean and the horizontal dashed line represents 50 
copies of plasma HIV RNA/mL. 
 
 
Figure S2. The CD4+ T cell counts rate of increase is similar between individuals with quite distinct CD4+ T cell 
counts at baseline. A. CD4+ T cell progression for three defined CD4+ T cell strata. The mean of each time-point is 
represented for the three strata independently. B. The progression of the CD4+ T cells counts is represented for each 
individual independently (black thin lines) and for the mean of all the individuals (thicker a green line). C. 
Comparison of the rates of CD4+ T cell recovery during the 24 months of HAART between the three defined strata. 
Slopes were calculated by the least square estimation method, as previously described [33]. Each dot represents a 
single individual and the solid horizontal line the mean. Comparisons were performed using a one-way ANOVA test 
followed by Bonferroni’s multiple comparison tests; no statistical significant differences were observed. 
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It has been previously described that for HIV-infected HAART-naïve individuals, Treg 
percentages correlate negatively with the CD4+ T cell counts [39]. This observation is confirmed 
in the present study (r=-0.3195, p=0.0046; Pearson correlation). To understand whether Treg 
percentage evolution during therapy differs accordingly to the disease stage at HAART initiation, 
individuals were stratified based on their CD4+ T cell counts at baseline (<200, 200-350, and 
>350 CD4+ T cells/μL). Interestingly, the differences observed on the Treg percentages of the 
overall HIV-infected individuals are only evident for the individuals that initiate HAART at very low 
CD4+ cell counts (Figure 1B). Due to the high variability on the Treg percentages depicted in 
Figure 1A and B, we consider that it would be of relevance to show the evolution of Treg 
percentages for each individual (Figure 1C and D). Overall, we can see a great diversity on the 
evolution of the Treg percentages (Figure 1C). Nevertheless, a decline in the Treg percentages is 
observed, that becomes significantly different from the baseline from 12 months of HAART on 
(Figure 1C). As can be seen in Figure 1D, the evolution of Treg percentages in most individuals 
with CD4+ T cell counts above 200 is quite similar, with a few individuals showing fluctuations. 
This is not the case for individuals that initiate HAART with <200 CD4+
The role of Treg in the immune recovery process in HIV-infected patients upon effective 
HAART remains to be elucidated. Some cross-sectional studies with individuals on HAART 
suggested a negative role of a high Treg percentage on the immune reconstitution during HAART 
[18, 31-34], but also the contrary has been proposed [41]. 
 T cell/μL; for the majority 
of these individuals, a high range of Treg percentages is present at baseline and their evolution is 
also very diverse (Figure 1D). 
  To evaluate whether Treg percentages at baseline affects CD4+ T cell reconstitution 
among HIV-infected individuals under effective HAART, we assess the correlation between Treg 
percentage at baseline and CD4+ T cell reconstitution. We observed that high Treg percentages at 
baseline negatively correlate with CD4+ T cell counts at 24 months (Figure 2A). As a result, when 
HIV-infected individuals were subdivided according to their Treg percentage at baseline (<10% 
and ≥ 10% as in [41]), those that present higher Treg percentages at baseline, showed lower 
CD4+ T cell counts at 24 months (Figure 2B). To evaluate whether this difference could be related 
to the 10% Treg cut-off, the same analysis was performed upon stratification of individuals based 
on Treg percentages quartiles of or our healthy control group (<5th, 5th to 95th and >95th; upper 5th 
percentile limit = 4.2%; lower 95th percentile limit = 13.3%) and similar results were found (Figure 
S3). 
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Figure 1. The most immunosuppressed individuals at HAART onset tend to show higher percentages of Treg, which 
decline with HAART for most patients. A. Overall comparison of the Treg percentages of healthy controls and HIV-
infected individuals at different time-points upon HAART initiation. B. Comparison of the Treg percentages of healthy 
controls and HIV-infected patients stratified accordingly to their CD4+ T cell counts at baseline. C. Longitudinal 
evaluation of Treg percentages throughout the first 24 months of HAART. D. Stratification of HIV-infected individuals 
accordingly to CD4+ T cell counts at baseline and longitudinal evaluation of Treg percentages throughout the first 24 
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months of HAART. For panels A and B, each dot represents a single individual, the horizontal black line the group 
mean and the shaded green horizontal bar represents the range of Treg percentages among CD4+
 
 T cells described 
for healthy individuals using similar markers [14]. Comparisons were performed using a one-way ANOVA test 
followed by Bonferroni’s multiple comparison tests using as reference group the HIV-uninfected individuals. For 
panels C and D, each thin line represents the Treg evolution of a single individual and the bold lines represent the 
means of the individuals for each time-point. The evolution of Treg percentage with HAART was evaluated using 
repeated measurements ANOVA test followed by Bonferroni’s multiple comparison tests using as reference the 
HAART-naïve individuals. 
 
 
 
Figure 2. Individuals with higher Treg percentages at baseline have lower CD4+ T cell counts at 24 months. A. 
Relation between Treg percentage at baseline and CD4+ T cell counts at 24 months of HAART (n=77) by Pearson’s 
correlation. B. Comparison of the CD4+
 
 T cells counts at 24 months of HAART between individuals with low (<10%; 
n=38) and high (≥10%; n=39) Treg percentages at baseline using an unpaired T-test. Each dot represents a single 
individual and the horizontal line the mean.  
 
 
 
Figure S3. Individuals with higher Treg percentages at baseline have lower CD4+ T cell counts at 24 months. Data on 
figure 2B was re-analyzed upon stratification of the individuals by percentiles of Treg percentages of the HIV-
uninfected group (higher 5th percentile limit of 4.2%; lower 95th
 
 percentile limit of 13.3%). Comparisons were 
performed between the three groups using one-way ANOVA test followed by Bonferroni’s multiple comparison tests. 
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The variation in the CD4+ T cell counts (i.e. the difference between the CD4+ T cell counts 
at 24 and 0 months) and the CD4+ T cell counts slope in the first 24 months of therapy (calculate 
by the mean square estimation model, as described in [33]) were independent of the CD4+ T cell 
counts at baseline (respectively, r=-0.0288, p=0.7887 and r=-0.0086, p=0.9390 by Pearson’s 
correlation) as it has been reported by previous studies [6, 42-44]. To evaluate whether the Treg 
percentages at baseline could affect this outcome, we stratified individuals according to Treg 
percentage at baseline (<10% and ≥ 10%) and the CD4+ T cell counts were evaluated throughout 
therapy and found no differences (Figure 3A). However, at baseline, individuals with higher Treg 
percentages have lower CD4+ T cell counts in comparison to individuals with lower Treg 
percentages (211 ± 146 vs. 313 ± 243 CD4+ T cell counts, p=0.030 by unpaired T-test). For this 
reason, and in order to evaluate reconstitution of individuals on the same stage of lymphopenia 
at HAART initiation but with distinct Treg percentages, we stratified individuals first based on their 
CD4+ T cell counts and then on the Treg percentage, both at baseline. No differences were 
observed on the pathern of CD4+ T cell recovery independently of the CD4+
Figure 3. Evolution of CD4
 T cell strata at 
baseline (Figure 3B). 
+ T cell counts with HAART is not associated with Treg percentage at baseline. A. 
Stratification of HIV-infected individuals based on their Treg percentages at baseline (<10%, n=38, blue line; ≥10%, 
n=39, red line) and evaluation of the CD4+ T cell reconstitution during HAART. Each line represents the median of all 
individuals in each specific time-point. B. Stratification of HIV-infected individuals based first on their CD4+ T cell 
counts at baseline (<200, 200-350 and >350 cells/μL) and afterwards on their Treg percentages at baseline (<10%, 
blue lines; ≥10%, red lines) and evaluation of the CD4 + T cell reconstitution with HAART. Each thin line represents a 
single individual and bold lines represent the median of all individuals from each group in each specific time-point. In 
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all graphs, a two-way ANOVA repeated measurements was performed to compare the evolution of the two groups 
throughout time of HAART and no significant differences were observed. 
 
 
Taken together, this data suggest that the negative effect observed of the higher Treg 
percentages at baseline on the CD4+ T cell reconstitution is dependent on the baseline CD4+ T 
cell counts. To test this hypothesis, and considering that several other different factors account 
for the immune reconstitution (e.g. age, gender, basal viral load, residual viral replication during 
HAART, co-infections, immune activation status [4]), hierarchical linear regression models were  
performed. As can be observed in Table 2, model 1, age, gender, co-infections, viral load at 
baseline and at 24 months and immune activation status (HLA-DR+ cells among CD4+ T cells) at 
24 months of HAART, by themselves are able to significantly predict 30% of the CD4+ T cell 
counts at 24 months of HAART. When the Treg percentages at baseline were included in the 
model (Table2, model 2) the predictive capacity of the model increases to 35% (5% difference 
from the 1st model) with Treg percentages at baseline showing up as a significant predictor of 
CD4+ T cell reconstitution. Taking all the afore mentioned variables in consideration, for the gain 
of each percentage unit of Treg at baseline, the predicted CD4+ T cell counts at 24 months 
decreases in 11 cells/μL. However, when the CD4+
  
 T cell counts at baseline are taken into 
consideration (Table 2, model 3) the predictability of the model raises to 70% (35% and 40% 
difference relatively to the 1st and 2nd models, respectively) but the contribution of the Treg 
percentage at baseline loses its significance. 
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Table 2.  Hierarchical linear regression models to predict CD4+ T cell counts at 24 months of HAART. 
1At baseline; 2Reference category: female; 3Reference category: no chronic co-morbidity (HCV 
infection/cancer/medical condition leading to recurrent infections; consider positive when at least one of them 
occurred during the 24 months of HAART). Variables were considered to significantly contribute to the model when 
p<0.05. 
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HIV-infected individuals showed Treg subset disturbances that are not restored with HAART 
initiation 
The human Treg population is heterogeneous and can be subdivided in naïve and memory 
Treg (CD45RA+
We observed a clear disturbance in Treg subpopulations distribution; in chronically 
untreated HIV-infected individuals, the percentage of CD45RA
 and CD45RA-, respectively), which are developmentally related cells [38, 40]. 
Because these cells, upon in vitro stimulation, present distinct phenotypes (proliferative but 
highly resistant to apoptosis cells vs. hyporesponsive and apoptotic cells, respectively) [38], the 
maintenance of the right proportion of these subpopulations is considered of relevance for the 
functioning of the immune system. In order to evaluate whether the Treg compartments were 
restored with HAART initiation to levels similar to healthy controls, we evaluated the percentage of 
naïve and cycling Treg. 
+ cells among total Treg was lower 
in comparison to healthy individuals and this difference persisted even upon 24 months of 
HAART (Figure 4A). These differences were more evident for individuals with less than 350 CD4+
As for the percentage of Treg undergoing proliferation, overall the percentage of Ki67
 
T cells/μL at baseline (Figure 4B). 
+ 
Treg is increased in HAART-naïve HIV-infected individuals in comparison to healthy controls 
though it normalizes with HAART initiation (Figure 5A). When HIV-infected individuals are 
stratified accordingly to their stage of lymphopenia at baseline, only the individuals with the 
lowest CD4+ T cell counts before HAART initiation (<200 cells/μL) presented higher Ki67+
 
 cells in 
comparison to healthy controls. This difference is maintained up until the end of follow-up (Figure 
5B). 
2.3.5. Discussion 
 
The evolution of Treg percentages during HAART and their contribution to the immune 
reconstitution of HIV-infected individuals is still a controversial issue that deserves attention. This 
lack of consensus might be related to several factors such as the type of studies performed, the 
heterogeneity and size of the study population, the time on therapy, the markers used to define 
this cell subset, among others. In an attempt to clarify this matter, we performed a longitudinal 
cohort study with 81 HIV-infected individuals being followed since HAART onset and for the 
following 24 months. During this time-period all individuals showed a decrease in their plasma 
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viral loads and most of them presented an increment of the CD4+
 
 T cell counts in a fashion 
similar to the one described previously [45]. However, it is important to notice that not all 
individuals are able to achieve proper immune reconstitution. Several factors have been 
inconsistently related with this lack of success, among them Treg. 
Figure 4. The percentage of naïve cells among Treg is not restored to levels similar to healthy controls at the end of 
24 months of HAART. A. Percentage CD45RA+ cells among Treg on healthy controls and on HIV-infected individuals 
from baseline up until 24 months of therapy. B. Percentage CD45RA+ cells among Treg upon stratification of the 
individuals accordingly to their CD4+
 
 T cell counts at baseline. In all graphs, each dot represents a single individual; 
horizontal black lines represent the mean. Comparison between healthy controls and HIV-infected individuals naïve 
for HAART or on different time-points upon HAART initiation performed using a one-way ANOVA test followed by 
Bonferroni’s multiple comparison tests. 
As most of the studies describe [23-28], we have observed an increase of Treg 
percentages in HAART-naïve HIV-infected individuals in comparison to healthy controls. However, 
when individuals were stratified accordingly to their CD4+ T cell counts at baseline this 
observation was more evident for individuals with less than 200 CD4+ T cells/μL at baseline, 
indicating that Treg evolution with HAART varies accordingly to the state of immunosuppression 
at the beginning of therapy. In fact, the lack of alterations in the Treg percentage of HIV-infected 
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individuals with CD4+ T cell counts above 200 cells/μL goes along with the observation made by 
Simmoneta et al. that evaluated a cohort of individuals with CD4+ T cell counts at baseline above 
350 cells/μL [14]. Thus, we added to the established knowledge that, although in general the 
percentage of Treg is increased in the HAART-naïve HIV-chronically infected individuals, the 
diversity is very high and the higher Treg percentages are clearly enriched among the individuals 
with very low CD4+
 
 T cells. 
Figure 5. Highly lymphopenic individuals at baseline maintain high proportions of Treg undergoing proliferation 
throughout HAART. A. Percentage Ki67+ cells among Treg on healthy controls and on HIV-infected individuals from 
baseline up until 24 months of therapy. B. Percentage Ki67+ cells among Treg upon stratification of the individuals 
accordingly to their CD4+
 
 T cell counts at baseline. In all graphs, each dot represents a single individual; horizontal 
black lines represent the mean. Comparison between healthy controls and HIV-infected individuals naïve for HAART 
or on different time-points upon HAART initiation performed using a one-way ANOVA test followed by Bonferroni’s 
multiple comparison tests. 
Disturbances in Treg subsets homeostasis in chronically untreated HIV-infected patients 
have been described in other studies [14, 32, 34, 46-48]. Some of these reports evaluated the 
percentages of Treg subsets among CD4+ T cells [14, 47]. However, because the percentage of 
total Treg among CD4+ T cells is highly variable for HIV-infected individuals (being or not on 
HAART), looking at percentages of Treg subsets among total CD4+ T cells, and not among Treg 
cells specifically was not the best option to analyse the diversity between patients. So, taking into 
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account only studies that evaluate naïve cells among Treg, the study by Gaardbo et al. observed 
that the percentage of naïve cells in healthy controls is higher than that in HIV-infected individuals 
on HAART, irrespective of their outcome in what concerns immune reconstitution (non-
responders, intermediate responders and responders) [48]. On the other hand, on the study 
published by Serana et al. no significant differences were observed on the percentages of this 
Treg subset in healthy controls vs. individuals on long-term HAART (>6 years) [46]. The 
discrepancy on these results might now be justified in light of our data as we observe that the 
evolution of the naïve cells among Treg varies accordingly to the CD4+
Several cross-sectional reports have proposed a role for Treg on the accomplishment of 
immune reconstitution [18, 31-34, 50]. In fact, we have previously shown that individuals with 
impaired immune reconstitution (i.e. less than 500 CD4
 T cell counts at baseline. 
Nevertheless, the low percentages of naïve cells among Treg may reflect an increased turnover of 
these cells into memory phenothype. In fact, we observe higher percentages of Treg cells 
undergoing cell division for the most immunosuppressed individuals at baseline (<200 cells/μL), 
even after initiating HAART, in comparison to the healthy controls. However, as natural Treg are 
generated in the thymus [38], one may not exclude the possibility that lower percentages of naïve 
cells among Treg could be related to lower thymic output, since it is known that HIV infection 
impacts thymic function [49]. 
+ T cells/μL after 1 to 15 years on 
HAART) were the ones with the highest Treg percentages (≥ 10%) and lower nadir values (the 
lowest CD4+ T cell count ever achieved by an HIV-infected individual) [33]. More recently, Saison 
et al., observed in a multivariate model adjusted for age, nadir, Treg percentage and CD8+ T cell 
activation (CD38+) that nadir and Treg percentages were the only two parameters associated with 
immunological response to HAART [31]. To our knowledge, no reports until now are available on 
the impact of Treg percentages at baseline on the immune reconstitution process. In our point of 
view this is a relevant issue especially if we take into consideration the observed high variability of 
Treg percentages at baseline. In fact, we perceive that Treg percentages at baseline correlates 
negatively with CD4+ T cell counts at 24 months of HAART. However no differences are observed 
on the CD4+ T cell counts progression of individuals with high vs. low Treg percentages at 
baseline (<10% and ≥10%) even after being stratified accordingly to their baseline CD4+ T cell 
counts. Taking into account in hierarchical linear regression models other factors known to affect 
immune reconstitution we observed that Treg percentages at baseline affect CD4+ T cell counts at 
24 months in a way dependent of CD4+ T cell counts at baseline. Despite the fact that some 
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reports show no alterations on the suppressive capacity of Treg during HIV-infection [51], 
recently, the reports by Pion et al. [52] and by Angin et al. [53], have described in vitro that HIV-
infected Treg show impaired suppressive capacity and a decreased expression of genes critical to 
Treg function. We have no information on the suppressive function of the Treg cells from our 
patients which is a weakness of the present study. We observed that Treg percentages at 
baseline positively correlate with the percentages of CD4+ T cells with an activation phenotype 
(HLA-DR+) and undergoing proliferation (Ki67+; data not shown). In vitro studies should be 
performed to evaluate Treg suppressive capacity from individuals with the highest Treg 
percentages among the ones with less that 200 CD4+
Taken together, our data shows that the evolution of Treg proportions and of its 
subpopulations in the onset of HAART varies differently accordingly to the baseline state of 
immunosuppression. Moreover, we show for individuals with very low CD4
 T cells/μL.  
+ T cell counts at 
baseline that the Treg percentage is extremely diverse which might explain some of the 
controversy on the data previously published by others. In addition we show that the Treg cell 
subsets are disrupted due to lymphopenia and the normal proportion of these Treg cell subsets is 
not recovered, even when the CD4+ T cell counts rise to numbers similar to non-infected 
individuals. Our work adds to others that very low nadir leads to disruptions at different levels of 
the T cells and that part of these alterations are not recovered during HAART. Further studies 
should be carried out to evaluate the suppressive capacity of Treg in HIV-infected individuals with 
very low numbers of CD4+
 
 to determine if the great diversity in percentage is associated with 
diversity also in function. Finally, these patients, as well as other cohorts, have to be followed for 
longer periods to clearly define the role of Treg, and other cells on the quality of the immune 
reconstitution of HIV-infected patients under HAART. 
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2.4 Newly Detected Spinal Cord Lesions in a Patient Infected with HIV, with a History of Cerebral  
Toxoplasmosis under Correct Treatment – a Case of Immune Reconstitution Inflammatory 
Syndrome and regulatory T cells deregulation? 
A Case report 
 
2.4.1. Abstract 
 
Background: Patients infected with HIV, especially in advanced stages of AIDS, are frequently 
affected by neurological disorders. Neurological disorders in AIDS patients might be a 
consequence of several mechanisms like: direct HIV infection of cells from the central nervous 
system (CNS); infection of the central nervous system by opportunistic pathogens; or immune 
reconstitution inflammatory syndrome (IRIS). Despite the great prevalence of toxoplasmic 
encephalitis, only few cases of neuro-IRIS related to this AIDS defining condition have been 
described. 
Case presentation: We present a case of a patient infected with HIV that upon being successfully 
treated for a cerebral toxoplasmosis unexpectedly deteriorated two months after antiretroviral 
therapy initiation and developed lesions in the spinal cord. Since this patient was included in our 
longitudinal cohort, it was possible to follow the values of regulatory CD4+
Conclusions: The case presented is strongly suggestive of a paradoxical toxoplasmosis-IRIS with 
the involvement of the spinal cord. The rarity, not only of the toxoplasmosis related IRIS, but also 
the localization of the lesions (spinal cord), renders this presentation a case of particular interest. 
In what concerns Treg and Treg subsets, although we have found a large diversity of the values 
and in their evolution over time after antiretroviral treatment initiation between all patients (case 
and controls), the variation of those values in the case seems to be more pronounced than in 
controls, and more pronounced in the first three months of antiretroviral therapy coinciding with 
the manifestations of IRIS. 
 T cells (Treg) and Treg 
subsets from the moment of antiretroviral treatment onset and throughout all events that 
occurred thereafter. We have also been able to compare the results obtained with those 
presented by nine matched patients also from the longitudinal cohort as controls. 
Keywords: CNS inflammation, HIV/AIDS, IRIS, Toxoplasmosis, myelophaty 
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2.4.2. Introduction 
 
The vast majority of untreated HIV-infected patients suffer from a gradual decrease of the 
CD4+ T cell counts rendering patients highly susceptible to several opportunistic diseases that 
can occur in almost all the body systems including the central nervous system (CNS). Agents that 
are known to be involved in neurological complications in AIDS patients are on one hand the HIV 
itself [1] and on the other hand opportunistic pathogens [2]. Furthermore, in patients initiating 
HAART and within the first weeks or months, the recovery of the CD4+
 IRIS was first reported in 1992 [4]. Since then, it became a distinct clinical condition 
affecting a growing number of patients due to the increasing use of HAART worldwide [5]. The 
frequency of IRIS among HIV-infected patients starting HAART, in a meta-analysis involving 54 
cohort studies from 22 countries (of high, high-middle, low-middle, and low income), was 
estimated at 16% (11,1 – 22,9%) with 4,5% (2,1 – 8,6%) mortality [6]. IRIS is a challenging 
condition as the clinical features are nonspecific and consequently, there is no consensual case 
definition. Since the immunopathogenesis of IRIS is poorly understood, the optimal preventive 
and treatment strategies are still controversial [7]. 
 T cells might be followed 
by an aberrant pathogen-specific immune response, leading to a heightened inflammatory 
process and, consequently, to a worsening of the state of health of the patient. This process has 
been defined as immune reconstitution inflammatory syndrome (IRIS). IRIS occurs following the 
restoration of the host defenses against an active living and replicating pathogen (previously 
subclinical and undiagnosed opportunistic infection – unmasking IRIS) or against a non-active 
residual pathogen/antigens (opportunistic infection previously diagnosed and correctly treated – 
paradoxical IRIS) [3].  
Several immune events occur during immune restoration that might, independently or 
synergistically, lead to IRIS [7 and references therein]. Data from numerous reports suggest 
deregulated CD4+
During IRIS, a powerful and aberrant pathogen-specific immune response by 
conventional T cells occurs, and some events concerning these cells could in part explain this 
exacerbated antigen-specific immune reaction in a IRIS scenario: 1) due to the previous 
encounter between immune cells and specific antigens of the pathogen, occurred an expansion 
of memory T cell (CD4
 T and/or natural killer (NK) cell responses as responsible for the exacerbated 
inflammation response and consequent tissue damage [7 and references therein].  
+ and CD8+ T cells residing in lymphoid tissues) which specificities are 
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limited in diversity [8]; 2) this limited diversity might be even enhanced in lymphopenic scenarios 
as these situations lead to a homeostatic proliferation of T cells that are T cell receptor (TCR) 
stimulation dependent [9]; 3) moreover, these latter memory T cells, expanded during 
proliferation lymphopenia-induced are more permissive to commit into effector T cells as a result 
of the activation by present antigens [10]; 4) since that the first rapidly peripheral increase in 
CD4+ T cells after HAART initiation is caused by a redistribution of memory CD4+ and CD8+
The regulatory T cells (Treg), a subset of CD4
 T cells 
from lymphoid tissues to the periphery [11], the highly specific and asymmetrical expanded 
memory T cells already resided within tissues reach the periphery [12]; and also, 5) a potential 
contribution to be considered is an autoimmune response - self-antigens derived from debris 
and/or from the uptake of dying cells by antigen presenting cells could turn T and B cell 
responses able to perpetuate tissue damage [13]. 
+ T cells, are essential to blunt the immune-
response, helping to maintain the immune system homeostasis and protecting the host from 
exaggerated immune-mediated damage. These cells have also been suggested to be involved in 
IRIS deregulated immune response by several reports [7,14-17]. It is known that after HAART 
initiation, a rapid rebound of conventional T cells is not always followed by a parallel raise of Treg 
which could lead to a decreased proportion of Treg in respect to the conventional CD4+ T cells 
[14]. However, Treg proportion has also been demonstrated to raise in patients suffering from 
IRIS suggesting that although present, Treg might be dysfunctional [15,16,17], or that the new 
conventional CD4+
 IRIS affecting the CNS (CNS-IRIS) presents, compared with other IRIS-associated organ, 
the aggravating circumstance that the CNS is of poor access to clinical investigation and that 
CNS-IRIS is associated with greater morbidity and mortality, frequently resulting in severe 
neurologic disability or even death [3]. CNS-IRIS is estimated to occur in 0.9 to 1.5% of patients 
during the first months on HAART [18]. Despite the fact that toxoplasmic encephalitis is the most 
prevalent opportunistic infection of the CNS among AIDS patients, only few cases of unmasking 
and, even less of paradoxical toxoplasmic encephalitis-IRIS have been reported [7,19-24]. In 
addition, the involvement of the spinal cord in AIDS associated toxoplasmosis is rare [19,25,26], 
and only one case report of paradoxical toxoplasmic medullar-IRIS has been published [19]. The 
strong ability of Toxoplasma gondii to evade the immune system (with mechanisms to reduce its 
visibility to the immune system by decreasing the expression of immunogenic surface proteins 
and maintaining a low-metabolism), and to hamper an immune response (favoring the expansion 
 T cells might be refractory to Treg function [14].  
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of Treg and interfering with the MHC class I and class II antigen presentation pathway and 
interferon-γ signaling) could explain the low predisposition of this pathogen to cause CNS-IRIS 
[7,19,20,27,28]. Hence we consider important to present here a strongly suggestive case of 
paradoxical toxoplasmosis IRIS with spinal cord involvement. Moreover it was interesting to 
investigate the dynamic of Treg and its subsets in parallel with all events occurred after HAART 
onset. 
 
2.4.3. Case presentation 
  
Four months after HIV diagnosis and three months after HAART onset, a 37-year-old man 
presented (Figure 1), in a routine medical appointment, decreased sensory sensation of the right 
lower limb that lasted for about 1 month. The beginning of the hyposensitivity had been 
somewhat abrupt but progressively worsening. At the moment of the medical appointment, it 
extended to the entire right lower limb and half of the abdomen. He showed no fever, headaches, 
vomiting, vertigo, numbness, weakness, seizures, other neurologic, and neither symptom of the 
respiratory, digestive, or urinary systems.  
  
 
 
 
 
 
 
 
 
Figure 1. Events chronology. The color arrows point out crucial events and will be used in the Figures 8-12. 
 
When HIV infection was diagnosed (four months before), the patient presented 
headache, psychomotor retardation and left hemiparesis, and a diagnosis of cerebral 
toxoplasmosis was made, based on: diagnosis of HIV infection, advanced immunodeficiency 
(CD4+ T cell count of 20/mm3, and a plasma HIV-1 load of 301000 copies/ml), a computed 
tomography scan (CT) showing scattered lesions in the brain parenchyma with perilesional 
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edema, mass effect, and some with ring contrast enhancement (Figure 2), a positive serology for 
toxoplasmosis, and a clinical and radiologic improvement after specific anti-toxoplasmosis 
treatment without corticosteroid therapy (a CT scan, performed 14 days after the initiation of the 
anti-toxoplasmose theraphy showed scattered smaller lesions with only little residual edema and 
no ring contrast enhancement – Figure 3). 
 
 
 
  
 
Figure 2. First brain CT, after contrast injection. Multiple hypo-density lesions, perilesional edema and sulcal 
effacement suggesting mass effect. After contrast injection, some of these lesions revealed ring enhancement. 
 
HAART (with tenofovir, emtricitabine and darunavir boosted with ritonavir) was initiated 
one month after HIV diagnosis, toxoplasmosis diagnosis, and specific anti-toxoplasmosis 
treatment onset (Figure 1). Toxoplasmosis treatment was maintained during two and an half 
months and then changed to suppressive therapy whereas prophylaxis for other primary 
opportunistic infections was maintained. 
 
128 
 
   
  
Figure 3. Brain CT realized after 14 days under specific anti-toxoplasma therapy, after contrast injection. 
Improvement of previous lesions is seen. No more mass effect, or ring contrast enhancement were seen. 
 
Three months after HAART initiation, in the above mentioned routine medical 
appointment, the patient stated that he was always taking his medication correctly: HAART, 
suppressive therapy for toxoplasmosis, and primary prophylaxis for Mycobacterium avium 
complex disease. Despite a slight sequelar left hemiparesis, the mental status of the patient was 
normal, no papilledema or neck stiffness were present, and the cranial nerves exam was normal, 
but an upper right unilateral sensory level at D-9 was present with loss of touch sensation and of 
the ability to feel pain bellow this level across the entire right lower limb and right hemi-abdomen. 
The position sensation was normal, and normal muscular force and reflexes were present in the 
correspondent area. The patient was immediately admitted to the hospital to be studied: 
- A cerebral CT scan was performed (Figure 4) revealing the previous lesions (a couple 
revealing worsening with a slight ring contrast enhancement and perilesional edema, others 
revealing improvement), and some new lesions. A magnetic resonance imaging (MRI) of the 
dorsal spinal cord (Figure 5) revealed myelitis: multiple areas of high signal intensity on the T2-
weighted images (one of them, at D4, presenting contrast enhancement on T1-weighted images), 
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located between D3 and D9, mainly peripheral and on the left side, and probably a posterolateral 
lesion on the right side at D7-D8. 
 
 
 
Figure 4. Brain CT after contrast injection. Several hypo-density lesions, some of them with slight perilesional edema 
and ring enhancement after contrast enhancement. 
 
- The CD4+ T cell count was 128/mm3 and the plasma HIV-1 viral load, 121 copies/ml. 
The cerebrospinal fluid (CSF) evaluation revealed the following values: 5 cells/ml; 58 mg/dl of 
protein; 51 mg/dl of glucose; negative results for stain and cultures for bacteria (Gram and acid-
fast) and fungi; negative results for the cryptococcal antigen; a nonreactive Venereal Disease 
Research Laboratory (VDRL) test; and the results from the polymerase chain reactions (PCR) to 
identify other common agents (JC virus, BK virus, cytomegalovirus, herpes simplex virus, human 
herpesviruses 6, varicella-zoster virus, and enterovirus) were also negative. A CSF PCR for 
Toxoplasma gondii was not performed due to technical limitations. The CSF PCR for Epstein-Barr 
virus was positive; but a normal CSF lymphocyte phenotype assay and a whole-body positron 
emission tomography scan (PET) revealing neither hyper metabolic cerebral nor medullar lesions, 
ruled out a CNS lymphoma. Serological HTLV-1/II antibody assay was also negative. 
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Figure 5.  Spinal cord MRI A and B. Area of high signal intensity on the T2-weighted images, peripheral and on the 
left side on D4. Axial and sagittal planes respectively. C. Areas of high signal intensity on the T2-weighted images 
(sagittal plane), below D4. D. Area presenting contrast enhancement on T1-weighted images on coronal plane (D4). 
E. Area of high signal intensity on the T2-weighted images on coronal plane (D4). 
 
Although the clinical and laboratory information suggested a potential case of CNS-IRIS, 
the toxoplasmosis suppressive treatment was changed to initial treatment by precaution, and 
HAART and prophylaxis for opportunistic infections maintained. Corticosteroid therapy was not 
A 
 
B 
 
 
C 
D 
 
E 
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administered. One month after the anti-toxoplasmosis treatment re-initiation, the clinical status of 
the patient was stable, and indeed, a new brain and medullar MRI performed was similar to that 
performed one month before (images not shown). A stereotactic brain or medulla biopsy was 
considered of relevance. However, while we were waiting for the possibility to perform this 
intervention, the patient showed a slight spontaneous improvement of the symptoms, the biopsy 
was delayed and a new brain and medulla MRI was schedule to four months later (the patient 
was maintained under surveillance). In fact, the patient steadily improved his clinical status 
confirmed by the brain and medullar MRI performed. That MRI revealed the disappearance of 
some previous lesions and the improvement of the others (one of them now with clastic aspect – 
image not shown) in the brain and the complete resolution of the lesions in the medulla (Figure 
6). The patient presented then fully sensory recovery of the right lower limb, only maintaining the 
sequelar left hemiparesis. The CD4+ T cell count was 244/mm3
 
 and HIV viral load below the 
detection limit (20 copies/ml). He maintained HAART and suppressive treatment for 
toxoplasmosis. 
 
Figure 6. Brain and medullar (T2-weighted images) MRI A: Improvement of previous brain lesions  
B: Absence of spinal cord lesions. 
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The evaluation of Treg and its subsets percentages was performed over time on HAART 
and analyzed in parallel with the clinical course of the case, and in other nine patients as 
controls. The nine controls were individuals also from our longitudinal cohort (subchapter 2.1) 
with similar characteristics (gender, age, CD4+
 
 T cell count at baseline) as the individual of the 
clinical case (Figure 7), but for which neither opportunistic infections were diagnosed at baseline 
neither the control-patients developed signs of IRIS. 
 
 
 
 
 
 
 
Figure 7. Demographic characterization of the clinical case and control group 
 
HAART resulted in a rapid decline of the plasma viral load and in an improvement of 
CD4+ T cells count both in the clinical case and controls (Figure 8). Both the decrease in HIV viral 
load and the increase in CD4+
 
 T cells of the case seemed to be similar to those of controls.  
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Decrease in HIV viral load and increase in CD4+
 
 T cells under HAART in clinical case and controls. The 
color arrows point out crucial events in the clinical case and are defined in the Figure 1. 
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Concerning the total Treg percentage on total CD4+
 
 T cells (Figure 9), we noted in the 
clinical case, a decline in the first month of HAART immediately followed by a pointy rise, peaking 
at third month of HAART. This peak was coincident with the peak of symptoms of IRIS. After the 
third month, the Treg percentages progressively went back to the value observed before IRIS 
symptoms manifestation coinciding with clinical recovery. From 6 months on, Treg percentages 
of the case did not greatly differ from the majority of the individuals in the control group (Figure 
9).  
 
 
 
 
 
Figure 9. Total Treg frequency on total CD4+
 
 T cells, we noted a sharp decline in the first month of HAART 
immediately followed by a pointy rise, peaking at third month. The color arrows point out crucial events in the clinical 
case and are defined in the Figure 1. 
As Treg can be separated into functionally and phenotypically different subpopulations 
[33] we next, analyzed the Treg subsets (Figure 10) over time. And we also analyzed the dynamic 
of percentages of cycling Treg (Ki67+) and of recent thymus emigrants Treg (using the markers 
CD45RA+CD31+
    
 ) among Treg [34]. 
 
 
 
Figure 10. The naïve Treg (CD45RA+ on Treg) and non naïve Treg (CD45RA-
 
 on Treg), percentage on Treg, dynamic 
over time. The color arrows point out crucial events in the clinical case and are defined in the Figure 1. 
We found that the first decrease, in the first month, in Treg percentage was synchronized 
with a sharply decrease in naïve Treg percentage (CD45RA+
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expectable, with an increase on memory Treg percentage (CD45RA-
 
 on Treg) (Figure 10). We also 
found an increase in the percentage of cycling Treg and a decrease in percentage of recent 
thymus emigrants Treg (Figure 11). The high proliferation rate of Treg could have augmented the 
conversion rate of naïve Treg in memory Treg [33].  
Figure 11. The dynamic of percentages of cycling Treg (Ki67+) and recent thymus emigrants Treg (CD45RA+CD31+
 
), 
on Treg, over time. The color arrows point out crucial events in the clinical case and are defined in the Figure 1. 
During the second month (1 to 2 months of HAART), we noted that almost all Treg in 
clinical case seemed to be non naïve Treg (activated plus non suppressive Treg) (Figure 10), the 
percentage of cycling Treg decreased and that the percentage of recent thymus emigrants Treg 
was maintained at a very low level (Figure 11). Still, there was an increase in the Treg percentage 
(on total CD4+
After the second month and until the third month on HAART, when the symptoms 
peaked, we noted a progressive increase in naïve Treg over a decrease in non naïve Treg, that 
the percentage of cycling Treg continued to decrease and that the percentage of recent thymus 
emigrants Treg begun to increase.  
 T cells). It is worth to note that IRIS-related symptoms initiated at the end of the 
second month when practically all Treg were non-naïve Treg (Figure 10). 
After the third month on HAART, the Treg and Treg subsets changes were less evident 
showing a tendency to stabilize. Yet it is worth noting the sustained increase verified on 
percentage of recent thymus emigrants Treg and percentage of naïve Treg (Figures 10 and 11). 
It is also worth to note that in the reported case, the percentage of cycling CD4+ T cells 
(Ki67+ on CD4+
 
 T cells) (Figure 12) showed the highest peak comparing to controls. That peak 
was noted at the end of the first month, one month before the symptoms appearance. 
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Figure 12. Ki67+ on CD4+
  
 T cells (%) over time. The color arrows point out crucial events in the clinical case and are 
defined in the Figure 1. 
2.4.4. Discussion 
 
 Although no firm conclusions can be drawn, we are strongly convinced this patient 
presented a case of paradoxical toxoplasmosis-IRIS with the involvement of the spinal cord. 
The initial event was clearly due to toxoplasmic encephalitis – the high incidence of this 
disease among immunecompromised HIV-patients, the presence of typical brain lesions, the 
positivity of toxoplasma serology, and the improvement under specific anti-toxoplasma therapy, 
strongly support our diagnosis. We did not use corticosteroid therapy that could cause the false 
feeling of improvement as its use would decrease brain swelling whether or not the mass was 
caused by infection. Although CSF PCR for T. gondii was not performed, its negativity would not 
exclude the diagnosis because the sensitivity of the exam is only 50% [29].  
The diagnosis of a CNS-IRIS, since there are no specific biomarkers, is presently made 
on the basis of a multi-parametric assessment [7] that was identified in this patient, namely: 1) a 
high pathogen load as revealed by the multiple brain lesions; 2) a positive response to HAART 
with evidence of controlled HIV replication (the HIV load decreased from 301000 to 121 
copies/ml in 3 months) and a immunological improvement (the CD4+ T cell count increased from 
20 to 128 cells/mm3 in 3 months); 3) a short temporal gap (2months) between HAART initiation 
and the disease worsening; 4) an inflammatory reaction causing the worsening of previous 
lesions and the appearance of new lesions revealed in neurologic imaging studies; 5) the 
exclusion of other differential diagnosis through negative results on specific tests; and 6) clinical 
and radiologic improvement without particular empiric therapies. Yet, an incomplete anti-
toxoplasma medication compliance could lead to a worsening of the first disease - still we 
consider that if it happened, a marked worsening of all the previous lesions would be present 
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instead of the appearance of new lesions while other were stabilized, and also the patient stated 
that he had correctly took his medication. 
 Regarding the pathogen causing the CNS-IRIS, although our perception is to consider 
toxoplasma the causative agent, we cannot exclude a CNS-IRIS related to HIV itself. The most 
common cause of myelopathy in AIDS patients is vacuolar myelopathy caused by HIV (even if 
asymptomatic) [30,31] and only few cases of myelitis by toxoplasma were described [19 and 
reference therein,25,26]. The appearance at MRI of a vacuolar myelopathy caused by HIV could, 
however, be quite different (although it is more frequent at thoracic medulla, also the portion of 
medulla more affected in this case); usually it is more diffuse, and with atrophy [31] 
characteristics not present herein. Although rare, a reduced number of reports described the 
occurrence or worsening of HIV-associated neurocognitive disorder after HAART initiation [7 and 
reference therein], but as far as we know, cases of HIV-associated myelo-CNS-IRIS have not been 
described. On the other hand, at least one case of toxoplasma-associated myelo-CNS-IRIS has 
already been described [19]. We consider that an under-diagnosed involvement of the spinal cord 
by T. gondii could be present in this patient when the symptoms only revealed brain involvement, 
and that the inflammation caused by IRIS rendered the spinal cord involvement clinically evident. 
A critical question is if it could be a miscellaneous-IRIS: a toxoplasmic cerebral IRIS plus 
a HIV medullar IRIS. It seems to us a quite unlikely coincidence. A negative CSF HIV load could 
help to dismiss this diagnosis although a positive value would not however confirm the diagnosis 
since we know that HIV could be present in CSF and not causing cerebral or medullar lesions 
[32]. 
A excisional brain or medullar biopsy could probably dispel any doubt; the demonstration 
of an inflammatory perivascular infiltrate dominated by CD8+ T cells and macrophages that is 
typical of IRIS triggered by not only HIV, but also by toxoplasma, would provide evidence about 
the existence of an IRIS [7]. The demonstration, on the spinal cord, of a granulomatous 
inflammation and of scarce toxoplasma pseudocysts (or bradyzoites) surrounded by 
inflammation, and an attenuated immunoperoxidase reaction meaning sequelae of effective 
antitoxoplasmosis therapy, would dissipate any doubt about the causative agent of myelo-IRIS. 
However, as this is most probably a case of paradoxical-IRIS, and given that HAART was initiated 
one month after the onset of specific anti-toxoplasma therapy, the chance to detect replicative 
forms of toxoplasma – tachyzoites would be very low, and we very probably would not see any 
toxoplasma pseudocysts nor immunoperoxidase reaction, that is what happened in the clinical 
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case reported by Cabral et al [22]. In the other four cases of paradoxical toxoplasmosis-IRIS 
described in the literature [19,23,24], however, tachyzoites have been found in brain or in spinal 
cord biopsies what could be explain by the simultaneous onset of anti-toxoplasma and 
antiretroviral therapies. The demonstration of vacuolation in the spinal white matter in association 
with a few lipid-laden macrophages within the vacuoles or the myelin sheath are 
neuropathological findings of HIV-related vacuolar myelopathy [30] but in a case of HIV-myelo-
IRIS, those findings could also not be present as the specific treatment (HAART) has already been 
taken for three months. 
The decision to postpone the biopsy, as soon as the patient showed signals of 
improvement, was based on inherent risks for the patient of the invasive procedure. The use of 
MRI imaging in association with the clinical and laboratory data, and a good clinical judgment 
prevented the performance of an unnecessary and perilous brain or medullar biopsy.  
During the probable CNS-IRIS event, we also did not use corticosteroid therapy because 
we were frightened that an undiagnosed condition could worsen due to the impairment of 
immune function and also that it could facilitate the occurrence of other opportunistic infections. 
As our patient did not reveal severe manifestations and the efficacy of corticosteroids in IRIS is 
not consensual, we choose not to use them. Accordingly, in all cases of CNS-IRIS related to 
toxoplasmosis described, but one [19], the clinical outcome was favorable with no corticosteroid 
treatment. Concerning HIV vacuolar myelopathy and myelo-HIV-IRIS, as far as we know, data 
concerning the use of corticosteroids in those conditions do not exist. In HIV vacuolar 
myelopathy, the prognosis is often bad even continuing the specific therapy (HAART) what did not 
happen in our case, the patient’s health state improved with the maintenance of HAART. 
To our knowledge, this clinical case of paradoxical toxoplasmosis IRIS is the sixth 
reported [19,20,21,22,23,24], and only the second with spinal cord involvement [19]. 
An early diagnosis and therapy of HIV infection will avoid severe immunodeficiency and 
opportunistic infections and, consequently IRIS related conditions after HAART onset. A very close 
monitoring is recommendable in cases of CNS-IRIS, including when CNS toxoplasmosis is 
present. Although both the biopsy and steroids therapy might be of use and need to be 
considering for these patients, they were both not necessary in the present case. 
Concerning the brief analysis of Treg and its subsets performed at several time-points of 
the clinical case and controls, the more pronounced changes, Treg and Treg subsets related, in 
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the reported case comparing to controls, indicate that probably changes in this CD4+
The peak of IRIS-related symptoms in the reported case, however coincides with the peak 
in Treg percentages. Unfortunately, the characterization of Treg in naïve and memory does not 
allow us to infer about the suppressive function of Treg. It will be of paramount importance to 
well characterize in terms of function Treg subsets since these Treg could be non-suppressive. It 
will be also of importance to determine the responsiveness of the new CD4
 T cells 
subset contributed for IRIS. 
+ T cells to Treg since 
the Treg detected could be functional but trying to counter CD4+
  
 T cells that are in a state of 
refractoriness.  Another hypothesis would be that the observed peak of Treg at third month was a 
feedback reactive increase in Treg trying to counteract the exaggerated inflammation. A high 
dynamic rate of conversion of Treg (naïve to memory, and on the memory subset from activated 
to non-supressive and probably consequently, death by apoptosis [33]) could probably explain 
both the changes in the Treg subsets and the inability of those cells to counterbalance the strong 
immune response against the microbial agent, in this case, Toxoplasma gondii. 
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3.1. Final Remarks, General Discussion and Conclusions 
 
The Acquired Immunodeficiency Syndrome (AIDS) is a disease of the human immune 
system caused by a virus – the human immunodeficiency virus (HIV). AIDS was first recognized 
in 1981 [1,2] and dramatically evolved to a global pandemic. In 2012, globally, an estimated 
35.3 (32.2–38.8) million people were living with HIV, there were 2.3 (1.9–2.7) million new HIV 
infections, and the number of AIDS deaths was 1.6 (1.4–1.9) million [3]. 
 In the beginning, in the 1980s and early 1990s, AIDS was a virtual death sentence; 
patients had to endure numerous hospitalizations to treat opportunistic infections before they 
eventually succumbed to the illness. Those terrible times still remain in the memory of patients’ 
family members and health care professionals who, at the time, began to take care of patients 
suffering from this disease. 
 Fortunately, huge advances were made until now in this field, being the emergence of 
drugs with potent antiretroviral activity, and their use in combination (highly active antiretroviral 
therapy or HAART), started from 1996, the most important landmark on the evolution of the 
disease that had markedly reduced morbidity and mortality AIDS-related. HIV infection is now 
considered a chronic disease easy to stabilize, at least, when patients are early diagnosed, where 
therapy and laboratory support are available, and when patients adhere to treatment and health 
care. There is a striking contrast between how we felt as physicians in the 1980s and early 
1990s and the confidence we experience today in the increase over time of the expectancy and 
quality of life of patients suffering from this disease, making it closer and closer to ones of those 
not infected by HIV.  
Some issues related to this infection, even if patients are maintained many years under 
effective therapy, however, remain to be solved and are still a concern for patients and their 
physicians: the impossibility to achieve a complete eradication of the virus; the persistence of a 
residual immune activation and inflammation accounting for faster aging and for a number of 
non-AIDS-related co-morbidities [4,5]; and also the inability of some patients to reconstitute their 
immune system maintaining an increased risk of suffering from AIDS-related and non-AIDS-
related complications and death [6-10]. 
A percentage of HIV-patients that initiate HAART (ranging between 15-40% depending on 
the study), although being virological suppressed during several years, do not reach a normal 
(700-1100 cells/mm3), a near normal (> 500 cells/mm3) or, at least, a satisfactory CD4+ T cells 
count (a number higher than a threshold of 250-350 cells/mm3, a level that would enable 
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patients to be protected from more severe opportunistic infections), and therefore are more 
prone to suffer from AIDS-related and non-AIDS-related complications and death [6-10]. These 
patients have been referred in many ways; as immunological non-responders or discordant, or 
inadequate or incomplete responders. There is no agreement on the definition of immunological 
response failure and several definitions have been reported including a diverse range of patients 
– some authors give more importance to the value of CD4+ T cells reached, others to the 
increase in percentage or to the difference (in numbers) compared to baseline level. Several 
scientific explanations may support that incomplete recovery (reviewed in Subchapter 1.1) [6-16]. 
Immunological response failure is a subject which is hard to deal with at a clinical basis, patients 
do not understand why their CD4+
T regulatory T cells (Treg) (reviewed in Subchapter 1.2) are a subset of CD4
 T cells count stop to increase and do not reach a optimal level 
although they correctly adhere to medication. And also for physicians, it is difficult to explain to 
their patients the reasons for that to happen, to prove and demonstrate why it happens, and 
above all, to offer effective solutions to protect patients from the increased risk for AIDS-related 
and non-AIDS-related complications and death.  
+ T cells that 
are able to suppress potentially excessive immune responses, therefore being essential for the 
maintenance of the immune system’s equilibrium. The role of these cells has been for long 
discussed as potentially important not only in HIV infection progression but also in immune 
recovery under effective HAART. Moreover, these cells have also been proposed to be an 
important factor/intervener in the immune reconstitution inflammatory syndrome (IRIS). Despite 
a great number of reports concerning the role of Treg in the HIV infection, their precise role 
remains to be clarified. A huge amount of uncertainty and ambiguity subsist concerning the 
effective role of Treg in the HIV infection scenario. Two mainly opposite roles in this situation 
have been endorsed to Treg: a beneficial role by dampening the immune activation/inflammation 
[17-19]; and a detrimental role by fading HIV-specific CD4+ and CD8+ T cell responses [20-22]. 
Also, supporting a beneficial effect of this T cell subset, it has been suggested that Treg could 
suppress HIV-replication in conventional CD4+ T cells [23]. On the other hand, it has also been 
advocated that Treg may inhibit lymphopenia-induced proliferation [24,25], can lead to a more 
intense gut microbial translocation accounting for the augmented immune activation [26,27], or 
may account for exacerbated fibrosis of lymphoid tissues (by increasing levels of TGF-α1 and so 
exacerbating collagen deposition) jeopardizing therefore the immune reconstitution process [28].  
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The uncertainty found in the numerous papers about the real role of these cells in HIV 
infection progression could be driven by several factors such as: 1) Treg may be beneficial or 
detrimental depending on the disease stage; 2) studies may have been characterizing and 
measuring Treg with distinct methods by using different markers/gating strategies; 3) it is not yet 
clarified if HIV itself or HIV infection scenario modifies the potency of suppressive activity of Treg; 
4) also, it remains ill-defined what is the dynamic and redistribution of the different Treg subsets 
that have distinct suppressive activity and probably different roles in HIV infection [29-31]; 5) it is 
also not known how and when plasticity of Treg can occur leading to modifications or even loss of  
their suppressive function and even became pro-inflammatory cells; and 6) it is not known if the 
relationship between Treg and beneficial or detrimental effect on HIV infection disease depends 
more on Treg absolute number or Treg percentage; it could be that, for example concerning the 
beneficial effect of Treg decreasing immune activation, the most important would be absolute 
numbers instead of Treg percentages [19,32,33]. 
It is of paramount importance to know exactly what the Treg role in HIV infection is, so 
that with the possibility to manipulate them, an improvement in HIV infection disease 
management could be achieved. 
Having all this in consideration, and the fact that the majority of the studies addressing 
Treg in HIV infection are cross-sectional or small longitudinal studies, we endeavor a work 
involving HIV-infected patients selected from the hospital where they underwent medical care. 
Thereby, the main goals of this thesis were to know: i) if and how, in untreated HIV-infected 
patients, Treg and their subsets are disturbed and how this is related to disease severity; ii) how, 
in HIV-infected patients under HAART, Treg and their subsets behave over time; iii) if Treg 
influence the immune recovery in patients under HAART; and also iv) if the deregulation of Treg 
or their subsets were implicated in IRIS. 
Thus, we constituted 2 cohorts; a cohort for a single-moment evaluation and a cohort for 
a prospective longitudinal evaluation of Treg as well as several other parameters. A control group 
composed by healthy individuals not HIV-infected was also constituted (these cohorts were 
described at Subchapter 2.1). The constitution of these cohorts initiated a more profound and 
serious collaboration between the hospital (HJUU)/the clinicians/the patients and the research 
laboratory (ICVS). For the moment these studies are completed or close to be completed but the 
material and information generated, as well as the dynamic between the hospital and the ICVS 
will allow several other studies to be performed. These studies present in this thesis were 
148 
 
performed with the results of the evaluation of 53 patients from the cross-sectional cohort (all of 
them aviremic under effective HAART for more than a year) (described at Subchapter 2.2), and 
the longitudinal study (described at Subchapter 2.3) that presented the results of the evaluation 
of the first two years under treatment of 81 patients (patients adherent to therapy and aviremic at 
the 24 month time-point). Moreover, one of the patients of the longitudinal cohort presented IRIS 
toxoplasmosis-related (presented in the subchapter 2.4), allowing us to analyze Treg and Treg 
subsets dynamics of this patient before, and throughout this pathologic process.  
It is worth noting that as far as we know, and concerning Treg cells in the HIV infection 
context, our cohort is the longitudinal cohort with the highest number of patients for such a 
period (from the 100 patients recruited, 77 are still in the study, 83 completed two years, 59 
completed three years, and 11 completed four years of follow-up).  
 
Among chronically HIV-infected untreated patients, the ones in advance stage of the disease 
present higher Treg percentage and higher diversity of these values 
Some disagreement exists on the reported evaluation of Treg percentages from HIV-
infected patients. However, the majority of the studies show that the absolute number of Treg is 
decreased in HIV-infected individuals, but in a lower proportion than the whole CD4+ T cell 
population, resulting in a increased blood Treg percentage on CD4+
 Taking into account our results we consider that part of the contradictory data published 
concerning Treg percentages (Treg percentages similar or lower than healthy individuals) 
[21,29,30,38,39] may be explained by the use of different Treg markers and/or distinct gating 
strategies [21,39], from the use of FOXP3 mRNA measured by quantitative reverse transcriptase 
polymerase chain reaction  (qRT-PCR) [21] in T cells to define Treg instead of flow cytometry (a 
distinct FOXP3 mRNA expression per cell may occur thus do not enabling the correct evaluation 
about the number of Treg) [21], from different biological samples analyzed (whole blood, fresh 
peripheral blood cells, or cryopreservated blood [29,39]), or also from heterogeneity in the HIV 
population studied between studies (acute infected, untreated long-term viremic, or aviremic 
under treatment patients, and elite controllers - EC - or long-term non-progressors patients - 
LTNP) [30,38]. 
 T cells comparing to healthy 
controls [20,32,34,35, reviewed in 36,37]. 
In our study, we employed the currently used and apparently the most reliable multicolor 
antibodies cocktail for Treg markers - CD3+CD4+CD127lowCD25highFOXP3+ [40-43] (although the 
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purity of Treg reached using such strategy remains under debate [44]). Also, all the samples 
were processed on the day of the collection so all the analysis was performed on fresh blood and 
in similar conditions for all individuals at all time-points. And, probably, more importantly, the 
study included a great number of individuals (n=81) that were all chronically HIV-infected without 
HAART (baseline) and presenting a wide range of CD4+
We found that these 81 patients displayed a significant higher Treg percentage median 
comparing to control individuals. Interestingly and looking to the data more behind the median 
level, we noticed that Treg percentage range was much wider in HIV patients than healthy 
controls. So, even being chronically infected and naïve for treatment, the values for Treg 
percentage were extremely diverse. When patients were stratified according to their nadir counts 
of CD4
 T cells (however, all of them presented 
progressive disease and criteria to initiate HAART considering the National and International 
Guidelines [45-48]). 
+ T cell count, we noticed that in the strata of those with lowest nadir (<200 cells/mm3
Previous studies had already showed an inverse relationship between Treg percentage 
and CD4
), 
those findings (higher Treg median and wider range of Treg percentages) were much more 
evident than when the data from all individuals were analyzed as a whole. In fact, only in this 
strata the Treg baseline median was significantly higher than that of control group. Thus, a link 
between high Treg percentage (and also high range of values) and more advanced disease 
seems to exist.  
+ T cells counts [14,24,34,49-51], and even some authors [19,52] had already noted a 
high variability inter-individual in Treg percentages. But, in our study when we stratified the 
sample by CD4+ T cells, we showed clearly negative correlation - as lower was the CD4+
Concerning to the link between high Treg proportions among CD4
 T cells 
counts at baseline, the higher the Treg percentage and the variability between individuals. The 
reason why HIV-infected patients in advanced stages of the disease, have so distinct Treg 
percentages remains to be elucidated. We are hopeful that through the analysis of all the patients 
and their clinical and laboratorial data collected from this cohort, we can be able, in the future to 
clarify, or at least provide more information that will contribute to clarify, the mechanisms behind 
this phenomenon. 
+ T cells and low CD4+ 
T cells; although it might indicate that Treg play a detrimental role, or that high levels of Treg are, 
at least, not an advantage for a good evolution of the disease, the nature of our study does not 
allow us to conclude that.  
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The questions about the real role of Treg in the progression of HIV infection cannot be 
answered by a static view of the Treg in a given moment of the disease evolution as we did when 
we analyzed patients on the day they initiated HAART. With such analysis it is not possible to 
determine whether the alterations detected existed prior to the progression of the disease, or 
emerged after the progression of the disease by a negative feedback loop trying to control the 
disturbances generated by the disease. To answer this question it will be necessary to perform in 
the future a longitudinal study including patients since the moment of infection and during the 
progressive disease without treatment to clarify the precise role of Treg in the progression of the 
disease. Also, studies aiming the interrelationship between Treg and specific anti-HIV immune 
response and between Treg and immune activation over time will be necessary for that 
clarification. Only in that way we will be able to understand the temporal order of events and 
characterize the direction and the magnitude of potential cause-and-effect relationships between 
Treg and HIV disease progression. We must not forget, however, that such a study could face 
ethical problems and couldn’t certainly be done up to an advanced stage of the disease. 
Currently, it is advocated that HAART begins earlier and earlier in the disease course once that 
was shown to be beneficial to patients [45].  
 
In addition to causing alteration on the proportion of total Treg among the CD4+
Concerning the analysis of Treg subsets in untreated HIV-infected patients, a disturbance 
in Treg subsets homeostasis was consistently found by other studies [29-31]. However, the 
heterogeneity in the HIV population studied, the heterogeneity of the characterization methods to 
identify Treg subsets [53-55] and/or different proportions utilized (Treg subsets on Treg versus 
Treg subsets on CD4
 T cells, HIV 
infection disturbs the subsets distribution within Treg 
+ T cells) by the authors of the diverse studies turn the comparison not 
straightforward. Simonetta et al [29], and Serana et al [30] found that the effector (CD45RA-
FOXP3high) or central memory (CD45RA-CCR7+) Treg cells, respectively, were the ones more 
affected in untreated HIV-infected patients. Contrary, Zhou et al [31] found to be the naïve Treg 
those more affected in the patients (although they used a different approach to identify Treg 
subsets). We also used a different Treg subset identification strategy based on CD45RA 
expression that allowed us to identify naïve (CD45RA+) Treg, and memory (CD45RA-) Treg [55] 
and contrary to other authors we used Treg proportions on total Treg instead of Treg subsets on 
CD4+ T cells. We found that in chronically untreated HIV-infected patients, in those most 
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immunosuppressed (<200 CD4+ T cell/mm3), the percentage of naïve Treg on total Treg are 
lower comparing to healthy controls. As already mentioned above, although an accurate 
comparison between studies is not possible, one explanation to the differences found could be 
the more advance stage of the disease in our patients and in the ones evaluated by Zhou [31] 
than those analyzed in the studies of Simonetta [29] and Serana [30]. The percentage of cycling 
Treg (Ki67+ Treg) on Treg in the most immunosuppressed untreated HIV-infected patients (<200 
CD4+ T cell/mm3
It has been advanced that phenotypically and functionally distinct Treg subsets may exert 
different suppressive effects, or even being ones beneficial and others deleterious in the HIV 
infection context [29,57]. The accurate characterization of Treg subsets, rather than an 
evaluation of the total Treg population, may lead to a deeper understanding of the Treg role in 
HIV infection.  
) was also different from the one in healthy individuals, being higher in patients. 
Other studies have also found this disturbance [31,56]. 
 
HAART tend to normalize total Treg proportion on CD4+
According to most studies, providing that reliable Treg markers/gating strategy were 
used, Treg percentage value tends to normalize reaching, after a certain time of treatment, 
values similar to the ones of controls [32,34,50,58]. Some of those studies showed a transient 
early increase of Treg percentage just after the therapy onset (probably explained by the 
liberation of Treg from lymphatic tissues to periphery due to the down-regulation of adhesion 
molecules associated in turn with a decline in viral replication) and before the consistent 
decrease [34,50]. Some studies, however, postulated that Treg expansion persists despite viral 
control under HAART [20,35,49,59,60]. Explanations for that discrepancy have already been 
proposed in subchapter 2.3: heterogeneity of patients included (treated but not aviremic, short 
time vs long-term under treatment, low nadirs vs high nadirs at baseline), or suboptimal 
combination of Treg cell markers. 
 T cells but not the high variability inter-
individual and the proportions of the Treg subsets 
In our longitudinal study we found that upon therapy initiation, in those patients more 
imunosupressed (<200 CD4+ T cells/mm3), who presented at baseline a Treg median percentage 
higher than the one of healthy individuals; Treg percentage progressively decreased reaching for 
the majority of the patients values within the normal range. We did not find the initial transitory 
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increase after HAART initiation suggested by others [34,50]. Also, the Treg percentage range that 
was wider in HIV patients tended to become progressively more restricted along the treatment. 
Both in our cross-sectional study (involving patients under treatment for several years 
and at least 1 year) and in 24M time-point of the longitudinal study, we found that, comparing to 
a control group of healthy individuals, although Treg median percentage were not different from 
the one of healthy controls, a heterogeneous distribution of Treg percentages among HIV-infected 
individuals under HAART persists upon several years of therapy (in the cross-sectional study, the 
media time under HAART was of 6,5 years, ranging from one to 14 years) and with 24M of 
therapy (longitudinal study). And, although the median Treg percentage was not significantly 
different, the number of patients with a Treg percentage ≥10% was sign ificantly superior to those 
within the healthy group. In our cross-sectional study, we tried to see if this highly diversity in 
Treg percentages values was explained by some factor such age, years under HAART, infection 
by hepatitis C virus, or overall immune activation, but no impact of these variables in Treg 
percentage was found. Also, all the patients were virological suppressed not suffering from 
opportunistic infections or other AIDS-related conditions that could explain so different values. 
Also the alterations seen in Treg subsets in patients at baseline of the longitudinal study 
(lower naïve Treg and high proliferation of Treg than ones of healthy controls) persisted despite 
24M under HAART in those patients more imunossupressed (<200 CD4+ T cells/mm3
The studies already referenced [29-31] found a tendency for HAART to promote the 
normalization of Treg subsets, although a persistent lower value of activated/effector Treg cells 
count was found in the study of Simonetta et al [29], and a persistent high Treg proliferation was 
found by Zhou et al [31]. 
). 
Stratifying by nadir values and following-up patients for longer periods will be necessary to 
determine if more time under HAART would completely restore Treg homeostasis in all patients, 
only in those less imunosupressed or in none of them (being those alterations irreversible despite 
many years under HAART). This information could help to define cut-offs for HAART initiation. 
 
Treg percentages at treatment initiation do not seem to represent an additional variable affecting 
T cell reconstitution 
The role of Treg in the immune recovery process in HIV-infected patients upon effective 
HAART remains to be elucidated. Some cross-sectional studies [14,24,56,61] including our 
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cross-sectional study suggested a negative role of Treg percentage in the immune reconstitution 
after HAART, but also the contrary was shown [16].  
A cross-sectional study provides only a static view in a given moment of the immune 
recovery. A longitudinal cohort study involving a population of patients, from the moment they 
initiate HAART, followed-up at the same several time-points of their evolution, and evaluated using 
a gating strategy for a reliable set of Treg and functionally distinct Treg subsets markers, was 
needed to better understand the temporal order of events. Only with such study, it was possible 
to determine the definition of the direction and the magnitude of potential cause-and-effect 
relationships between factors, namely Treg and its functional subsets, taking place in the 
immune reconstitution process just before HAART onset and during the treatment. The majority 
of the studies have been performed comparing groups of patients with control groups but they 
are not longitudinal studies. Longitudinal studies concerning this matter are few and include a 
small number of patients [31,32,34,49,50,51,59,60,62]. 
Concerning to the probably link found in our cross-sectional study between higher Treg 
percentages and a poorer immune reconstitution in a given time-point, we hypothesized that a 
high percentage of Treg at the onset of HAART could be an additional predictor of worse immune 
reconstitution. This hypothesis was not confirmed, at least after 24 months of treatment in our 
longitudinal study. However, a correlation analysis showed that high Treg percentages at baseline 
correlated with lower CD4+ T cells count at the 24 months time-point. Nevertheless, we found 
that individuals with higher Treg frequency at baseline have also lower CD4+ T cell counts at 
baseline. And those patients consistently showed a lower CD4+ T cell counts throughout the 
follow-up period (as it would be expected according to CD4+ T cell counts at baseline). Performing 
a multivariate analysis, in fact, we found that although Treg percentage at baseline seemed to be 
a good negative predictor of immune recovery, it lost its power when we introduced the nadir of 
CD4+ T cell in the model, showing that the high Treg percentage is linked to a low CD4+ T cell 
count, and what predicts the number of CD4+ T cells after a given period of time is the CD4+ T 
cells count at baseline and not the Treg percentage at baseline. Thus, Treg percentage seems to 
be no more than an indirect negative predictor of CD4+ T cells reconstitution as its value is linked 
to of CD4+ T cells count that itself is the direct predictor of the CD4+
Apparently, the results found in our longitudinal study failed in demonstrating a link 
between high Treg and poor immune reconstitution (under HAART) suggested by our previous 
 T cells count after a given 
period under effective HAART. 
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cross-sectional study. However, while in the cross-sectional study, we analyzed patients with CD4+ 
T cell counts under 500 cells/mm3 at baseline, and patients who were for a long time under 
HAART (media of time under HAART=6,5 years; range: 1–14 years), in the longitudinal study, we 
analyzed patients showing a diverse range of CD4+ T cell counts, at baseline (ranging from 8 to 
1033 cells/mm3), and after only 2 years under HAART. We consider of relevance to keep the 
follow-up of these patients at least up to the 5 years under HAART to clearly understand if the 
disturbed percentage of Treg among the CD4+
 
 T cells is an additional factor contributing for 
incomplete immune reconstitution. 
Treg and Treg deregulation seem to be involved in IRIS 
IRIS’s immune-pathogenesis is poorly understood; it is characterized by an exaggerated 
immune-response against a specific pathogen (already present when HAART was initiated) that 
occurs after the restoration of the host defenses [63]. Treg are cells that are able to 
suppress/reduce exacerbated immune responses being essential for the maintenance of the 
immune system’s equilibrium. Thus, It has been suggested that Treg may be involved in IRIS 
pathogenesis: i) due to a rapid rebound of conventional T cells after HAART initiation that is not 
followed by a parallel raise of Treg, which could lead to a decreased on Treg percentages and 
thus to an unbalanced proportion of CD4+ T conventional/Treg [51]; ii) although present, Treg 
might be dysfunctional [58,64,65]; or iii) the new conventional CD4+
Taking advantage of the fact that one of the patients of our longitudinal cohort developed 
toxoplasmosis-paradoxal IRIS, we analyzed Treg and Treg subsets dynamics before, throughout 
and after that pathologic process (described at subchapter 2.4). A small control group was also 
composed to allow us to search for differences and consistent pattern in our case that would help 
to understand the pathologic condition. We noticed a high variability inter-individual between all 
the patients (the case and other patients). However a more pronounced variation of Treg/Treg 
subsets during IRIS was noticed in our case which seems to indicate that a deregulation in 
Treg/Treg subsets could be involved in IRIS. Unexpectedly, the peak of IRIS-related symptoms 
and the peak of Treg percentage among CD4
 T cells might be refractory to 
Treg function [51]. 
+ T cells occurred simultaneously. We also noted 
that at that peak, almost all of Treg were memory Treg. It remains to know about the suppressor 
function of those cells. To better clarify this event, it would be of central importance to identify 
and quantify the phenotypically and functionally distinct Treg subsets. Unfortunately we 
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characterized the different Treg subsets based only on CD45RA expression that allowed us to 
divide Treg between naives and memory but do not allowed us to know about the functional 
potency of the Treg subsets involved. The use of the expression of CD45RA or CD45RO 
combined with FOXP3 (low vs high) would allow us to know better about the functional power of 
the subsets present in our case. Memory Treg comprises both activated Treg (those supposedly 
more suppressive – CD45-FOXP3high) and nonsupresive Treg (those supposedly without 
suppressive function – CD45RA-FOXP3low
 
) [53]. It will be also important to test the responsiveness 
of T cells to these Treg to understand all the factors involved in this process. Another hypothesis 
would be that the observed peak of Treg at the third month was a feedback reactive increase in 
Treg trying to counteract the exaggerated inflammation.   
Final remarks 
Despite the occurrence of major breakthroughs in recent years to the understanding of 
the role of Treg in HIV disease, much remains to be investigated before it will be possible to 
manipulate these cells in the right direction to use in clinical practice in benefit of our patients 
suffering from this disease.  
We have given, with this work a small contribution to the knowledge of the relationship 
Treg/HIV infection. In addition we think that we can still do a lot with the cohorts that we 
gathered. We think that to characterize the subsets of Treg, know them in terms of function, 
distribution and dynamics in the context of this disease will be of extreme importance. Try to 
understand why the higher but also more varied percentages presented by patients in more 
advanced stages of the disease occur will be also one of our next goals. We may further deeply 
study the relationship between Treg (and its subsets) and the appearance of IRIS in patients 
initiating HAART in advanced stages of the disease. Perceive as a lack of standardization (or his 
delay) after HAART, either in variability of the percentages of Treg, either in the proportions of 
different subsets may be important in immune reconstitution process under HAART will certainly 
help us to improve medical care to our patients. HIV causes a steady imbalance mainly at the 
level of the cell-mediated immunity being Treg and its subsets also affected. These alterations 
and disturbances may be irreversible even under HAART mainly if the therapy onset is delayed. 
These findings further reinforce the need to initiate HAART early in the course of the disease. 
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Annexes 
Annex 1 
 
 
Declaro que o sangue que me foi colhido, poderá ser utilizado para investigação no 
estudo “Reconstituição e Homeostasia do Sistema Imunitário e na Infecção por HIV”, que me foi 
explicado pelo técnico abaixo assinado, poderá ser utilizado neste e apenas neste estudo ou 
outro da mesma instituição exclusivamente para efeitos de investigação cientifica. 
TERMO DE CONSENTIMENTO INFORMADO 
Fui informada/o de que a amostra de sangue não será identificada, tendo apenas como 
informação o género e a idade, pelo que os resultado não me serão divulgados. 
Fui também informada/o de que, mesmo concordando agora, poderei no futuro retirar 
esta autorização, e também de que, qualquer que seja  a minha decisão, agora ou no futuro, não 
serei prejudicado no meu direito à assistência na doença. 
Nome completo do dador: _______________________________ 
 
Local: Instituto de Investigação em Ciências da Vida e Saúde, Escola de Ciências da Saúde, 
Universidade do Minho, Campus Gualtar  
 
Data: ____/ ____/ ____ 
 
Assinatura do dador: ___________________________________ 
Assinatura do Técnico: __________________________________  
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Annex 3  
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Annex 4 
Protocolo – Doutoramento 
Dinâmica da reconstituição e homeostase do sistema imune em indivíduos com infecção 
VIH/SIDA - tratados 
 
 
 
 
 
 
Data da colheita:_______________________ 
Identificação do doente:___________________________________________________ 
 História anterior 
Modo de transmissão: ____________________________________________________  
Data provável de Infecção: ________________________________________________ 
Data do diagnóstico: _____________________________________________________ 
Infecções/patologias oportunistas: 
          Data dos diagnósticos/ quais: 
 ________________________________________________________________ 
 ________________________________________________________________ 
 ________________________________________________________________ 
 ________________________________________________________________ 
 ________________________________________________________________ 
Autocolante do doente 
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 ________________________________________________________________ 
 ________________________________________________________________ 
Outros Antecedentes: ____________________________________________________ 
 ________________________________________________________________ 
 ________________________________________________________________ 
Co-infecção VHC/VHB: __________________________________________________ 
TARV actual (sim/não/qual): ______________________________________________ 
Regular? _______________________________________________________________ 
Data de início do esquema actual: ___________________________________________ 
Datas e esquemas anteriores, motivo da mudança: 
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________ 
Últimos CD4 e CV VIH (data e valores): 
______________________________________________________________________ 
Outras notas: 
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Annex 5 
Formulário de Consentimento Informado 
Nome do Estudo: Reconstituição e Homeostasia do Sistema Imune na Infecção por VIH 
Investigador Principal: Ana Aboim Horta 
Convidamo-lo a participar num estudo de investigação com a duração de cerca de três anos. 
O VIH infecta e destrói essencialmente um determinado tipo de células de defesa do nosso 
organismo, as células T CD4
Introdução 
+ ou como são mais conhecidos, os CD4, impedindo assim o 
desenvolvimento de respostas de defesa apropriadas contra diversos agentes infecciosos. Desta 
forma, indivíduos infectados com o VIH, principalmente aqueles em que o número de CD4 se 
encontra abaixo de 200 células/mm3 (o valor normal é de 700 a 1000/mm3
Quando temos uma infecção, o nosso sistema imune (as nossas defesas) entra em acção na 
tentativa de eliminar o agente infeccioso e, quando este objectivo é conseguido, tem que existir 
uma outra fracção do nosso sistema imune que faça parar essa defesa pois ela, em excesso, 
pode causar dano ao nosso organismo. Tem que haver sempre um equilíbrio entre as diversas 
fracções do nosso sistema imune e nestes doentes infectados por VIH, questões fundamentais 
vão surgindo: i) como é que o sistema imune destes pacientes recupera com a terapia 
antirretroviral após um tão grande desequilíbrio; ii) que tipo de homeostase ou equilíbrio é 
atingido; iii) como é que factores como o próprio indivíduo, a sua idade e o seu sexo ou o início 
da doença clínica afectam o novo equilíbrio do sistema imune. 
), são muito 
susceptíveis a diversas doenças infecciosas podendo adoecer e mesmo morrer devido a essas 
infecções. O aparecimento de medicamentos com actividade antirretrovírica potente (actividade 
contra o VIH), e o seu uso em combinação no tratamento da infecção pelo VIH, veio, a partir de 
1996, reduzir de forma marcada a morbilidade e a mortalidade associadas a esta doença e 
aumentar a esperança de vida destes pacientes. Estes medicamentos impedem o vírus de se 
multiplicar e, assim, de destruir as células de defesa, ficando o doente capaz de evitar as 
infecções. 
Estudos recentes sugerem que durante as fases iniciais da terapia antirretroviral os pacientes, 
juntamente com um aumento dos CD4, mostram também uma maior predisposição para o 
desenvolvimento de respostas inflamatórias exuberantes contra infecções (respostas de defesa 
exageradas). Essas infecções podiam já estar identificadas e a ser tratadas com eficácia 
previamente ao início da terapêutica antirretrovírica mas, após o início desta, voltam a piorar (por 
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exemplo uma Tuberculose que já estava a ser tratada e em que o indivíduo já tinha melhorado e 
não apresentava sintomas, volta a piorar após o início da terapêutica antirretrovírica) ou podem 
ser provocadas por agentes ainda não identificados mas presentes antes do início da terapêutica 
antirretrovírica. Neste último caso, o baixo número de células de defesa, a apatia do sistema 
imune perante esses agentes infecciosos eram responsáveis pela ausência de sintomas e o 
doente apesar de já ter a infecção não a sentia. Ao iniciar a terapêutica, a recuperação das 
nossas defesas vai ser responsável pelo reconhecimento desses agentes, e por uma forte 
resposta à sua presença, o que provoca o aparecimento de sintomas de forma muito acentuada. 
Estas respostas exuberantes, apesar de permitirem o reconhecimento dessa infecção poderão 
ser perigosas. 
A compreensão dos mecanismos base desta resposta imune exacerbada que acompanha a 
recuperação dos CD4 é pois essencial e, até à data, inexistente. Estes conhecimentos poderão 
ser utilizados para reconhecer os doentes em que isso poderá mais provavelmente ocorrer para, 
assim, podermos estar mais alertas e mesmo, talvez, evitá-lo. 
Este estudo tem como objectivo estudar e recuperação imune através da caracterização de 
células e tentar perceber porque é que o nosso sistema imune, por vezes, não recupera de 
forma equilibrada. Pretende também identificar os agentes infecciosos contra os quais o nosso 
sistema imune, em recuperação, responde de forma mais exagerada. 
Objectivo do estudo 
Todos os doentes, infectados por VIH que necessitem de terapêutica antirretrovírica conforme as 
orientações internacionais e nacionais. Só poderão entrar no estudo os doentes que nunca 
fizeram terapêutica no passado ou o fizeram apenas durante um período inferior a três meses e 
há mais de um ano.  
Que doentes podem entrar no estudo? 
Se participar neste estudo, necessitará de fazer o seguinte: 
O que lhe irá ser pedido? 
- Visitar o seu médico no dia em que iniciar a medicação, uma vez por mês nos primeiros três 
meses, de três em três meses até ao fim do primeiro ano e depois, de quatro em quatro meses, 
até ao fim do estudo (o plano das visitas embora mais pesado, não difere muito do dos doentes 
que não entrarem no estudo, estes são vistos normalmente de 3/3 ou 4/4 meses podendo no 
início ter mais uma consulta intermédia). 
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- Tomar a medicação conforme a orientação do seu médico. A medicação que irá tomar será a 
mesma que tomaria caso não entrasse no estudo e segue as orientações internacionais. 
- Se for mulher em idade fértil deverá concordar em utilizar métodos de controlo da natalidade 
aceitáveis durante o estudo. São considerados métodos contraceptivos aceitáveis os dispositivos 
intra-uterinos (DIU), o diafragma com espermicida, os preservativos e a abstinência sexual. Os 
contraceptivos orais isoladamente não são considerados aceitáveis de controlo da natalidade. Se 
engravidar durante o estudo deverá comunicar imediatamente ao seu médico pois a medicação 
poderá ter que ser ajustada. 
- Nalgumas visitas poderá ter que vir em jejum de oito horas. 
Quando comparecer no centro para as visitas, o investigador (o médico) ou outro pessoal do 
estudo envolvido (enfermeiro do estudo) poderão realizar um ou mais dos seguintes 
procedimentos: 
O que sucederá durante as visitas do estudo?  
- Questioná-lo sobre sintomas que tenha sentido. 
- Efectuar um exame físico completo. 
- Colher as amostras de sangue ou de urina requeridas para o estudo. Além das análises que 
faria mesmo que não entrasse no estudo, realizará colheita de sangue para caracterização das 
células de defesa e caracterização genotípica para identificação de factores genéticos de 
susceptibilidade genética a infecções (pode ter herdado uma maior sensibilidade às infecções). 
- Nalgumas visitas poder-lhe-á ser pedida a realização de alguns exames imagiológicos ou outros 
no sentido de procurar outras infecções coexistentes. 
Uma vez que visitarei o médico do estudo mais vezes do que o que seria realizado caso não 
entrasse no estudo, que serei observado e me serão realizados estudos analíticos/imagiológicos 
de forma mais regular do que o normal, poderão ser detectados infecções/problemas mais 
precocemente/atempadamente.  
Que benefícios poderei obter da minha participação no estudo?  
As informações colhidas durante o estudo poderão ajudar-me a mim e a outras pessoas no 
futuro. 
Ao assinar este documento, declaro que: 
Li este consentimento informado. 
- Tive a oportunidade de colocar perguntas e obtive as respectivas respostas. 
- Compreendo que a minha participação no estudo é voluntária e consinto-a. 
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- Posso optar por não participar no estudo ou abandonar o estudo em qualquer momento, desde 
que comunique o facto ao médico do estudo. Não serei penalizado nem perderei o direito a 
quaisquer benefícios que, noutras circunstâncias, me seriam devidos. 
- Autorizo que os meus dados pessoais e de saúde sejam recolhidos e tratados, desde que a 
minha privacidade seja resguardada. 
Irei receber uma cópia assinada deste consentimento informado 
Nome completo do participante (maiúsculas): 
______________________________________________________ 
Local:__________________________________________Data____/ ____/ ____ 
Assinatura do participante: 
 
Nome do investigador (maiúsculas): 
_________________________________________________________ 
Local:__________________________________________Data____/ ____/ ____ 
 
Assinatura do investigador: 
 
________________________________________________________________ 
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Annex 7 
Protocolo – Doutoramento 
Dinâmica da reconstituição e homeostase do sistema imune em indivíduos com infecção 
VIH/SIDA 
 
 
 
 
 
 
Profissão: _______________________ 
 História anterior 
 
Modo de transmissão: ____________________________________________________  
Data provável de Infecção: ________________________________________________ 
Data da última análise negativa: ____________________________________________ 
Data da 1ª análise positiva: ________________________________________________ 
Sintomatologia de primoinfecção? ________________________ Data: ____________ 
Infecções/patologias oportunistas: 
          Quais, data de diagnóstico, data do início do tratamento: 
 ________________________________________________________________ 
 ________________________________________________________________ 
 ________________________________________________________________ 
 ________________________________________________________________ 
 
Outros Antecedentes: ____________________________________________________ 
 ________________________________________________________________ 
 
Co-infecção VHC/VHB: __________________________________________________ 
 
TARV e data (baseline): 
______________________________________________________________________ 
 
Autocolante do doente 
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Protocolo de seguimento – Clínica/Exame Objectivo 
 -30 d Baseline 1ºMês 2ºMês 3ºMês 6ºMês 9ºMês 12ºMês 
DATA         
Adesão X X X X X X X X 
Astenia X X X X X X X X 
Anorexia X X X X X X X X 
Hipersud. X X X X X X X X 
Febre X X X X X X X X 
Alt.comport. X X X X X X X X 
Cefaleias X X X X X X X X 
Alt.visão X X X X X X X X 
Disfagia X X X X X X X X 
Dor torácica X X X X X X X X 
Tosse X X X X X X X X 
Expectoração X X X X X X X X 
Hemoptises X X X X X X X X 
Dispneia X X X X X X X X 
Náuseas X X X X X X X X 
Vómitos X X X X X X X X 
Disfagia X X X X X X X X 
Diarreia X X X X X X X X 
Obstipação X X X X X X X X 
Dor abdom. X X X X X X X X 
Parestesias X X X X X X X X 
         
Peso X X X X X X X X 
Altura X X X X X X X X 
TA X X X X X X X X 
Pulso X X X X X X X X 
Temp. ax. X X X X X X X X 
Déficites focais X X X X X X X X 
Sinais mening. X X X X X X X X 
Candid. orof. X X X X X X X X 
Aftas X X X X X X X X 
Outra (cav.buc.) X X X X X X X X 
Gânglios X X X X X X X X 
Ex. ocular X X X X X X X X 
Freq. Resp. X X X X X X X X 
Alt. Pele X X X X X X X X 
Qual X X X X X X X X 
Ausc. Pulm X X X X X X X X 
Ausc. Card X X X X X X X X 
Palp. Abdom. X X X X X X X X 
Alt. MS X X X X X X X X 
Alt. MI X X X X X X X X 
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 16º Mês 20º Mês 24º Mês 28ºMês 32ºMês 36ºMês 
DATA       
Adesão X X X X X X 
Astenia X X X X X X 
Anorexia X X X X X X 
Hipersud. X X X X X X 
Febre X X X X X X 
Alt.comport.  X X X X X X 
Cefaleias X X X X X X 
Alt.visão X X X X X X 
Disfagia X X X X X X 
Dor torácica X X X X X X 
Tosse X X X X X X 
Expectoração X X X X X X 
Hemoptises X X X X X X 
Dispneia X X X X X X 
Náuseas X X X X X X 
Vómitos X X X X X X 
Disfagia X X X X X X 
Diarreia X X X X X X 
Obstipação X X X X X X 
Dor abdom. X X X X X X 
Parestesias X X X X X X 
       
Peso X X X X X X 
Altura X X X X X X 
TA X X X X X X 
Pulso X X X X X X 
Temp. ax. X X X X X X 
Déficites focais X X X X X X 
Sinais mening. X X X X X X 
Candid. orof. X X X X X X 
Aftas X X X X X X 
Outra (cav.buc.) X X X X X X 
Gânglios X X X X X X 
Ex. ocular X X X X X X 
Freq. Resp. X X X X X X 
Alt. Pele X X X X X X 
Qual X X X X X X 
Ausc. Pulm X X X X X X 
Ausc. Card X X X X X X 
Palp. Abdom. X X X X X X 
Alt. MS X X X X X X 
Alt. MI X X X X X X 
 
  
 
182 
 
Protocolo de seguimento – Análises/exames  (SA – se aplicável) 
 -15d Baseline 1ºMês 2ºMês 3ºMês 6ºMês 9ºMês 12ºMês 
DATA         
Hgb X  X X X X X X 
Leucócitos X  X X X X X X 
Neutróf. X  X X X X X X 
Linfócitos X  X X X X X X 
Plaquetas X  X X X X X X 
VS X  X SA X X SA X 
Tpo Protr. X    SA X SA X 
INR X    SA X SA X 
AST X  X X X X X X 
ALT X  X X X X X X 
Bil. Total X  X X X X X X 
Bil. Dta X  X X X X X X 
DHL X  X X X X X X 
FA X  X X X X X X 
GGT X    X X X X 
Amilase X    X X SA X 
Lipase X    X X SA X 
Ureia X  X X X X X X 
Creatinina X  X X X X X X 
Ác. úrico X     X  X 
Proteínas Tot. X     X  X 
Albumina X     X  X 
Globulina X     X  X 
PCR X  X SA X X X X 
Glicose X    X X  X 
Col. Total X    X X  X 
Col. HDL X    X X  X 
Col. LDL X    X X  X 
TGS X    X X  X 
Lactato X     X  X 
Fósforo/Ca/VD X     X  X 
Anti-VHC X        
RNAVHC  SA   SA SA  SA 
Genótipo  SA       
Atg. HBs X        
AntiHBs X        
AntiHBc X        
AtgHBe X        
AntiHBe X        
DNAVHB  SA   SA   SA 
Genótipo  SA       
AntiHAV IgG X        
CV VIH X   X SA X SA X 
CD4 X  X X X X X X 
CD8 X  X X X X X X 
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 16º Mês 20º Mês 24º Mês 28ºMês 32ºMês 36ºMês 
DATA       
Hgb X X X X X X 
Leucócitos X X X X X X 
Neutróf. X X X X X X 
Linfócitos X X X X X X 
Plaquetas X X X X X X 
VS SA SA X SA SA X 
Tpo Protr. SA  X  SA X 
INR SA    SA X 
AST X X X X X X 
ALT X X X X X X 
Bil. Total X X X X X X 
Bil. Dta X X X X X X 
DHL X X X X X X 
FA X X X X X X 
GGT SA SA X SA SA X 
Amilase SA SA X SA SA X 
Lipase SA SA X SA SA X 
Ureia X X X X X X 
Creatinina X X X X X X 
Ác. úrico SA SA X SA SA X 
Proteínas Tot. SA SA X SA SA X 
Albumina SA SA X SA SA X 
Globulina SA SA X SA SA X 
PCR SA SA X SA SA X 
Glicose SA SA X SA SA X 
Col. Total SA SA X SA SA X 
Col. HDL SA SA X SA SA X 
Col. LDL SA SA X SA SA X 
TGS SA SA X SA SA X 
Lactato SA SA X SA SA X 
Fósforo SA SA X SA SA X 
Anti-VHC   SA   SA 
RNAVHC   SA   SA 
Genótipo       
Atg. HBs       
AntiHBs       
AntiHBc       
AtgHBe       
AntiHBe       
DNAVHB   SA   SA 
Genótipo       
AntiHAV IgG       
CV VIH X SA X SA X X 
CD4 X X X X X X 
CD8 X X X X X X 
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Protocolo de seguimento – Outras análises/exames  
 -30d Baseline 1ºMês 2ºMês 3ºMês 6ºMês 9ºMês 12ºMês 
DATA         
VDRL X    X   X 
MHA-TP X    X   X 
Serol. VVZ X       X 
Serol. VHS1 X       X 
Serol. VHS2 X       X 
Serol. CMV X       X 
Serol. EBV X       X 
Serol. Toxopl. X       X 
LCR-células  X SA SA SA SA SA SA 
LCR-proteínas  X SA SA SA SA SA SA 
LCR-glicose  X SA SA SA SA SA SA 
LCR-cript.(atgdc)  X SA SA SA SA SA SA 
LCR-bact  X SA SA SA SA SA SA 
LCR-BK  X SA SA SA SA SA SA 
LCR PCR JC  X SA SA SA SA SA SA 
LCR PCR EBV  X SA SA SA SA SA SA 
LCR PCR CMV   X SA SA SA SA SA SA 
LCR PCR Tox  X SA SA SA SA SA SA 
LCR PCR BK  X SA SA SA SA SA SA 
LCR PCR VIH  X SA SA SA SA SA SA 
PCR/HC sg? 
HSV,BKv,PvB19 
HTLV2 
 
 SA SA SA SA SA SA 
Mantoux X X(10-14d)   X   X 
Quantiferon X    X SA  X 
Rx 
 
 
X    X   X 
Ecografia Abd. 
 
 
 
X     X  X 
Fibroscan X     X  X 
TAC SA SA SA SA SA SA SA SA 
RMN SA SA SA SA SA SA SA SA 
TAC Timo X       X 
Outros: 
HLAB5701 
Teste Resist. VIH 
Ex ginecológico 
Ex. oftalmol.(SA) 
Osteodensit. (SA) 
ECG (SA) 
UrinaII 
 
X 
SA 
UII 
SA SA SA 
SA 
UII 
SA 
SA 
UII 
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 16º Mês 20º Mês 24º Mês 28ºMês 32ºMês 36ºMês 
DATA       
VDRL   SA   SA 
MHA-TP   SA   SA 
Serol. VVZ   SA   SA 
Serol. VHS1   SA   SA 
Serol. VHS2   SA   SA 
Serol. CMV   SA   SA 
Serol. EBV   SA   SA 
Serol. Toxopl.   SA   SA 
LCR-células SA SA SA SA SA SA 
LCR-proteínas SA SA SA SA SA SA 
LCR-glicose SA SA SA SA SA SA 
LCR-cript.(atg,dc) SA SA SA SA SA SA 
LCR-bact SA SA SA SA SA SA 
LCR-BK SA SA SA SA SA SA 
LCR PCR JC SA SA SA SA SA SA 
LCR PCR EBV SA SA SA SA SA SA 
LCR PCR CMV  SA SA SA SA SA SA 
LCR PCR Tox SA SA SA SA SA SA 
LCR PCR BK SA SA SA SA SA SA 
LCR PCR VIH SA SA SA SA SA SA 
PCR/HC sg? 
HSV,BKv,PvB19 
HTLV2 
SA SA SA SA SA SA 
Mantoux   X   X 
Quantiferon   X   X 
Rx 
 
 
  X   X 
Ecografia Abd. 
 
 
 
  X   X 
Fibroscan   X   X 
TAC SA SA SA SA SA SA 
RMN SA SA SA SA SA SA 
TAC Timo   X   X 
Outros: 
Ex. oftalmológico 
Urina II 
 
 
 
 
 
 
SA: se aplicável 
SA SA 
SA 
UII 
SA SA 
SA 
UII 
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Infecções/patologias oportunistas após início da TARV: 
Doenças AI: 
 
Patologia 
Data do início dos sintomas 
Data do diagnóstico 
Data do início do tratamento específico 
Corticoterapia? 
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________
______________________________________________________________________ 
 
 
 
 
 
 
 
